<?xml version="1.0" encoding="UTF-8"?>
<con:soapui-project name="NLM Validation - Regression Suite - Schema Rules" resourceRoot="" soapui-version="4.0.1" xmlns:con="http://eviware.com/soapui/config"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.actions.iface.tools.soapui.TestRunnerAction@values-local"><![CDATA[<xml-fragment xmlns:con="http://eviware.com/soapui/config">
  <con:entry key="Global Properties" value=""/>
  <con:entry key="TestSuite" value="NLM Transform - Java Service TestSuite"/>
  <con:entry key="Report to Generate" value=""/>
  <con:entry key="Password" value=""/>
  <con:entry key="soapui-setings.xml Password" value=""/>
  <con:entry key="TestRunner Path" value=""/>
  <con:entry key="Tool Args" value=""/>
  <con:entry key="Ignore Errors" value="true"/>
  <con:entry key="Host:Port" value=""/>
  <con:entry key="WSS Password Type" value=""/>
  <con:entry key="Save Project" value="false"/>
  <con:entry key="Enable UI" value="false"/>
  <con:entry key="System Properties" value=""/>
  <con:entry key="Domain" value=""/>
  <con:entry key="Coverage Report" value="false"/>
  <con:entry key="Export JUnit Results" value="true"/>
  <con:entry key="Open Report" value="false"/>
  <con:entry key="Project Properties" value=""/>
  <con:entry key="Project Password" value=""/>
  <con:entry key="Export All" value="true"/>
  <con:entry key="Report Format(s)" value=""/>
  <con:entry key="TestCase" value="&lt;all>"/>
  <con:entry key="Print Report" value="false"/>
  <con:entry key="Username" value=""/>
  <con:entry key="Root Folder" value="C:\NLM_NPG Transform Project\Sprint 1\Testing Deliverables\Functional results"/>
  <con:entry key="Save After" value="false"/>
  <con:entry key="Add Settings" value="false"/>
  <con:entry key="Endpoint" value="${#Project#ServiceEndpoint}"/>
</xml-fragment>]]></con:setting></con:settings><con:interface xsi:type="con:RestService" wadlVersion="http://research.sun.com/wadl/2006/10" name="NLM Transform - Java Service" type="rest" basePath="/${#Project#Basepath}" definitionUrl="http://test.npg-services.nature.com/nlm-service-java/application.wadl" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:settings/><con:definitionCache type="TEXT" rootPart="http://test.npg-services.nature.com/nlm-service-java/application.wadl"><con:part><con:url>http://test.npg-services.nature.com/nlm-service-java/application.wadl</con:url><con:content><![CDATA[<wadl:application xmlns:wadl="http://research.sun.com/wadl/2006/10" xmlns:xs="http://www.w3.org/2001/XMLSchema">
  <wadl:doc enunciate:generatedBy="Enunciate-1.24" xmlns:enunciate="http://enunciate.codehaus.org/"/>
  <wadl:grammars>
    <wadl:include href="ns0.xsd"/>
  </wadl:grammars>
  <wadl:resources base="http://localhost:8080/nlm service">
    <wadl:resource path="/rest/api/describe">
      <wadl:method name="GET">
        <wadl:response>
          <wadl:representation mediaType="text/plain"/>
        </wadl:response>
      </wadl:method>
    </wadl:resource>
    <wadl:resource path="/rest/api/validate">
      <wadl:method name="POST">
        <wadl:doc>Validates NLM Service</wadl:doc>
        <wadl:request>
          <wadl:representation mediaType="text/xml"/>
        </wadl:request>
        <wadl:response>
          <wadl:representation mediaType="application/xml" element="report"/>
        </wadl:response>
      </wadl:method>
    </wadl:resource>
  </wadl:resources>
</wadl:application>]]></con:content><con:type>http://research.sun.com/wadl/2006/10</con:type></con:part><con:part><con:url>http://test.npg-services.nature.com/nlm-service-java/ns0.xsd</con:url><con:content><![CDATA[<xs:schema version="1.0" xmlns:xs="http://www.w3.org/2001/XMLSchema">
  <xs:element name="message">
    <xs:complexType>
      <xs:annotation>
        <xs:documentation><![CDATA[<p>
Java class for anonymous complex type.
<p>
The following schema fragment specifies the expected content contained within this class.
<pre>
&lt;complexType>
&lt;complexContent>
&lt;restriction base="{http://www.w3.org/2001/XMLSchema}anyType">
&lt;attribute name="line" type="{http://www.w3.org/2001/XMLSchema}int" />
&lt;attribute name="validated-by" type="{http://www.w3.org/2001/XMLSchema}string" />
&lt;attribute name="code" type="{http://www.w3.org/2001/XMLSchema}string" />
&lt;attribute name="type" type="{http://www.w3.org/2001/XMLSchema}string" />
&lt;attribute name="column" type="{http://www.w3.org/2001/XMLSchema}int" />
&lt;attribute name="href" type="{http://www.w3.org/2001/XMLSchema}string" />
&lt;attribute name="location" type="{http://www.w3.org/2001/XMLSchema}string" />
&lt;/restriction>
&lt;/complexContent>
&lt;/complexType>
</pre>]]]]>><![CDATA[</xs:documentation>
      </xs:annotation>
      <xs:simpleContent>
        <xs:extension base="xs:string">
          <xs:attribute name="line" type="xs:int"/>
          <xs:attribute name="validated-by" type="xs:string"/>
          <xs:attribute name="code" type="xs:string"/>
          <xs:attribute name="type" type="xs:string"/>
          <xs:attribute name="column" type="xs:int"/>
          <xs:attribute name="href" type="xs:string"/>
          <xs:attribute name="location" type="xs:string"/>
        </xs:extension>
      </xs:simpleContent>
    </xs:complexType>
  </xs:element>
  <xs:element name="report">
    <xs:complexType>
      <xs:annotation>
        <xs:documentation><![CDATA[<p>
Java class for anonymous complex type.
<p>
The following schema fragment specifies the expected content contained within this class.
<pre>
&lt;complexType>
&lt;complexContent>
&lt;restriction base="{http://www.w3.org/2001/XMLSchema}anyType">
&lt;sequence>
&lt;element ref="{http://ns.nature.com/nlm/validator}message" maxOccurs="unbounded" minOccurs="0"/>
&lt;/sequence>
&lt;/restriction>
&lt;/complexContent>
&lt;/complexType>
</pre>]]]]>><![CDATA[</xs:documentation>
      </xs:annotation>
      <xs:sequence>
        <xs:element ref="message" minOccurs="0" maxOccurs="unbounded"/>
      </xs:sequence>
    </xs:complexType>
  </xs:element>
</xs:schema>]]></con:content><con:type>http://www.w3.org/2001/XMLSchema</con:type></con:part></con:definitionCache><con:endpoints><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:endpoint>http://test.npg-services.nature.com/nlm-service/rest/validate/stream/xml</con:endpoint><con:endpoint>${#Project#ServiceEndpoint}</con:endpoint></con:endpoints><con:resource name="/rest/api/validate" path="${#Project#path}"><con:settings/><con:parameters/><con:method name="POST" method="POST"><con:settings/><con:parameters/><con:representation type="REQUEST" id=""><con:mediaType>application/xml</con:mediaType><con:params/><con:element xsi:nil="true"/><con:description xsi:nil="true"/></con:representation><con:representation type="RESPONSE" id=""><con:mediaType>text/xml</con:mediaType><con:params/><con:element>report</con:element><con:description xsi:nil="true"/></con:representation><con:request name="Valid XML" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date>
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:request><con:request name="XML with DTD Errors" mediaType="text/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>http://test.npg-services.nature.com/nlm-service-java/rest/api/validate</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="tmech"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2008.1091</article-id>
        <article-id pub-id-type="publisher-id">scibx.2008.1091</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">tmech</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-11</subject>
        </subj-group>
        </article-categories>
        <title-group>
            <article-title>Cancer's fuel duel</article-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Haas</surname>
                <given-names>Michael J</given-names>
            </name>
                <role>Senior Writer</role>
            </contrib>
        </contrib-group>
        <pub-date>
            <day>18</day>
            <month>12</month>
            <year>2008</year>
        </pub-date>
        <volume>1</volume>
        <issue>45</issue>
        <fpage>1</fpage>
        <lpage>4</lpage>
        <permissions><copyright-year>2008</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2008.1069" ext-link-type="article-id"/>
        <related-article related-article-type="see-also" xlink:href="scibx.2008.1096" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Belgian and U.S. researchers have elucidated a symbiosis between hypoxic and oxygenated tumor cells that could be harnessed to kill the former cell type by targeting a <underline>lactate transporter</underline> on the latter type. If a suitable inhibitor of the transporter is identified, it could complement existing therapies.</p>
        </abstract>
        <custom-meta-group>
            <custom-meta specific-use="change">
                <meta-name>erratum</meta-name>
                <meta-value>
                    <named-content content-type="date-of-change">2009-02-12</named-content>
                    <named-content content-type="change">In the version of the supplementary information for this article originally posted online, the descriptions of Supplementary Videos 1&#x2014;6 were incorrect. The errors have been corrected as of 27 January 2009.</named-content>
                </meta-value>
            </custom-meta>
            <custom-meta specific-use="change">
                <meta-name>correctn</meta-name>
                <meta-value>
                    <named-content content-type="person-given-names">Sarada</named-content>
                    <named-content content-type="person-surname">Callison</named-content>
                    <named-content content-type="date-of-change">2006-05-08</named-content>
                    <named-content content-type="location">acknowledgments</named-content>
                    <named-content content-type="change">added note to HTML; replaced PDF</named-content>
                    <named-content content-type="reason">In the version of this article initially published, a funding source was omitted. The following statement should be added to the end of the Acknowledgments section: "D.A. Bosco is grateful to the National Institutes of Health for a postdoctoral fellowship. We thank the National Institutes of Health (NS050636), the Skaggs Institute for Chemical Biology and the Lita Annenberg Hazen Foundation for financial support." The error has been corrected in the PDF version of the article.</named-content>
                </meta-value>
            </custom-meta>
        </custom-meta-group>
    </article-meta>
</front>
<body>
    <p>A team of Belgian and U.S. researchers has demonstrated that hypoxic tumor cells can be killed by targeting solute carrier family 16, member 1 (monocarboxylic acid transporter 1), a membrane lactate transporter protein expressed on oxygenated tumor cells. The approach should mesh well with existing chemo- and radiotherapies, and systemic inhibition of the transporter is not likely to have severe side effects.</p>
    <p>For more than 50 years it has been known that the tumor microenvironment consists of two distinct compartments&#x2014;the oxygenated compartment, which is located near tumor blood vessels, and the hypoxic compartment, which is typically located near the tumor core. Hypoxic tumor cells are difficult to target with conventional chemo- and radiotherapies because of their low-oxygen environment and distance from blood vessels.<disp-quote id="pq1"><p>&#x201C;What's clever about MCT1 inhibition is that it targets the oxygenated tumor compartment, but its effect is on the hypoxic one.&#x201D;</p><address><institution>Threshold Pharmaceuticals Inc.</institution></address><attrib>Charles Hart</attrib></disp-quote>
    </p>
    
    <p>Tumor hypoxia is associated with progression to malignancy and cancer relapse&#x2014;making hypoxic tumor cells important, if elusive, drug targets.</p>
    <p>The relationship between tumor compartments was previously thought to be strictly one way: oxygenated cells used most of the available oxygen to produce energy from glucose, leaving hypoxic cells to produce most of their energy via anaerobic fermentation, releasing lactate as a by-product.</p>
    <p>In a paper in the <italic>Journal of Clinical Investigation</italic>, however, researchers demonstrated that the relationship is symbiotic and that the symbiosis can be exploited therapeutically.<xref  ref-type="bibr" rid="b1"/></p>
    <sec>
        <title>Fuel service</title>
        <p>First, the team found that oxygenated human cervical squamous carcinoma cells could metabolize exogenous lactate. This led to the hypothesis that lactate released by hypoxic cells&#x2014;conventionally viewed as a waste product&#x2014;could actually fuel oxygenated tumor cells.</p>
        <p>To confirm this, the team injected mice bearing squamous cervical carcinoma xenografts with <sup>13</sup>C-labeled lactate, then excised the tumors 30 minutes later. NMR experiments in extracts from those tumors detected <sup>13</sup>C-labeled glutamate, a lactate metabolite, which demonstrated that oxygenated tumor cells could indeed take up and metabolize lactate.</p>
        <p>Next, the team used either RNAi or &#x3B1;-cyano-4-<sc>L</sc>-hydroxycinnamate, a commercially available selective solute carrier family 16, member 1 (monocarboxylic acid transporter 1) (SLC16A1; MCT1) inhibitor, to block MCT1 activity in squamous cervical carcinoma cell cultures. MCT1 is a membrane protein that mediates lactate uptake in human muscle cells during intense exercise.</p>
        <p>Both methods of MCT1 inhibition completely blocked the uptake of lactate by the cancer cells.</p>
        <p>Moreover, the lactate blockade caused the cells to switch from a balance between lactate metabolism and glycolysis to only glycolysis for energy production. This result led the team to hypothesize that forcing oxygenated cells to switch to glycolysis only <italic>in vivo</italic> might in turn cut off the glucose supply to hypoxic cells.</p>
        <p>In mouse models of lung and colorectal cancer, inhibition of MCT1 with &#x3B1;-cyano-4-<sc>L</sc>-hydroxycinnamate slowed tumor growth by inducing the same glycolytic switch in oxygenated tumor cells, which indeed had the added benefit of depriving hypoxic cells of glucose and killing them.</p>
        <p>Moreover, a combination of &#x3B1;-cyano-4-<sc>L</sc>-hydroxycinnamate treatment and radiation had a synergistic effect on decreasing tumor growth compared with using either treatment alone.</p>
        <p>Lastly, the team confirmed that MCT1 is expressed in the oxygenated compartments of a range of human cancers, including breast, head and neck, colorectal, lung and neuroblastoma tumors. This suggests that the combination of MCT1 inhibition and radiation could have broad clinical applications, said Pierre Sonveaux, an associate professor of pharmacology and therapeutics at the <ext-link xlink:href="http://www.uclouvain.be/"><bold>Universit&#xE9; Catholique de Louvain</bold></ext-link> (UCL) and lead author on the <italic>JCI</italic> paper.</p>
        <p>The research team was led by Olivier Feron, associate professor of pharmacology and therapeutics at UCL, and Mark Dewhirst, professor of radiation oncology and pathology and biomedical engineering at <ext-link xlink:href="http://medschool.duke.edu/"><bold>Duke University Medical Center</bold></ext-link>.</p></sec>
    <sec>
        <title>Compartmentalized strategy</title>
        <p>Companies contacted by <italic>SciBX</italic> agreed that MCT1 inhibition could be a potent addition to combination therapy, but they wanted to know more about the potential side effects on muscles and neurons.</p>
        <p>Charles Hart, VP of biology at <ext-link xlink:href="http://www.biocentury.com/companies/Threshold_Pharmaceuticals_Inc?utm_source=1"><bold>Threshold Pharmaceuticals Inc.</bold></ext-link>, said the elucidation of a two-way, symbiotic interaction between tumor compartments was &#x201C;a revolutionary, paradigm-shifting idea&#x201D; that could lead researchers to think about cancer differently.</p>
        <p>Although lactate transport between hypoxic and oxygenated cells in muscle tissue is well characterized, no one had thought to apply that mechanism to the tumor microenvironment&#x2014;as the <italic>JCI</italic> authors did&#x2014;to find out whether the oxygenated compartment was using lactate to fuel growth and proliferation, he said.</p>
        <p>Instead, Hart said researchers were interested in how cancer cells responded to the acidifying environment that lactate caused, and sought to take advantage of that acidic environment, for example by developing compounds that were highly membrane-permeable under acidic conditions.</p>
        <p>&#x201C;What's clever about MCT1 inhibition is that it targets the oxygenated tumor compartment, but its effect is on the hypoxic one,&#x201D; said Hart. Thus an MCT1 inhibitor could work well in combination with a therapy that targeted either the oxygenated or hypoxic compartment, he said.</p>
        <p>But Hart added that the timing of dosing would be important: an MCT1 inhibitor would have to be given before any drug that was cytotoxic to oxygenated cells. Otherwise, the cytotoxic molecule could kill off the oxygenated cells before the MCT1 inhibitor could target them and kill hypoxic cells via glucose deprivation.</p>
        <p>Hart said an MCT1 inhibitor should also combine well with other agents that selectively target the hypoxic compartment.</p>
        <p>Threshold's TH-302 is a hypoxia-activated cytotoxic prodrug. It is in Phase I/II trials to treat soft tissue sarcoma, solid tumors, non&#x2013;small cell lung cancer (NSCLC) and pancreatic and prostate cancers.</p>
        <p>Emma Shtivelman, director of cancer research at <ext-link xlink:href="http://www.biocentury.com/companies/BioNovo_Inc?utm_source=1"><bold>BioNovo Inc.</bold></ext-link>, said the <italic>JCI</italic> paper highlighted &#x201C;a peculiarity of tumor cell biology&#x201D; that suggested a new approach to treating cancer. &#x201C;MCT1 is clearly a novel target whose inhibition could not only affect the ability of some tumor cells to take up lactate, but also disrupt glycolysis in other cells present in the same tumor,&#x201D; she said.</p>
        <p>Shtivelman added that &#x201C;the strategy of MCT1 inhibition is clearly complementary to the strategies targeting glycolysis in tumors,&#x201D; whether with glycolytic inhibitors such as 2-deoxyglucose or compounds that target enzymes in the glycolytic pathway.<xref ref-type="bibr"  rid="b2"/><disp-quote id="pq2"><p>&#x201C;The strategy of MCT1 inhibition is clearly complementary to the strategies targeting glycolysis in tumors.&#x201D;</p><address><institution>BioNovo Inc.</institution></address><attrib>Emma Shtivelman</attrib></disp-quote></p>
        <p>One potential strategy would be to give an MCT1 inhibitor to switch oxygenated tumor cells to glycolysis, then use a selective inhibitor of glycolysis to kill both the oxygenated and hypoxic cells, Shtivelman said.</p>
        <p>BioNovo's BZL101 is an aqueous extract from the herb <italic>Scutellaria barbata</italic> &#x201C;D. Don&#x201D; of the Lamiaceae family that inhibits glycolysis and selectively induces cell death in tumors. The compound is in a Phase II trial to treat advanced breast cancer and has completed a Phase I trial in pancreatic cancer.</p></sec>
    <sec>
        <title>Lactate on the mind (and muscle)</title>
        <p>Going forward, Threshold's Hart thought the <italic>JCI</italic> paper provided sufficient proof of concept that MCT1 is a viable drug target&#x2014;assuming that additional experiments demonstrated no major adverse effects on healthy cells.</p>
        <p>Shtivelman said the safety issue needs to be probed, because one potential drawback to MCT1 inhibition is that at least two types of normal tissues&#x2014;skeletal white muscle and red muscle&#x2014;can rely on lactate oxidation for energy production. She added that lactate has also been shown to play a role in the metabolic interactions between neurons and glia.<xref ref-type="bibr" rid="b3"/></p>
        <p>Indeed, a paper in <italic>Nature Cell Biology</italic> by researchers at the <ext-link xlink:href="http://www.unc.edu/"><bold>University of North Carolina at Chapel Hill</bold></ext-link> has elucidated a role for glycolysis in the antiapoptotic mechanisms of both cancer cells and healthy neurons (<italic>see</italic>&#xA0;<bold><xref ref-type="boxed-text" rid="bx1">Box 1</xref></bold><bold>, &#x201C;Un-reducing apoptosis&#x201D;</bold>).<xref ref-type="bibr"  rid="b4"/></p>
        <p>Thus, Shtivelman said, the combination of an inhibitor of lactate uptake or oxidation, plus a glycolysis inhibitor, could have dangerous effects on muscle and neuronal tissues.</p>
        <p>UCL's Sonveaux disagreed that MCT1 inhibition could have serious toxic effects. He said MCT1 has a lower affinity for lactate than other MCTs found in healthy tissues.</p>
        <p>&#x201C;This means that MCT1 exerts a physiological role only when the other transporters are saturated&#x2014;as it is the case, for example, during intensive exercise&#x201D; or recovery from ischemic injuries, Sonveaux said.
            <disp-quote id="pq3"><p>&#x201C;MCT1 exerts a physiological role only when the other transporters are saturated.&#x201D;</p><address><institution>Universit&#xE9; Catholique de Louvain</institution></address><attrib>Pierre Sonveaux</attrib></disp-quote></p>
        <p>Sonveaux also noted that patients with exercise intolerance due to ubiquitous <italic>MCT1</italic> deletion have no symptoms while at rest. &#x201C;These patients experience muscle cramps only during <italic>intensive</italic> exercise, and the symptoms are reversible,&#x201D; he said.</p>
        <p>Similarly, he noted that whereas both MCT1 and MCT2 can facilitate lactate transport in neurons, MCT2 has the higher lactate affinity of the two, suggesting that the effects of MCT1 inhibition on neurons might be limited to transient lethargy.</p>
        <p>Finally, Sonveaux said the team that published the <italic>JCI</italic> paper observed no pathological symptoms or gross behavioral changes in mice given &#x3B1;-cyano-4-hydroxycinnamate.</p></sec>
    <sec>
        <title>Fuel speed ahead</title>
        <p>Sonveaux added that other known MCT1 inhibitors have off-target effects due to poor selectivity for MCT1. But despite its selectivity for MCT1, Sonveaux said &#x3B1;-cyano-4-hydroxycinnamate was not a drug candidate because it is poorly soluble in water. The team is collaborating with chemists to develop more drug-like analogs, he said.</p>
        <p>The team is also designing high throughput screens to identify new MCT1 inhibitors.</p>
        <p>Sonveaux and Feron declined to disclose the IP status of their findings. Sonveaux did say the team was seeking to collaborate with at least two undisclosed companies that already have MCT1 inhibitors in discovery for noncancer indications.</p>
        <p>Meanwhile, Dewhirst and colleagues at Duke Medical Center have found genetic correlations between the <italic>in vitro</italic> responses of cancer cells to lactate accumulation and clinical outcomes <italic>in vivo</italic>.</p>
        <p>In a report in <italic>PLoS Genetics</italic>, the Duke team showed that human mammary epithelial cells can respond to the accumulation of extracellular lactate (lactic acidosis) by shutting down glycolysis&#x2014;a negative-feedback loop that minimized the extent of glycolysis and hypoxia in those tumors.<xref ref-type="bibr" rid="b5"/></p>
        <p>The genetic markers associated with a strong response to lactic acidosis were also associated with positive clinical outcomes in breast cancer patients. This led the team to write that those genetic markers could be prognostic indicators for breast and possibly other cancers.</p>
        <p>The findings could lead to new therapeutic strategies to treat cancer, according to Jen-Tsan Ashley Chi, leader of the <italic>PLoS</italic> research team and assistant professor of molecular genetics and microbiology at Duke University Medical Center.</p>
        <p>&#x201C;The cancer cell has a way of sensing the pH outside itself and adjusting its lactate production accordingly,&#x201D; he said.</p>
        <p>The group is investigating the molecular and transcriptional mechanisms by which the cell accomplishes this balancing act.</p>
        <p>A small molecule that triggered the same response to lactic acidosis&#x2014;even in the absence of extracellular lactate&#x2014;could be one possible therapeutic application of those ongoing studies, said Chi.</p>
        <p>Coauthor Dewhirst said the findings reported in <italic>PLoS Genetics</italic> are not patented.</p></sec>
    <sec>
        <title>Companies and institutions mentioned</title>
        <p><list id="l1">
            <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/BioNovo_Inc?utm_source=1"><bold>BioNovo Inc.</bold></ext-link> (NASDAQ:BNVI), Emeryville, Calif.</p></list-item>
            <list-item><p><ext-link xlink:href="http://medschool.duke.edu/"><bold>Duke University Medical Center</bold></ext-link>, Durham, N.C.</p></list-item>
            <list-item><p><ext-link xlink:href="http://www.ethz.ch/index_EN"><bold>Swiss Federal Institute of Technology</bold></ext-link>, Zurich, Switzerland</p></list-item>
            <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Threshold_Pharmaceuticals_Inc?utm_source=1"><bold>Threshold Pharmaceuticals Inc.</bold></ext-link> (NASDAQ:THLD), Redwood City, Calif.</p></list-item>
            <list-item><p><ext-link xlink:href="http://www.uclouvain.be/"><bold>Universit&#xE9; Catholique de Louvain</bold></ext-link>, Brussels, Belgium</p></list-item>
            <list-item><p><ext-link xlink:href="http://www.unc.edu/"><bold>University of North Carolina at Chapel Hill</bold></ext-link>, Chapel Hill, N.C.</p></list-item>
            <list-item><p><ext-link xlink:href="http://www.uzh.ch/"><bold>University of Zurich</bold></ext-link>, Zurich, Switzerland</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Sonveaux</surname><given-names>P</given-names></name>
            <etal/>
            <source>J. Clin. Invest.</source><year>2008</year><month>11</month><day>20</day>
            <elocation-id content-type="doi">10.1172/JCI36843</elocation-id>
            <named-content content-type="contact">Pierre Sonveaux, Universit&#xE9; Catholique de Louvain, Brussels, Belgium <email>pierre.sonveaux@uclouvain.be</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Pelicano</surname><given-names>H.</given-names></name> <etal/>
            <source>Oncogene</source> <volume>25</volume><fpage>4633</fpage><lpage>4646</lpage><year>2006</year>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Hashimoto</surname><given-names>T.</given-names></name> <etal/>
            <source>PLoS One</source> <volume>3</volume><fpage>e2915</fpage><year>2008</year><month>11</month><day>23</day>
            <elocation-id content-type="doi">10.1371/journal.pone.0002915</elocation-id>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Vaughn</surname><given-names>A.</given-names></name><name><surname>Deshmukh</surname><given-names>M.</given-names></name>
            <source>Nat. Cell Biol.</source><year>2008</year><month>11</month><day>23</day>
            <elocation-id content-type="doi">10.1038/ncb1807</elocation-id>
            <named-content content-type="contact">Mohanish Deshmukh, University of North Carolina at Chapel Hill, Chapel Hill, N.C. <email>mohanish@med.unc.edu</email></named-content>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Chen</surname><given-names>J.L.-Y.</given-names></name> <etal/>
            <source>PLoS Genet.</source> <volume>4</volume><fpage>e1000293</fpage><year>2008</year><month>12</month><day>5</day>
            <elocation-id content-type="doi">10.1371/journal.pgen.1000293</elocation-id>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="webpage">
            <collab>U.S. Food and Drug Administration</collab>
            <source>Notice of solicitation for the sequencing quality control project.</source>
            <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-N-0644-n.pdf">http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-N-0644-n.pdf</ext-link>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
    </ref-list>
    <boxed-text id="bx1">
        <caption><title>Un-reducing apoptosis.</title></caption>
        <p>Both cancer cells and healthy neurons outlive other normal cells by deregulating mechanisms of mitochondrial apoptosis, a key step of which is the release of the molecule cytochrome <italic>c</italic>, somatic (CYCS) from the mitochondrial membrane in response to apoptotic stimuli such as DNA damage and reactive oxygen species. Both cell types also rely heavily on glycolysis for energy, but how that process plays a role in antiapoptosis has been unknown.</p>
        <p>Researchers at the <ext-link xlink:href="http://www.unc.edu/"><bold>University of North Carolina at Chapel Hill</bold></ext-link> (UNC) have now shown that glycolysis in cancer cells and neurons keeps CYCS in a reduced state, thereby preventing the protein from activating proapoptotic pathways. Based on the findings, the researchers suggested that both neurodegeneration and cancer could be treated by modulating the redox state of CYCS.<xref ref-type="bibr" rid="b4"/></p>
        <p>To investigate the connection between glycolysis and antiapoptosis, the UNC group treated human cervical cancer cells, rat hepatocellular carcinoma cells and mouse embryonic fibroblasts with either hydrogen peroxide to raise the oxidation level of the cells or glutathione to lower the oxidation level. Cells treated with peroxide were more susceptible to CYCS-mediated apoptosis than cells treated with glutathione, indicating that CYCS requires an oxidizing environment to induce cell death.</p>
        <p>Inhibition of the pentose phosphate pathway&#x2014;by which glycolysis leads to glutathione production&#x2014;also increased the oxidation state of the cancer cells and made them more susceptible to CYCS-mediated apoptosis.</p>
        <p>Similarly, raising the oxidation level of healthy mouse neurons by treating them with peroxide or inhibiting the pentose phosphate pathway also promoted CYCS-mediated apoptosis.</p>
        <p>&#x201C;Our results suggest that forcing cancer cells to be in an oxidizing environment would make them more susceptible to apoptosis induced by cytochrome <italic>c</italic> release from the mitochondria,&#x201D; thereby increasing the effectiveness of chemotherapy, Mohanish Deshmukh told <italic>SciBX.</italic> This could be accomplished by inhibiting the pentose phosphate pathway to block glutathione synthesis or by directly delivering oxidized CYCS or CYCS mimetics to the tumors, he said.</p>
        <p>Deshmukh, an associate professor of cell and developmental biology at UNC, was an author on the <italic>Nature Cell Biology</italic> paper that described the results.</p>
        <p>Conversely, Deshmukh said blocking oxidation of CYCS in neurons might be a strategy to treat neurodegenerative disorders, such as Parkinson's disease (PD), in which the accumulation of reactive oxygen species and oxidized proteins play a role. &#x201C;Antioxidants could restrict the apoptotic pathway to spare a neuron's life,&#x201D; he said.</p>
        <p>&#x201C;The results are indeed very intriguing, and the link between neuronal glucose metabolism and cancer cell metabolism is appealing,&#x201D; said Nicolai Savaskan, a research group leader at the <ext-link xlink:href="http://www.uzh.ch/"><bold>University of Zurich</bold></ext-link>'s Institute of Brain Research.</p>
        <p>But before the <italic>Nature Cell Biology</italic> findings could be translated into cancer therapeutics, Savaskan said, more work is needed to understand how increasing the oxidation levels of normal cells&#x2014;thereby generating more reactive oxygen species in those cells&#x2014;would affect their survival.</p>
        <p>Savaskan is also a research group leader at the <ext-link xlink:href="http://www.ethz.ch/index_EN"><bold>Swiss Federal Institute of Technology</bold></ext-link>.</p>
        <p>Deshmukh said his group has already uncovered some differences between the apoptotic pathways of normal cells and cancer cells. He cited a paper the team published last year in the <italic>Proceedings of the National Academy of Sciences</italic>, showing that the direct injection of excess CYCS induced apoptosis in brain tumor cells but not healthy neurons.<xref ref-type="bibr" rid="b6"/></p>
        <p>&#x201C;This opens the possibility of using cytochrome <italic>c</italic> itself as a drug&#x201D; to treat brain tumors, Deshmukh said. To that end, his group is looking at nanoparticles to deliver CYCS into cells and screening for small molecule mimetics of CYCS.</p>
        <p>The group is also looking for other metabolic pathways and molecular mechanisms that are common to both cancer cells and neurons, he said.</p>
        <p>Deshmukh said the findings reported in <italic>Nature Cell Biology</italic> are not patented.</p>
        <attrib specific-use="byline"><italic>&#x2014;MJH</italic></attrib>
    </boxed-text>
</back>
    
</article>
]]></con:request><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:request><con:request name="XML with Schematron Errors" mediaType="text/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>http://test.npg-services.nature.com/nlm-service-java/rest/api/validate</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id>scibx</journal-id>
        <journal-title-group>
            <journal-title>Science-Business eXchange</journal-title>
            <journal-subtitle>a journal</journal-subtitle>
            <abbrev-journal-title>scibx</abbrev-journal-title>
        </journal-title-group>
        <issn pub-type="pub">1945-3477</issn>
        <issn pub-type="epub">195-3477</issn>
        <isbn>0 784 99923 1</isbn>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="publisher-id">scibx.test</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">csrory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">  
                <subject content-type="npg.subject">
                    <named-content content-type="id">693</named-content>
                    <named-content content-type="version">1.0</named-content>
                    <named-content content-type="path">/631/693</named-content>
                </subject>
                <subject content-type="npg.subject">
                    <named-content content-type="id">41</named-content>
                    <named-content content-type="version">1.0</named-content>
                    <named-content content-type="path">/631/701/41</named-content>
                </subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date>
            <day>29</day>
            <month>02</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>201O</copyright-year><copyright-holder>Macmillan</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:request><con:request name="XML with DTD and Schematron Errors" mediaType="text/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>http://test.npg-services.nature.com/nlm-service-java/rest/api/validate</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2009.1491</article-id>
        <article-id pub-id-type="publisher-id">scibx.2009.1491</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-10</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>A gut feeling for CD39</article-title>
            <alt-title>Treating IBD with CD39</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Fulmer</surname>
                <given-names>Tim</given-names>
            </name>
                <role>Senior Writer</role>
            </contrib>
        </contrib-group>
        <pub-date>
            <day>15</day>
            <month>10</month>
            <year>2009</year>
        </pub-date>
        <volume>2</volume>
        <issue>40</issue>
        <permissions><copyright-year>20O9</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2009.1486" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>American and German researchers have reported that enhancing CD39 activity in the gut could help treat inflammatory bowel disease. The researchers are now developing a soluble form of CD39 that they hope could become an infusible therapeutic to treat colitis and Crohn's disease.</p>
        </abstract>
         <custom-meta-group>
            <custom-meta specific-use="change">
                <meta-name>corrigendum</meta-name>
                <meta-value>
                    <named-content content-type="date-of-change">2009-10-16</named-content>
                    <named-content content-type="change">IThe original role of CD39 in converting ATP to adenosine was misstated and has been changed.</named-content>
                </meta-value>
            </custom-meta>
        </custom-meta-group>
    </article-meta>
</front>
<body>
	<p>Researchers have reported that enhancing CD39 activity in the gut could trigger a T<sub>reg</sub>-mediated immunosuppressive response to help treat inflammatory bowel disease.<xref ref-type="bibr" rid="b1"/> The researchers are now developing a soluble form of CD39 that they hope could become an infusible therapeutic to treat colitis and Crohn's disease.</p>
	<p>Multiple signaling pathways underlie the immunosuppressive function of T<sub>regs</sub>. One of those pathways involves the T<sub>reg</sub>-mediated generation of extracellular adenosine, which binds its receptor on the surface of proinflammatory T cells and decreases their development and proliferation (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;Targeting CD39 in inflammatory bowel disease&#x201D;</bold>).<xref ref-type="bibr" rid="b2"/></p>
	<p>A team of researchers led by Simon Robson of the <ext-link xlink:href="http://www.bidmc.org/"><bold>Beth Israel Deaconess Medical Center</bold></ext-link> has been looking for ways to increase levels of extracellular adenosine at sites of inflammation to treat inflammation and autoimmune diseases. The group has focused on enhancing the activity of CD39, an enzyme on the surface of T<sub>regs</sub> involved in the conversion of ATP to adenosine.<xref ref-type="bibr" rid="b3"/></p>
	<p>Previous work by the group showed that genetic knockout of CD39 led to aberrant proliferation of proinflammatory T cells and failure to prevent allograft rejection in mice.<xref ref-type="bibr" rid="b4"/></p>
	<p>Now the researchers have extended those findings to autoimmune disease. In a mouse model of chemically-induced acute colitis, animals with <italic>Cd39</italic> knockout had greater disease severity than controls that had colitis and expressed <italic>Cd39</italic>. The knockouts showed increased infiltration of leukocytes and thickening of the colon wall.</p>
	<p>Next, the researchers attempted to reverse disease severity by administering soluble apyrase, an enzyme that has the same activity as CD39. Compared with controls, <italic>Cd39</italic> knockouts receiving the enzyme showed no significant weight loss (<italic>p</italic>&lt;0.05), a proxy for colitis severity.</p>
	<p>Finally, the group analyzed publicly available genomewide expression profiles of humans and identified a SNP (rs10748643) near the promoter of <italic>CD39</italic> that was strongly linked to CD39 levels. The low CD39&#x2013;expressing genotype was significantly associated with Crohn's patients, whereas healthy controls were enriched for the high CD39&#x2013;expressing allele (<italic>p</italic>=0.0006).</p>
	<p>Thus, in both mice and humans, low CD39 expression correlated with severity of gastrointestinal autoimmune disease. The findings were published in the <italic>Proceedings of the National Academy of Sciences</italic>.</p>
	<sec>
	<title>Ligand vs. receptor</title>
	<p>The short serum half-life of adenosine makes direct delivery of the compound problematic for chronic inflammatory conditions. However, approaches for triggering its anti-inflammatory effects could include directly activating the adenosine receptor using agonists or delivering soluble CD39 to increase local adenosine levels.</p>
	<p>At least one biotech is developing an agonist. But Robson, a professor of medicine at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and attending physician at Beth Israel, said his group wants to design a soluble form of CD39 for delivery to patients with inflammatory bowel disease (IBD).</p>
	<p>&#x201C;The rationale is that delivering CD39 to, or potentially boosting endogenous levels of CD39 in IBD patients will increase the local pool of extracellular adenosine and therefore have an immunosuppressive effect on pathogenic T cell populations,&#x201D; he said.</p>
	<p>However, one researcher pointed out that increasing extracellular adenosine could activate all four types of adenosine receptors&#x2014;A<sub>1</sub> (ADORA<sub>1</sub>), A<sub>2A</sub> (ADORA<sub>2A</sub>), A<sub>2B</sub> (ADORA<sub>2B</sub>) and A<sub>3</sub> (ADORA<sub>3</sub>)&#x2014;not all of which are known to generate an immunosuppressive response.</p>
	<p>&#x201C;Given that the A<sub>2A</sub> and A<sub>2B</sub> receptors are primarily responsible for mediating adenosine's immunosuppressive effects, there's concern the additional activation of A<sub>1</sub> and A<sub>3</sub> could trigger unwanted side effects in tissues expressing those receptors,&#x201D; said Peter Ernst, professor of medicine at the <ext-link xlink:href="http://www.virginia.edu/"><bold>University of Virginia</bold></ext-link>. Even the ADORA<sub>2A</sub> and ADORA<sub>2B</sub> subtypes could mediate unwanted side effects at some ligand concentrations, he added.</p>
	<p>Indeed, the desire to avoid activation of adenosine receptors not involved in immunosuppression is part of the rationale behind the design of agonists that selectively activate a single receptor, in particular ADORA<sub>2A</sub>.</p>
	<p>Ernst and his colleague at Virginia, Joel Linden, have separately shown that a selective agonist of ADORA<sub>2A</sub> reduced tissue damage in multiple mouse models of IBD.<xref ref-type="bibr" rid="b5 b6"/></p>
	<p>PGxHealth, a division of <ext-link xlink:href="http://www.biocentury.com/companies/Clinical_Data_Inc?utm_source=1"><bold>Clinical Data Inc.</bold></ext-link>, has opted to develop an agonist. The company's lead ADORA<sub>2A</sub> agonist, Stedivaze (ATL146e), is in Phase III testing as a coronary artery vasodilator for use with cardiac stress imaging. The company has also developed second-generation ADORA<sub>2A</sub> agonists for anti-inflammatory indications. Those agonists are in preclinical development, according to Jayson Rieger, VP of research at PGxHealth.</p>
	<p>To get a better idea of whether enhancing CD39 activity would have advantages over agonizing the adenosine receptor, Ernst suggested looking at genetically engineered animal models of IBD and colitis in addition to the chemically-induced model of acute colitis used in the paper. The former might better reflect the aberrant cytokine levels and T cell responses that characterize autoimmune disease.</p>
	<p>&#x201C;Animals in which autoimmunity is induced by knockout of anti-inflammatory cytokines like IL-10 or by adoptive transfer of pathogenic, proinflammatory T cells could offer better models of IBD and colitis than the model used in the paper,&#x201D; he said.</p>
	<p>Such animal studies might also help show whether the anti-inflammatory effects of some marketed IBD therapies are mediated by CD39 or by the production of adenosine, said Alan Moss, assistant professor of medicine at Harvard Medical School and director of translational research for the Center for Inflammatory Bowel Disease at Beth Israel.</p>
	<p>&#x201C;Looking at CD39 activity in biopsy samples and peripheral blood mononuclear cells from IBD patients would provide evidence for the relevance of CD39 to disease in humans,&#x201D; said Moss.</p>
	<p>Indeed, Robson told <italic>SciBX</italic> that he, Moss and other colleagues are planning to study the levels of CD39 and adenosine receptors in blood and tissue T cell populations from IBD patients receiving anti&#x2013;tumor necrosis factor (TNF) antibodies. That could provide insight into how the anti-inflammatory activity of anti-TNF antibodies is, at least in part, mediated by extracellular adenosine at sites of disease, he said.</p>
	<p>Robson said he and colleagues own patents and have patents pending that cover both the use of conjugated, soluble CD39 to treat autoimmune disorders and the creation and use of CD39 mutant animals. The IP is available for licensing.</p></sec>
	<sec>
	<title>Companies and institutions mentioned</title>
	<list id="l1">
	<list-item><p><ext-link xlink:href="http://www.bidmc.org/"><bold>Beth Israel Deaconess Medical Center</bold></ext-link>, Boston, Mass.</p></list-item>
	<list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Clinical_Data_Inc?utm_source=1"><bold>Clinical Data Inc.</bold></ext-link> (NASDAQ:CLDA), Newton, Mass.</p></list-item>
	<list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	<list-item><p><ext-link xlink:href="http://www.virginia.edu/"><bold>University of Virginia</bold></ext-link>, Charlottesville, Va.</p></list-item></list></sec>
</body>
<back>
    <ref-list>
		<title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Friedman</surname><given-names>D.</given-names></name>
            <etal/>
            <source>Proc. Natl. Acad. Sci. USA</source>
            <year>2009</year>
            <month>09</month>
            <day>29</day>
            <elocation-id content-type="doi">10.1073/pnas.0902869106</elocation-id>
            <named-content content-type="contact">Simon Robson, Beth Israel Deaconess Medical Center, Boston, Mass. <email>srobson@bidmc.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Hasko</surname><given-names>G.</given-names></name> <etal/> 
            <source>Nat. Rev. Drug Discov.</source><volume>7</volume><fpage>759</fpage><lpage>770</lpage>
            <year>2008</year>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Dwyer</surname><given-names>K.</given-names></name> <etal/> 
            <source>Purinergic Signal.</source>
            <volume>3</volume><fpage>171</fpage><lpage>180</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Deaglio</surname><given-names>S.</given-names></name> <etal/> 
            <source>J. Exp. Med.</source>
            <volume>204</volume><fpage>1257</fpage><lpage>1265</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Naganuma</surname><given-names>M.</given-names></name> <etal/> 
            <source>J. Immunol.</source>
            <volume>177</volume><fpage>2765</fpage><lpage>2769</lpage><year>2006</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Odashima</surname>, <given-names>M.</given-names></name> <etal/> 
            <source>Gastroenterol.</source>
            <volume>129</volume><fpage>26</fpage><lpage>33</lpage><year>2005</year>
        </element-citation></ref>
    </ref-list>
    </back>
    <floats-group>
	<fig id="f1" position="float">
        <caption>
            <title>Targeting CD39 in inflammatory bowel disease.</title>
            <p>Research published in the <italic>Proceedings of the National Academy of Sciences</italic> suggests that enhancing the activity of CD39, an enzyme expressed on the surface of T<sub>regs</sub>, could help treat inflammatory bowel disease (IBD).</p>
<p>Inflammation in the gut starts with dendritic cells (DCs) present at the mucosal epithelial layer of the lumen. These cells sense pathogenic bacteria and other antigens. Upon activation by pathogens, local DCs migrate to the lymph nodes to activate na&#xEF;ve T cells [<bold>a</bold>], which undergo differentiation into antigen-specific, proinflammatory effector T cells that fight infection in the lamina propria [<bold>b</bold>].</p>
<p>T<sub>regs</sub> help prevent excess activation of proinflammatory T cells such as T helper type 1 (Th1), Th2 and Th17 cells, and they do so, at least in part, by increasing levels of extracellular adenosine. Two enzymes expressed on the surface of T<sub>reg</sub> cells&#x2014;CD39 and CD73&#x2014;catalyze the formation of adenosine, which binds the adenosine A<sub>2A</sub> receptor (ADORA<sub>2A</sub>) on effector T cells and blocks their activation and proliferation [<bold>c</bold>].</p>
<p>Thus, enhancing levels of CD39 could offer an anti-inflammatory strategy for treating IBD. The authors of the <italic>PNAS</italic> study are developing a soluble form of CD39 to administer as a therapeutic. Meanwhile, biotechs are developing ADORA<sub>2A</sub> agonists that are predicted to have a similar anti-inflammatory effect for a variety of indications.</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2009.1491-F1.jpg" position="anchor"/>
        </alternatives>
    </fig>
</floats-group>
</article>
]]></con:request><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:request><con:request name="NOt well formed XML" mediaType="text/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>http://test.npg-services.nature.com/nlm-service-java/rest/api/validate</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="dther"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2008.1098</article-id>
        <article-id pub-id-type="publisher-id">scibx.2008.1098</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">dther</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-12</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Cardiovascular disease</subject>
                <subject>fibrosis</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>MicroRNA-21 (miRNA-21)</article-title>
        </title-group>
        <pub-date>
            <day>18</day>
            <month>12</month>
            <year>2008</year>
        </pub-date>
        <volume>1</volume>
        <issue>45</issue>
        <permissions><copyright-year>2008</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <abstract abstract-type="editor">
            <p>Studies in mice suggest that antagonizing miRNA-21 could potentially lower cardiac fibrosis and treat cardiovascular disease.</p>
        </abstract>
         <custom-meta-group>
            <custom-meta specific-use="change">
                <meta-name>erratum</meta-name>
                <meta-value>
                    <named-content content-type="date-of-change">2009-02-13</named-content>
                    <named-content content-type="change">In the original version of this article, the information about Regulus Therapeutics LLC was omitted.</named-content>
                </meta-value>
            </custom-meta>
        </custom-meta-group>
   </article-meta>
</front>
<body>
    <sec>
		 <title>Summary</title>
		 <p>Studies in mice suggest that antagonizing miRNA-21 could potentially lower cardiac fibrosis and treat cardiovascular disease. Myocardial miRNA-21 was upregulated in three different mouse models of cardiac failure and in patients with end-stage heart failure compared with what was seen in healthy controls. An antagomir targeting miRNA-21 lowered cardiac fibrosis, cardiomyocyte size and heart weight and improved cardiac function in two different mouse models of cardiac failure compared with what was seen in mice that received saline control. Further studies in larger animal models of heart failure are necessary to determine the therapeutic efficacy of an antagomir approach to silencing miRNA-21.</p>
		 <p><ext-link xlink:href="http://www.biocentury.com/companies/Regulus_Therapeutics_LLC?utm_source=1"><bold>Regulus Therapeutics LLC</bold></ext-link>, which was an author on the paper, has an early-stage miRNA program targeting miRNA-21 for cardiovascular diseases and fibrosis. Regulus is a joint venture between <ext-link xlink:href="http://www.biocentury.com/companies/Alnylam_Pharmaceuticals_Inc?utm_source=1"><bold>Alnylam Pharmaceuticals Inc.</bold></ext-link> and <ext-link xlink:href="http://www.biocentury.com/companies/Isis_Pharmaceuticals_Inc?utm_source=1"><bold>Isis Pharmaceuticals Inc.</bold></ext-link></p>
		 
		 <p><ext-link xlink:href="http://www.biocentury.com/companies/miRagen_Therapeutics_Inc?utm_source=1"><bold>miRagen Therapeutics Inc.</bold></ext-link> has multiple miRNA-targeting compounds in preclinical development to treat cardiovascular indications.</p>
	</sec>
	 <sec>
		 <title>Licensing Status</title>
		 <p>Several patent applications filed covering diagnostic and therapeutic application of miRNAs in cardiovascular disease; available for licensing</p>
		 </sec>
	</body>
	<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Thum</surname><given-names>T.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2008</year>
            <month>11</month>
            <day>30</day>
            <elocation-id content-type="doi">10.1038/nature07511</elocation-id>
            <named-content content-type="contact">Stefan Engelhardt, University of W&#xFC;rzburg, W&#xFC;rzburg, Germany
<email>stefan.engelhardt@virchow.uni-wuerzburg.de</email></named-content>
        </element-citation></ref>
     </ref-list>
    </back>
]]></con:request><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:request><con:request name="Not XML" mediaType="text/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>http://test.npg-services.nature.com/nlm-service-java/rest/api/validate</con:endpoint><con:request>
abc
</con:request><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:request></con:method></con:resource></con:interface><con:testSuite name="Regression Suite - NLM Service - Schema Rules"><con:description>TestSuite generated for REST Service [NLM Transform - Java Service]</con:description><con:settings/><con:runType>PARALLELL</con:runType><con:testCase failOnError="false" failTestCaseOnErrors="true" keepSession="false" maxResults="0" name="/rest/api/validate TestCase" searchProperties="true" id="b1bcaf62-8d79-499c-8633-5f9ff94cfe76" timeout="0" wsrmEnabled="false" wsrmVersion="1.0" wsrmAckTo="" amfAuthorisation="false" amfEndpoint="" amfLogin="" amfPassword=""><con:description>TestCase generated for REST Resource [/rest/api/validate] located at [/rest/api/validate]</con:description><con:settings/><con:testStep type="restrequest" name="Valid XML"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="Valid XML" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:encoding>UTF-8</con:encoding><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="qa">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">stemcells</journal-id>
         <journal-title-group>
            <journal-title>Nature Reports Stem Cells</journal-title>
         </journal-title-group>
         <issn pub-type="epub">1754-8705</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">stemcells.2009.75</article-id>
         <article-id pub-id-type="doi">10.1038/stemcells.2009.75</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>qa</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Elaine Fuchs: more secrets of skin renewal</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>14</day>
            <month>05</month>
            <year>2009</year>
         </pub-date>
         <permissions>
            <copyright-year>2009</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p><ext-link ext-link-type="uri" xlink:href="http://www.rockefeller.edu/research/abstract.php?id=42">Elaine Fuchs</ext-link> of Rockefeller University in New York City studies how stem cells in the skin maintain their orderly but complicated cycle of skin renewal, how they adjust so effectively to heal wounds and what goes wrong in disease.</p>
      <list list-content="interview">
         <list-item>
            <list list-content="question"><list-item>
                  <p>Possible to have two paras in question - so adding this in for illustration purposes.</p>
                  <p>If you could list only five markers or transcription factors that people who study skin stem cells really need to know, what would they be?</p>
            </list-item></list>
            <list list-content="answer">
               <list-item><p>Key factors for the hair follicle stem cells are Sox9, Tcf3, K15, CD34 and Lgr5. Key markers that encompass epidermal and hair follicle stem cells are p63, K14 and K5, but these proteins are expressed by all keratinocytes with proliferative capacity, irrespective of whether they are stem cells or transit amplifying cells.</p></list-item>
            </list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>One thing you've done a lot of is marking and following cells. How do you decide what labels to use?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>There is no crystal ball as to how to accomplish this, as you always run the risk of altering the biology of the protein. You just have to do the controls to test for preservation of protein function. Let me offer a few examples:</p>
               <p>If we just want to look at Sox9 expression, but only in cells that express Sox9, then we would engineer the Sox9 locus to express GFP [green fluorescent protein] under the control of the Sox9 promoter, so that GFP expression will be exclusive to the cells that express endogenous Sox9. Here it would be important to use a short-lived GFP, such that the minute the cell switches off endogenous Sox9 expression, you'll lose GFP protein.</p>
               <p>If you want to follow what happens to progeny of Sox9-expressing cells, then you want to first engineer a gene encoding Cre-lox recombinase driven by a Sox9 promoter. Then, mate this mouse to another mouse harbouring a gene containing a constitutively active promoter followed by a stop codon that's flanked by lox recombinant sites and then [a] GFP coding sequence. In that way, whenever the cells express Sox9 they activate the recombinase, the recombinase removes the stop codon and those cells start expressing GFP. Then all the progeny will always be marked by GFP, because from this point onward, GFP expression is regulated by a constitutively active promoter.</p>
               <p>And then if you control the timing of when cells express the Cre (using [a] progesterone or tamoxifen inducible system), you can choose when to start marking and following the GFP-expressing progeny that came from cells that express Sox9.</p>
            </list-item></list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>I wanted to talk to you about the orientation of skin cell division. It seems like in the embryo, skin cells are dividing out to cover the embryo, whereas in the adult skin, cells are dividing up to be shed from the surface. What are the big questions in understanding this transition?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>One surprising finding for us really built off an observation made many years back when I was still at the University of Chicago. We noticed that the plane of the spindle orientation undergoes a quite dramatic change during embryonic development, where it goes from being parallel to the basement membrane to [being] perpendicular. We now have some insights on the molecular features that enable the epithelium to undergo these changes in the division plane.</p>
               <p>A simple epithelium doesn't have to think about this &#x2014; it's always dividing parallel to the basement layer. But if you're going to have a stratified epithelium, organized in layers, there has to be some mechanism that allows this stratification. When embryonic epidermal cells divide asymmetrically relative to the basement membrane, they do so by sensing polarity cues. Genetics has told us that flies use a set of evolutionarily conserved proteins to polarize divisions in the neuroblasts and produce divisions that yield one undifferentiated daughter and one daughter committed to make a neuron. We've found that this group of proteins is there at the right place in time to play a similar role in orienting divisions in the skin epithelium, perhaps to generate one proliferative daughter and one daughter committed to stratify and terminally differentiate. What's interesting about the skin is that the epidermis doesn't restrict divisions to be exclusively symmetric or asymmetric. It does <italic>both</italic>. When and how the skin controls these division choices will be interesting to decipher in the future.</p>
            </list-item></list>
         </list-item>
      </list>
      <p>Editor's note: These are some more specialized questions than the ones discussed in a broader interview.</p>
   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="XML with DTD Errors"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="XML with DTD Errors" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:encoding>UTF-8</con:encoding><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="tmech" xmlns:xlink="http://www.w3.org/1999/xlink">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">scibx</journal-id>
            <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
            <issn pub-type="ppub">1945-3477</issn>
            <issn pub-type="epub">1945-3477</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.1038/scibx.2008.1091</article-id>
            <article-id pub-id-type="publisher-id">scibx.2008.1091</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject content-type="article-type">tmech</subject>
                </subj-group>
                <subj-group subj-group-type="subjects">
                    <subject content-type="subject">scibx-11</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Cancer's fuel duel</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Haas</surname>
                        <given-names>Michael J</given-names>
                    </name>
                    <role>Senior Writer</role>
                </contrib>
            </contrib-group>
            <pub-date pub-type="issue-date">
                <day>18</day>
                <month>12</month>
                <year>2008</year>
            </pub-date>
            <volume>1</volume>
            <issue>45</issue>
            <fpage>1</fpage>
            <lpage>4</lpage>
            <permissions><copyright-year>2008</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
            <related-article related-article-type="see-also" xlink:href="scibx.2008.1069" ext-link-type="article-id"/>
            <related-article related-article-type="see-also" xlink:href="scibx.2008.1096" ext-link-type="article-id"/>
            <abstract abstract-type="editor">
                <p>Belgian and U.S. researchers have elucidated a symbiosis between hypoxic and oxygenated tumor cells that could be harnessed to kill the former cell type by targeting a <underline>lactate transporter</underline> on the latter type. If a suitable inhibitor of the transporter is identified, it could complement existing therapies.</p>
            </abstract>
            <custom-meta-group>
                <custom-meta specific-use="change">
                    <meta-name>erratum</meta-name>
                    <meta-value>
                        <named-content content-type="date-of-change">2009-02-12</named-content>
                        <named-content content-type="change">In the version of the supplementary information for this article originally posted online, the descriptions of Supplementary Videos 1—6 were incorrect. The errors have been corrected as of 27 January 2009.</named-content>
                    </meta-value>
                </custom-meta>
                <custom-meta specific-use="change">
                    <meta-name>correctn</meta-name>
                    <meta-value>
                        <named-content content-type="person-given-names">Sarada</named-content>
                        <named-content content-type="person-surname">Callison</named-content>
                        <named-content content-type="date-of-change">2006-05-08</named-content>
                        <named-content content-type="location">acknowledgments</named-content>
                        <named-content content-type="change">added note to HTML; replaced PDF</named-content>
                        <named-content content-type="reason">In the version of this article initially published, a funding source was omitted. The following statement should be added to the end of the Acknowledgments section: "D.A. Bosco is grateful to the National Institutes of Health for a postdoctoral fellowship. We thank the National Institutes of Health (NS050636), the Skaggs Institute for Chemical Biology and the Lita Annenberg Hazen Foundation for financial support." The error has been corrected in the PDF version of the article.</named-content>
                    </meta-value>
                </custom-meta>
            </custom-meta-group>
        </article-meta>
    </front>
    <body>
        <p>A team of Belgian and U.S. researchers has demonstrated that hypoxic tumor cells can be killed by targeting solute carrier family 16, member 1 (monocarboxylic acid transporter 1), a membrane lactate transporter protein expressed on oxygenated tumor cells. The approach should mesh well with existing chemo- and radiotherapies, and systemic inhibition of the transporter is not likely to have severe side effects.</p>
        <p>For more than 50 years it has been known that the tumor microenvironment consists of two distinct compartments—the oxygenated compartment, which is located near tumor blood vessels, and the hypoxic compartment, which is typically located near the tumor core. Hypoxic tumor cells are difficult to target with conventional chemo- and radiotherapies because of their low-oxygen environment and distance from blood vessels.<disp-quote id="pq1"><p>“What's clever about MCT1 inhibition is that it targets the oxygenated tumor compartment, but its effect is on the hypoxic one.”</p><address><institution>Threshold Pharmaceuticals Inc.</institution></address><attrib>Charles Hart</attrib></disp-quote>
        </p>
        
        <p>Tumor hypoxia is associated with progression to malignancy and cancer relapse—making hypoxic tumor cells important, if elusive, drug targets.</p>
        <p>The relationship between tumor compartments was previously thought to be strictly one way: oxygenated cells used most of the available oxygen to produce energy from glucose, leaving hypoxic cells to produce most of their energy via anaerobic fermentation, releasing lactate as a by-product.</p>
        <p>In a paper in the <italic>Journal of Clinical Investigation</italic>, however, researchers demonstrated that the relationship is symbiotic and that the symbiosis can be exploited therapeutically.<xref ref-type="bibr" rid="b1"/></p>
        <sec>
            <title>Fuel service</title>
            <p>First, the team found that oxygenated human cervical squamous carcinoma cells could metabolize exogenous lactate. This led to the hypothesis that lactate released by hypoxic cells—conventionally viewed as a waste product—could actually fuel oxygenated tumor cells.</p>
            <p>To confirm this, the team injected mice bearing squamous cervical carcinoma xenografts with <sup>13</sup>C-labeled lactate, then excised the tumors 30 minutes later. NMR experiments in extracts from those tumors detected <sup>13</sup>C-labeled glutamate, a lactate metabolite, which demonstrated that oxygenated tumor cells could indeed take up and metabolize lactate.</p>
            <p>Next, the team used either RNAi or α-cyano-4-<sc>L</sc>-hydroxycinnamate, a commercially available selective solute carrier family 16, member 1 (monocarboxylic acid transporter 1) (SLC16A1; MCT1) inhibitor, to block MCT1 activity in squamous cervical carcinoma cell cultures. MCT1 is a membrane protein that mediates lactate uptake in human muscle cells during intense exercise.</p>
            <p>Both methods of MCT1 inhibition completely blocked the uptake of lactate by the cancer cells.</p>
            <p>Moreover, the lactate blockade caused the cells to switch from a balance between lactate metabolism and glycolysis to only glycolysis for energy production. This result led the team to hypothesize that forcing oxygenated cells to switch to glycolysis only <italic>in vivo</italic> might in turn cut off the glucose supply to hypoxic cells.</p>
            <p>In mouse models of lung and colorectal cancer, inhibition of MCT1 with α-cyano-4-<sc>L</sc>-hydroxycinnamate slowed tumor growth by inducing the same glycolytic switch in oxygenated tumor cells, which indeed had the added benefit of depriving hypoxic cells of glucose and killing them.</p>
            <p>Moreover, a combination of α-cyano-4-<sc>L</sc>-hydroxycinnamate treatment and radiation had a synergistic effect on decreasing tumor growth compared with using either treatment alone.</p>
            <p>Lastly, the team confirmed that MCT1 is expressed in the oxygenated compartments of a range of human cancers, including breast, head and neck, colorectal, lung and neuroblastoma tumors. This suggests that the combination of MCT1 inhibition and radiation could have broad clinical applications, said Pierre Sonveaux, an associate professor of pharmacology and therapeutics at the <ext-link xlink:href="http://www.uclouvain.be/"><bold>Université Catholique de Louvain</bold></ext-link> (UCL) and lead author on the <italic>JCI</italic> paper.</p>
            <p>The research team was led by Olivier Feron, associate professor of pharmacology and therapeutics at UCL, and Mark Dewhirst, professor of radiation oncology and pathology and biomedical engineering at <ext-link xlink:href="http://medschool.duke.edu/"><bold>Duke University Medical Center</bold></ext-link>.</p></sec>
        <sec>
            <title>Compartmentalized strategy</title>
            <p>Companies contacted by <italic>SciBX</italic> agreed that MCT1 inhibition could be a potent addition to combination therapy, but they wanted to know more about the potential side effects on muscles and neurons.</p>
            <p>Charles Hart, VP of biology at <ext-link xlink:href="http://www.biocentury.com/companies/Threshold_Pharmaceuticals_Inc?utm_source=1"><bold>Threshold Pharmaceuticals Inc.</bold></ext-link>, said the elucidation of a two-way, symbiotic interaction between tumor compartments was “a revolutionary, paradigm-shifting idea” that could lead researchers to think about cancer differently.</p>
            <p>Although lactate transport between hypoxic and oxygenated cells in muscle tissue is well characterized, no one had thought to apply that mechanism to the tumor microenvironment—as the <italic>JCI</italic> authors did—to find out whether the oxygenated compartment was using lactate to fuel growth and proliferation, he said.</p>
            <p>Instead, Hart said researchers were interested in how cancer cells responded to the acidifying environment that lactate caused, and sought to take advantage of that acidic environment, for example by developing compounds that were highly membrane-permeable under acidic conditions.</p>
            <p>“What's clever about MCT1 inhibition is that it targets the oxygenated tumor compartment, but its effect is on the hypoxic one,” said Hart. Thus an MCT1 inhibitor could work well in combination with a therapy that targeted either the oxygenated or hypoxic compartment, he said.</p>
            <p>But Hart added that the timing of dosing would be important: an MCT1 inhibitor would have to be given before any drug that was cytotoxic to oxygenated cells. Otherwise, the cytotoxic molecule could kill off the oxygenated cells before the MCT1 inhibitor could target them and kill hypoxic cells via glucose deprivation.</p>
            <p>Hart said an MCT1 inhibitor should also combine well with other agents that selectively target the hypoxic compartment.</p>
            <p>Threshold's TH-302 is a hypoxia-activated cytotoxic prodrug. It is in Phase I/II trials to treat soft tissue sarcoma, solid tumors, non–small cell lung cancer (NSCLC) and pancreatic and prostate cancers.</p>
            <p>Emma Shtivelman, director of cancer research at <ext-link xlink:href="http://www.biocentury.com/companies/BioNovo_Inc?utm_source=1"><bold>BioNovo Inc.</bold></ext-link>, said the <italic>JCI</italic> paper highlighted “a peculiarity of tumor cell biology” that suggested a new approach to treating cancer. “MCT1 is clearly a novel target whose inhibition could not only affect the ability of some tumor cells to take up lactate, but also disrupt glycolysis in other cells present in the same tumor,” she said.</p>
            <p>Shtivelman added that “the strategy of MCT1 inhibition is clearly complementary to the strategies targeting glycolysis in tumors,” whether with glycolytic inhibitors such as 2-deoxyglucose or compounds that target enzymes in the glycolytic pathway.<xref ref-type="bibr" rid="b2"/><disp-quote id="pq2"><p>“The strategy of MCT1 inhibition is clearly complementary to the strategies targeting glycolysis in tumors.”</p><address><institution>BioNovo Inc.</institution></address><attrib>Emma Shtivelman</attrib></disp-quote></p>
            <p>One potential strategy would be to give an MCT1 inhibitor to switch oxygenated tumor cells to glycolysis, then use a selective inhibitor of glycolysis to kill both the oxygenated and hypoxic cells, Shtivelman said.</p>
            <p>BioNovo's BZL101 is an aqueous extract from the herb <italic>Scutellaria barbata</italic> “D. Don” of the Lamiaceae family that inhibits glycolysis and selectively induces cell death in tumors. The compound is in a Phase II trial to treat advanced breast cancer and has completed a Phase I trial in pancreatic cancer.</p></sec>
        <sec>
            <title>Lactate on the mind (and muscle)</title>
            <p>Going forward, Threshold's Hart thought the <italic>JCI</italic> paper provided sufficient proof of concept that MCT1 is a viable drug target—assuming that additional experiments demonstrated no major adverse effects on healthy cells.</p>
            <p>Shtivelman said the safety issue needs to be probed, because one potential drawback to MCT1 inhibition is that at least two types of normal tissues—skeletal white muscle and red muscle—can rely on lactate oxidation for energy production. She added that lactate has also been shown to play a role in the metabolic interactions between neurons and glia.<xref ref-type="bibr" rid="b3"/></p>
            <p>Indeed, a paper in <italic>Nature Cell Biology</italic> by researchers at the <ext-link xlink:href="http://www.unc.edu/"><bold>University of North Carolina at Chapel Hill</bold></ext-link> has elucidated a role for glycolysis in the antiapoptotic mechanisms of both cancer cells and healthy neurons (<italic>see</italic> <bold><xref ref-type="boxed-text" rid="bx1">Box 1</xref></bold><bold>, “Un-reducing apoptosis”</bold>).<xref ref-type="bibr" rid="b4"/></p>
            <p>Thus, Shtivelman said, the combination of an inhibitor of lactate uptake or oxidation, plus a glycolysis inhibitor, could have dangerous effects on muscle and neuronal tissues.</p>
            <p>UCL's Sonveaux disagreed that MCT1 inhibition could have serious toxic effects. He said MCT1 has a lower affinity for lactate than other MCTs found in healthy tissues.</p>
            <p>“This means that MCT1 exerts a physiological role only when the other transporters are saturated—as it is the case, for example, during intensive exercise” or recovery from ischemic injuries, Sonveaux said.
                <disp-quote id="pq3"><p>“MCT1 exerts a physiological role only when the other transporters are saturated.”</p><address><institution>Université Catholique de Louvain</institution></address><attrib>Pierre Sonveaux</attrib></disp-quote></p>
            <p>Sonveaux also noted that patients with exercise intolerance due to ubiquitous <italic>MCT1</italic> deletion have no symptoms while at rest. “These patients experience muscle cramps only during <italic>intensive</italic> exercise, and the symptoms are reversible,” he said.</p>
            <p>Similarly, he noted that whereas both MCT1 and MCT2 can facilitate lactate transport in neurons, MCT2 has the higher lactate affinity of the two, suggesting that the effects of MCT1 inhibition on neurons might be limited to transient lethargy.</p>
            <p>Finally, Sonveaux said the team that published the <italic>JCI</italic> paper observed no pathological symptoms or gross behavioral changes in mice given α-cyano-4-hydroxycinnamate.</p></sec>
        <sec>
            <title>Fuel speed ahead</title>
            <p>Sonveaux added that other known MCT1 inhibitors have off-target effects due to poor selectivity for MCT1. But despite its selectivity for MCT1, Sonveaux said α-cyano-4-hydroxycinnamate was not a drug candidate because it is poorly soluble in water. The team is collaborating with chemists to develop more drug-like analogs, he said.</p>
            <p>The team is also designing high throughput screens to identify new MCT1 inhibitors.</p>
            <p>Sonveaux and Feron declined to disclose the IP status of their findings. Sonveaux did say the team was seeking to collaborate with at least two undisclosed companies that already have MCT1 inhibitors in discovery for noncancer indications.</p>
            <p>Meanwhile, Dewhirst and colleagues at Duke Medical Center have found genetic correlations between the <italic>in vitro</italic> responses of cancer cells to lactate accumulation and clinical outcomes <italic>in vivo</italic>.</p>
            <p>In a report in <italic>PLoS Genetics</italic>, the Duke team showed that human mammary epithelial cells can respond to the accumulation of extracellular lactate (lactic acidosis) by shutting down glycolysis—a negative-feedback loop that minimized the extent of glycolysis and hypoxia in those tumors.<xref ref-type="bibr" rid="b5"/></p>
            <p>The genetic markers associated with a strong response to lactic acidosis were also associated with positive clinical outcomes in breast cancer patients. This led the team to write that those genetic markers could be prognostic indicators for breast and possibly other cancers.</p>
            <p>The findings could lead to new therapeutic strategies to treat cancer, according to Jen-Tsan Ashley Chi, leader of the <italic>PLoS</italic> research team and assistant professor of molecular genetics and microbiology at Duke University Medical Center.</p>
            <p>“The cancer cell has a way of sensing the pH outside itself and adjusting its lactate production accordingly,” he said.</p>
            <p>The group is investigating the molecular and transcriptional mechanisms by which the cell accomplishes this balancing act.</p>
            <p>A small molecule that triggered the same response to lactic acidosis—even in the absence of extracellular lactate—could be one possible therapeutic application of those ongoing studies, said Chi.</p>
            <p>Coauthor Dewhirst said the findings reported in <italic>PLoS Genetics</italic> are not patented.</p></sec>
        <sec>
            <title>Companies and institutions mentioned</title>
            <p><list id="l1">
                <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/BioNovo_Inc?utm_source=1"><bold>BioNovo Inc.</bold></ext-link> (NASDAQ:BNVI), Emeryville, Calif.</p></list-item>
                <list-item><p><ext-link xlink:href="http://medschool.duke.edu/"><bold>Duke University Medical Center</bold></ext-link>, Durham, N.C.</p></list-item>
                <list-item><p><ext-link xlink:href="http://www.ethz.ch/index_EN"><bold>Swiss Federal Institute of Technology</bold></ext-link>, Zurich, Switzerland</p></list-item>
                <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Threshold_Pharmaceuticals_Inc?utm_source=1"><bold>Threshold Pharmaceuticals Inc.</bold></ext-link> (NASDAQ:THLD), Redwood City, Calif.</p></list-item>
                <list-item><p><ext-link xlink:href="http://www.uclouvain.be/"><bold>Université Catholique de Louvain</bold></ext-link>, Brussels, Belgium</p></list-item>
                <list-item><p><ext-link xlink:href="http://www.unc.edu/"><bold>University of North Carolina at Chapel Hill</bold></ext-link>, Chapel Hill, N.C.</p></list-item>
                <list-item><p><ext-link xlink:href="http://www.uzh.ch/"><bold>University of Zurich</bold></ext-link>, Zurich, Switzerland</p></list-item></list></p></sec>
    </body>
    <back>
        <ref-list>
            <title>References</title>
            <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
                <name><surname>Sonveaux</surname><given-names>P</given-names></name>
                <etal/>
                <source>J. Clin. Invest.</source><year>2008</year><month>11</month><day>20</day>
                <elocation-id content-type="doi">10.1172/JCI36843</elocation-id>
                <named-content content-type="contact">Pierre Sonveaux, Université Catholique de Louvain, Brussels, Belgium <email>pierre.sonveaux@uclouvain.be</email></named-content>
            </element-citation></ref>
            <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
                <name><surname>Pelicano</surname><given-names>H.</given-names></name> <etal/>
                <source>Oncogene</source> <volume>25</volume><fpage>4633</fpage><lpage>4646</lpage><year>2006</year>
            </element-citation></ref>
            <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
                <name><surname>Hashimoto</surname><given-names>T.</given-names></name> <etal/>
                <source>PLoS One</source> <volume>3</volume><fpage>e2915</fpage><year>2008</year><month>11</month><day>23</day>
                <elocation-id content-type="doi">10.1371/journal.pone.0002915</elocation-id>
            </element-citation></ref>
            <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
                <name><surname>Vaughn</surname><given-names>A.</given-names></name><name><surname>Deshmukh</surname><given-names>M.</given-names></name>
                <source>Nat. Cell Biol.</source><year>2008</year><month>11</month><day>23</day>
                <elocation-id content-type="doi">10.1038/ncb1807</elocation-id>
                <named-content content-type="contact">Mohanish Deshmukh, University of North Carolina at Chapel Hill, Chapel Hill, N.C. <email>mohanish@med.unc.edu</email></named-content>
            </element-citation></ref>
            <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
                <name><surname>Chen</surname><given-names>J.L.-Y.</given-names></name> <etal/>
                <source>PLoS Genet.</source> <volume>4</volume><fpage>e1000293</fpage><year>2008</year><month>12</month><day>5</day>
                <elocation-id content-type="doi">10.1371/journal.pgen.1000293</elocation-id>
            </element-citation></ref>
            <ref id="b6"><element-citation xlink:role="original-article" publication-type="webpage">
                <collab>U.S. Food and Drug Administration</collab>
                <source>Notice of solicitation for the sequencing quality control project.</source>
                <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-N-0644-n.pdf">http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-N-0644-n.pdf</ext-link>
            </element-citation></ref>
            <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
                <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
                <person-group person-group-type="editor">
                    <name><surname>Leitner</surname><given-names>T</given-names></name>
                    <etal/>
                </person-group>
                <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
                <year>2005</year>
                <publisher-name>Los Alamos National Laboratory</publisher-name>
                <publisher-loc>Los Alamos, N.M.</publisher-loc>
                <elocation-id content-type="doi"/>
            </element-citation></ref>
        </ref-list>
        <boxed-text id="bx1">
            <caption><title>Un-reducing apoptosis.</title></caption>
            <p>Both cancer cells and healthy neurons outlive other normal cells by deregulating mechanisms of mitochondrial apoptosis, a key step of which is the release of the molecule cytochrome <italic>c</italic>, somatic (CYCS) from the mitochondrial membrane in response to apoptotic stimuli such as DNA damage and reactive oxygen species. Both cell types also rely heavily on glycolysis for energy, but how that process plays a role in antiapoptosis has been unknown.</p>
            <p>Researchers at the <ext-link xlink:href="http://www.unc.edu/"><bold>University of North Carolina at Chapel Hill</bold></ext-link> (UNC) have now shown that glycolysis in cancer cells and neurons keeps CYCS in a reduced state, thereby preventing the protein from activating proapoptotic pathways. Based on the findings, the researchers suggested that both neurodegeneration and cancer could be treated by modulating the redox state of CYCS.<xref ref-type="bibr" rid="b4"/></p>
            <p>To investigate the connection between glycolysis and antiapoptosis, the UNC group treated human cervical cancer cells, rat hepatocellular carcinoma cells and mouse embryonic fibroblasts with either hydrogen peroxide to raise the oxidation level of the cells or glutathione to lower the oxidation level. Cells treated with peroxide were more susceptible to CYCS-mediated apoptosis than cells treated with glutathione, indicating that CYCS requires an oxidizing environment to induce cell death.</p>
            <p>Inhibition of the pentose phosphate pathway—by which glycolysis leads to glutathione production—also increased the oxidation state of the cancer cells and made them more susceptible to CYCS-mediated apoptosis.</p>
            <p>Similarly, raising the oxidation level of healthy mouse neurons by treating them with peroxide or inhibiting the pentose phosphate pathway also promoted CYCS-mediated apoptosis.</p>
            <p>“Our results suggest that forcing cancer cells to be in an oxidizing environment would make them more susceptible to apoptosis induced by cytochrome <italic>c</italic> release from the mitochondria,” thereby increasing the effectiveness of chemotherapy, Mohanish Deshmukh told <italic>SciBX.</italic> This could be accomplished by inhibiting the pentose phosphate pathway to block glutathione synthesis or by directly delivering oxidized CYCS or CYCS mimetics to the tumors, he said.</p>
            <p>Deshmukh, an associate professor of cell and developmental biology at UNC, was an author on the <italic>Nature Cell Biology</italic> paper that described the results.</p>
            <p>Conversely, Deshmukh said blocking oxidation of CYCS in neurons might be a strategy to treat neurodegenerative disorders, such as Parkinson's disease (PD), in which the accumulation of reactive oxygen species and oxidized proteins play a role. “Antioxidants could restrict the apoptotic pathway to spare a neuron's life,” he said.</p>
            <p>“The results are indeed very intriguing, and the link between neuronal glucose metabolism and cancer cell metabolism is appealing,” said Nicolai Savaskan, a research group leader at the <ext-link xlink:href="http://www.uzh.ch/"><bold>University of Zurich</bold></ext-link>'s Institute of Brain Research.</p>
            <p>But before the <italic>Nature Cell Biology</italic> findings could be translated into cancer therapeutics, Savaskan said, more work is needed to understand how increasing the oxidation levels of normal cells—thereby generating more reactive oxygen species in those cells—would affect their survival.</p>
            <p>Savaskan is also a research group leader at the <ext-link xlink:href="http://www.ethz.ch/index_EN"><bold>Swiss Federal Institute of Technology</bold></ext-link>.</p>
            <p>Deshmukh said his group has already uncovered some differences between the apoptotic pathways of normal cells and cancer cells. He cited a paper the team published last year in the <italic>Proceedings of the National Academy of Sciences</italic>, showing that the direct injection of excess CYCS induced apoptosis in brain tumor cells but not healthy neurons.<xref ref-type="bibr" rid="b6"/></p>
            <p>“This opens the possibility of using cytochrome <italic>c</italic> itself as a drug” to treat brain tumors, Deshmukh said. To that end, his group is looking at nanoparticles to deliver CYCS into cells and screening for small molecule mimetics of CYCS.</p>
            <p>The group is also looking for other metabolic pathways and molecular mechanisms that are common to both cancer cells and neurons, he said.</p>
            <p>Deshmukh said the findings reported in <italic>Nature Cell Biology</italic> are not patented.</p>
            <attrib specific-use="byline"><italic>—MJH</italic></attrib>
        </boxed-text>
    </back>
    
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="207" validatedBy="DTD" type="error" column="12">The content of element type "back" must match "(label?,title*,(ack|app-group|bio|fn-group|glossary|ref-list|notes|sec)*)".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="XML with Schematron Errors"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="XML with Schematron Errors" mediaType="application/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id>scibx</journal-id>
        <journal-title-group>
            <journal-title>Science-Business eXchange</journal-title>
            <journal-subtitle>a journal</journal-subtitle>
            <trans-title-group xml:lang="de"><trans-title>Wissenschaft und Wirtschaft</trans-title></trans-title-group>
        </journal-title-group>
        <issn pub-type="pub">1945-3477</issn>
        <issn pub-type="epub">195-3477</issn>
        <isbn>0 784 99923 1</isbn>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="publisher-id">scibx.test</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject>csrory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
                <subject content-type="npg.subject">
                    <named-content content-type="id">693</named-content>
                    <named-content content-type="version">1.0</named-content>
                    <named-content content-type="path">/631/693</named-content>
                </subject>
                <subject content-type="npg.subject">
                    <named-content content-type="id">41</named-content>
                    <named-content content-type="version">1.0</named-content>
                    <named-content content-type="path">/631/701/41</named-content>
                </subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date>
            <day>29</day>
            <month>02</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>201O</copyright-year><copyright-holder>Macmillan</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
<kwd>PPARG</kwd>
<kwd>PPAR<sub>&#x3B3;</sub></kwd>
<kwd>insulin</kwd>
<kwd>INT131</kwd>
<kwd>Avandia  rosiglitazone</kwd>
<kwd>Actos pioglitazone</kwd>
<kwd>thiazolidinedione</kwd>
<kwd>TZD</kwd>
<kwd>cyclin dependent kinase 5</kwd>
<kwd>CDK<sup>5</sup></kwd>
<kwd>adiponectin</kwd>
<kwd>glucose</kwd>
<kwd>MBX-102</kwd>
<kwd>Balaglitazone</kwd>
<kwd>DRF 2593</kwd>
<kwd>Dana-Farber Cancer Institute</kwd>
<kwd>GlaxoSmithKline plc</kwd>
<kwd>Harvard Medical School</kwd>
<kwd>InteKrin Therapeutics Inc.</kwd>
<kwd>Metabolex Inc.</kwd>
<kwd>Scripps Florida</kwd>
<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
<p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
<p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
<p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
<p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
<p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
<p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
<p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
<p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
<p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
<p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
<p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
<p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
<sec>
<title>Agonizing over mechanism</title>
<p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
<p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
<p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
<p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
<p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
<p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
<p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
<p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
<p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
<sec>
<title>PPARanoia</title>
<p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
<p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
<p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
<p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
<p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
<p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
<p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
<sec>
<title>Companies and institutions mentioned</title>
<p><list id="l1">
<list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
<list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
<list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
<list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
<list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
<list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
<list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/>
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/>
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/>
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/>
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/>
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="6" validatedBy="schematron" column="21" location="/article[1]/front[1]/journal-meta[1]/journal-id[1]" id="jmeta1">The "journal-id" element should have attribute: journal-id-type="publisher".</message>
  <message line="12" validatedBy="schematron" column="30" location="/article[1]/front[1]/journal-meta[1]/issn[1]" id="jmeta5a">ISSN should have attribute pub-type="ppub" for print or pub-type="epub" for electronic publication.</message>
  <message line="13" validatedBy="schematron" column="31" location="/article[1]/front[1]/journal-meta[1]/issn[2]" id="jmeta5b">Unexpected ISSN value for Science-Business eXchange (195-3477)</message>
  <message line="5" validatedBy="schematron" column="19" location="/article[1]/front[1]/journal-meta[1]" id="jmeta7a">Journal metadata should include a "publisher" element.</message>
  <message line="16" validatedBy="schematron" column="19" location="/article[1]/front[1]/article-meta[1]" id="ameta1a">Article metadata should contain at least two "article-id" elements, one with attribute pub-id-type="doi" and one with attribute pub-id-type="publisher-id".</message>
  <message line="18" validatedBy="schematron" column="29" location="/article[1]/front[1]/article-meta[1]/article-categories[1]" id="ameta2b">Subject catgory (csrory) does not match root article type (cstory)</message>
  <message line="51" validatedBy="schematron" column="19" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate0a">"pub-date" element should have attribute "pub-type" declared. Allowed values are: issue-date, aop, collection, epub, epreprint and embargo. Please check with NPG Editorial Production.</message>
  <message line="51" validatedBy="schematron" column="19" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate2">Invalid publication date - the day value (29) does not exist for the month (02) in the year (2010).</message>
  <message line="58" validatedBy="schematron" column="38" location="/article[1]/front[1]/article-meta[1]/permissions[1]/copyright-year[1]" id="copy2">Invalid year value for copyright: 201O. It should be a 4-digit number starting with 19 or 20.</message>
  <message line="58" validatedBy="schematron" column="77" location="/article[1]/front[1]/article-meta[1]/permissions[1]/copyright-holder[1]" id="copy3">The copyright-holder for Science-Business eXchange should be: Nature Publishing Group</message>
  <message line="108" validatedBy="schematron" column="6" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="119" validatedBy="schematron" column="6" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="128" validatedBy="schematron" column="6" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="18" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="9" validatedBy="schematron" column="31" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]/journal-subtitle[1]" id="jmeta4">Unexpected use of "journal-subtitle" in "journal-title-group".</message>
  <message line="10" validatedBy="schematron" column="46" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]/trans-title-group[1]" id="jmeta4">Unexpected use of "trans-title-group" in "journal-title-group".</message>
  <message line="14" validatedBy="schematron" column="15" location="/article[1]/front[1]/journal-meta[1]/isbn[1]" id="jmeta6">Do not use the ISBN element in journal metadata.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="XML with DTD and Schematron Errors"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="XML with DTD and Schematron Errors" mediaType="application/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2009.1491</article-id>
        <article-id pub-id-type="publisher-id">scibx.2009.1491</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-10</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>A gut feeling for CD39</article-title>
            <alt-title>Treating IBD with CD39</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Fulmer</surname>
                <given-names>Tim</given-names>
            </name>
                <role>Senior Writer</role>
            </contrib>
        </contrib-group>
        <pub-date>
            <day>15</day>
            <month>10</month>
            <year>2009</year>
        </pub-date>
        <volume>2</volume>
        <issue>40</issue>
        <permissions><copyright-year>20O9</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2009.1486" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>American and German researchers have reported that enhancing CD39 activity in the gut could help treat inflammatory bowel disease. The researchers are now developing a soluble form of CD39 that they hope could become an infusible therapeutic to treat colitis and Crohn's disease.</p>
        </abstract>
         <custom-meta-group>
            <custom-meta specific-use="change">
                <meta-name>corrigendum</meta-name>
                <meta-value>
                    <named-content content-type="date-of-change">2009-10-16</named-content>
                    <named-content content-type="change">IThe original role of CD39 in converting ATP to adenosine was misstated and has been changed.</named-content>
                </meta-value>
            </custom-meta>
        </custom-meta-group>
    </article-meta>
</front>
<body>
	<p>Researchers have reported that enhancing CD39 activity in the gut could trigger a T<sub>reg</sub>-mediated immunosuppressive response to help treat inflammatory bowel disease.<xref ref-type="bibr" rid="b1"/> The researchers are now developing a soluble form of CD39 that they hope could become an infusible therapeutic to treat colitis and Crohn's disease.</p>
	<p>Multiple signaling pathways underlie the immunosuppressive function of T<sub>regs</sub>. One of those pathways involves the T<sub>reg</sub>-mediated generation of extracellular adenosine, which binds its receptor on the surface of proinflammatory T cells and decreases their development and proliferation (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;Targeting CD39 in inflammatory bowel disease&#x201D;</bold>).<xref ref-type="bibr" rid="b2"/></p>
	<p>A team of researchers led by Simon Robson of the <ext-link xlink:href="http://www.bidmc.org/"><bold>Beth Israel Deaconess Medical Center</bold></ext-link> has been looking for ways to increase levels of extracellular adenosine at sites of inflammation to treat inflammation and autoimmune diseases. The group has focused on enhancing the activity of CD39, an enzyme on the surface of T<sub>regs</sub> involved in the conversion of ATP to adenosine.<xref ref-type="bibr" rid="b3"/></p>
	<p>Previous work by the group showed that genetic knockout of CD39 led to aberrant proliferation of proinflammatory T cells and failure to prevent allograft rejection in mice.<xref ref-type="bibr" rid="b4"/></p>
	<p>Now the researchers have extended those findings to autoimmune disease. In a mouse model of chemically-induced acute colitis, animals with <italic>Cd39</italic> knockout had greater disease severity than controls that had colitis and expressed <italic>Cd39</italic>. The knockouts showed increased infiltration of leukocytes and thickening of the colon wall.</p>
	<p>Next, the researchers attempted to reverse disease severity by administering soluble apyrase, an enzyme that has the same activity as CD39. Compared with controls, <italic>Cd39</italic> knockouts receiving the enzyme showed no significant weight loss (<italic>p</italic>&lt;0.05), a proxy for colitis severity.</p>
	<p>Finally, the group analyzed publicly available genomewide expression profiles of humans and identified a SNP (rs10748643) near the promoter of <italic>CD39</italic> that was strongly linked to CD39 levels. The low CD39&#x2013;expressing genotype was significantly associated with Crohn's patients, whereas healthy controls were enriched for the high CD39&#x2013;expressing allele (<italic>p</italic>=0.0006).</p>
	<p>Thus, in both mice and humans, low CD39 expression correlated with severity of gastrointestinal autoimmune disease. The findings were published in the <italic>Proceedings of the National Academy of Sciences</italic>.</p>
	<sec>
	<title>Ligand vs. receptor</title>
	<p>The short serum half-life of adenosine makes direct delivery of the compound problematic for chronic inflammatory conditions. However, approaches for triggering its anti-inflammatory effects could include directly activating the adenosine receptor using agonists or delivering soluble CD39 to increase local adenosine levels.</p>
	<p>At least one biotech is developing an agonist. But Robson, a professor of medicine at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and attending physician at Beth Israel, said his group wants to design a soluble form of CD39 for delivery to patients with inflammatory bowel disease (IBD).</p>
	<p>&#x201C;The rationale is that delivering CD39 to, or potentially boosting endogenous levels of CD39 in IBD patients will increase the local pool of extracellular adenosine and therefore have an immunosuppressive effect on pathogenic T cell populations,&#x201D; he said.</p>
	<p>However, one researcher pointed out that increasing extracellular adenosine could activate all four types of adenosine receptors&#x2014;A<sub>1</sub> (ADORA<sub>1</sub>), A<sub>2A</sub> (ADORA<sub>2A</sub>), A<sub>2B</sub> (ADORA<sub>2B</sub>) and A<sub>3</sub> (ADORA<sub>3</sub>)&#x2014;not all of which are known to generate an immunosuppressive response.</p>
	<p>&#x201C;Given that the A<sub>2A</sub> and A<sub>2B</sub> receptors are primarily responsible for mediating adenosine's immunosuppressive effects, there's concern the additional activation of A<sub>1</sub> and A<sub>3</sub> could trigger unwanted side effects in tissues expressing those receptors,&#x201D; said Peter Ernst, professor of medicine at the <ext-link xlink:href="http://www.virginia.edu/"><bold>University of Virginia</bold></ext-link>. Even the ADORA<sub>2A</sub> and ADORA<sub>2B</sub> subtypes could mediate unwanted side effects at some ligand concentrations, he added.</p>
	<p>Indeed, the desire to avoid activation of adenosine receptors not involved in immunosuppression is part of the rationale behind the design of agonists that selectively activate a single receptor, in particular ADORA<sub>2A</sub>.</p>
	<p>Ernst and his colleague at Virginia, Joel Linden, have separately shown that a selective agonist of ADORA<sub>2A</sub> reduced tissue damage in multiple mouse models of IBD.<xref ref-type="bibr" rid="b5 b6"/></p>
	<p>PGxHealth, a division of <ext-link xlink:href="http://www.biocentury.com/companies/Clinical_Data_Inc?utm_source=1"><bold>Clinical Data Inc.</bold></ext-link>, has opted to develop an agonist. The company's lead ADORA<sub>2A</sub> agonist, Stedivaze (ATL146e), is in Phase III testing as a coronary artery vasodilator for use with cardiac stress imaging. The company has also developed second-generation ADORA<sub>2A</sub> agonists for anti-inflammatory indications. Those agonists are in preclinical development, according to Jayson Rieger, VP of research at PGxHealth.</p>
	<p>To get a better idea of whether enhancing CD39 activity would have advantages over agonizing the adenosine receptor, Ernst suggested looking at genetically engineered animal models of IBD and colitis in addition to the chemically-induced model of acute colitis used in the paper. The former might better reflect the aberrant cytokine levels and T cell responses that characterize autoimmune disease.</p>
	<p>&#x201C;Animals in which autoimmunity is induced by knockout of anti-inflammatory cytokines like IL-10 or by adoptive transfer of pathogenic, proinflammatory T cells could offer better models of IBD and colitis than the model used in the paper,&#x201D; he said.</p>
	<p>Such animal studies might also help show whether the anti-inflammatory effects of some marketed IBD therapies are mediated by CD39 or by the production of adenosine, said Alan Moss, assistant professor of medicine at Harvard Medical School and director of translational research for the Center for Inflammatory Bowel Disease at Beth Israel.</p>
	<p>&#x201C;Looking at CD39 activity in biopsy samples and peripheral blood mononuclear cells from IBD patients would provide evidence for the relevance of CD39 to disease in humans,&#x201D; said Moss.</p>
	<p>Indeed, Robson told <italic>SciBX</italic> that he, Moss and other colleagues are planning to study the levels of CD39 and adenosine receptors in blood and tissue T cell populations from IBD patients receiving anti&#x2013;tumor necrosis factor (TNF) antibodies. That could provide insight into how the anti-inflammatory activity of anti-TNF antibodies is, at least in part, mediated by extracellular adenosine at sites of disease, he said.</p>
	<p>Robson said he and colleagues own patents and have patents pending that cover both the use of conjugated, soluble CD39 to treat autoimmune disorders and the creation and use of CD39 mutant animals. The IP is available for licensing.</p></sec>
	<sec>
	<title>Companies and institutions mentioned</title>
	<list id="l1">
	<list-item><p><ext-link xlink:href="http://www.bidmc.org/"><bold>Beth Israel Deaconess Medical Center</bold></ext-link>, Boston, Mass.</p></list-item>
	<list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Clinical_Data_Inc?utm_source=1"><bold>Clinical Data Inc.</bold></ext-link> (NASDAQ:CLDA), Newton, Mass.</p></list-item>
	<list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	<list-item><p><ext-link xlink:href="http://www.virginia.edu/"><bold>University of Virginia</bold></ext-link>, Charlottesville, Va.</p></list-item></list></sec>
</body>
<back>
    <ref-list>
		<title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Friedman</surname><given-names>D.</given-names></name>
            <etal/>
            <source>Proc. Natl. Acad. Sci. USA</source>
            <year>2009</year>
            <month>09</month>
            <day>29</day>
            <elocation-id content-type="doi">10.1073/pnas.0902869106</elocation-id>
            <named-content content-type="contact">Simon Robson, Beth Israel Deaconess Medical Center, Boston, Mass. <email>srobson@bidmc.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Hasko</surname><given-names>G.</given-names></name> <etal/> 
            <source>Nat. Rev. Drug Discov.</source><volume>7</volume><fpage>759</fpage><lpage>770</lpage>
            <year>2008</year>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Dwyer</surname><given-names>K.</given-names></name> <etal/> 
            <source>Purinergic Signal.</source>
            <volume>3</volume><fpage>171</fpage><lpage>180</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Deaglio</surname><given-names>S.</given-names></name> <etal/> 
            <source>J. Exp. Med.</source>
            <volume>204</volume><fpage>1257</fpage><lpage>1265</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Naganuma</surname><given-names>M.</given-names></name> <etal/> 
            <source>J. Immunol.</source>
            <volume>177</volume><fpage>2765</fpage><lpage>2769</lpage><year>2006</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Odashima</surname>, <given-names>M.</given-names></name> <etal/> 
            <source>Gastroenterol.</source>
            <volume>129</volume><fpage>26</fpage><lpage>33</lpage><year>2005</year>
        </element-citation></ref>
    </ref-list>
    </back>
    <floats-group>
	<fig id="f1" position="float">
        <caption>
            <title>Targeting CD39 in inflammatory bowel disease.</title>
            <p>Research published in the <italic>Proceedings of the National Academy of Sciences</italic> suggests that enhancing the activity of CD39, an enzyme expressed on the surface of T<sub>regs</sub>, could help treat inflammatory bowel disease (IBD).</p>
<p>Inflammation in the gut starts with dendritic cells (DCs) present at the mucosal epithelial layer of the lumen. These cells sense pathogenic bacteria and other antigens. Upon activation by pathogens, local DCs migrate to the lymph nodes to activate na&#xEF;ve T cells [<bold>a</bold>], which undergo differentiation into antigen-specific, proinflammatory effector T cells that fight infection in the lamina propria [<bold>b</bold>].</p>
<p>T<sub>regs</sub> help prevent excess activation of proinflammatory T cells such as T helper type 1 (Th1), Th2 and Th17 cells, and they do so, at least in part, by increasing levels of extracellular adenosine. Two enzymes expressed on the surface of T<sub>reg</sub> cells&#x2014;CD39 and CD73&#x2014;catalyze the formation of adenosine, which binds the adenosine A<sub>2A</sub> receptor (ADORA<sub>2A</sub>) on effector T cells and blocks their activation and proliferation [<bold>c</bold>].</p>
<p>Thus, enhancing levels of CD39 could offer an anti-inflammatory strategy for treating IBD. The authors of the <italic>PNAS</italic> study are developing a soluble form of CD39 to administer as a therapeutic. Meanwhile, biotechs are developing ADORA<sub>2A</sub> agonists that are predicted to have a similar anti-inflammatory effect for a variety of indications.</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2009.1491-F1.jpg" position="anchor"/>
        </alternatives>
    </fig>
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="10" validatedBy="DTD" type="error" column="20">The content of element type "journal-meta" must match "(journal-id+,journal-title-group*,issn+,isbn*,publisher?,notes?)".</message>
  <message line="125" validatedBy="DTD" type="error" column="84">The content of element type "name" must match "(surname,given-names?,prefix?,suffix?)".</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="NOt well formed XML"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="NOt well formed XML" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="dther"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2008.1098</article-id>
        <article-id pub-id-type="publisher-id">scibx.2008.1098</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">dther</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-12</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Cardiovascular disease</subject>
                <subject>fibrosis</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>MicroRNA-21 (miRNA-21)</article-title>
        </title-group>
        <pub-date>
            <day>18</day>
            <month>12</month>
            <year>2008</year>
        </pub-date>
        <volume>1</volume>
        <issue>45</issue>
        <permissions><copyright-year>2008</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <abstract abstract-type="editor">
            <p>Studies in mice suggest that antagonizing miRNA-21 could potentially lower cardiac fibrosis and treat cardiovascular disease.</p>
        </abstract>
         <custom-meta-group>
            <custom-meta specific-use="change">
                <meta-name>erratum</meta-name>
                <meta-value>
                    <named-content content-type="date-of-change">2009-02-13</named-content>
                    <named-content content-type="change">In the original version of this article, the information about Regulus Therapeutics LLC was omitted.</named-content>
                </meta-value>
            </custom-meta>
        </custom-meta-group>
   </article-meta>
</front>
<body>
    <sec>
		 <title>Summary</title>
		 <p>Studies in mice suggest that antagonizing miRNA-21 could potentially lower cardiac fibrosis and treat cardiovascular disease. Myocardial miRNA-21 was upregulated in three different mouse models of cardiac failure and in patients with end-stage heart failure compared with what was seen in healthy controls. An antagomir targeting miRNA-21 lowered cardiac fibrosis, cardiomyocyte size and heart weight and improved cardiac function in two different mouse models of cardiac failure compared with what was seen in mice that received saline control. Further studies in larger animal models of heart failure are necessary to determine the therapeutic efficacy of an antagomir approach to silencing miRNA-21.</p>
		 <p><ext-link xlink:href="http://www.biocentury.com/companies/Regulus_Therapeutics_LLC?utm_source=1"><bold>Regulus Therapeutics LLC</bold></ext-link>, which was an author on the paper, has an early-stage miRNA program targeting miRNA-21 for cardiovascular diseases and fibrosis. Regulus is a joint venture between <ext-link xlink:href="http://www.biocentury.com/companies/Alnylam_Pharmaceuticals_Inc?utm_source=1"><bold>Alnylam Pharmaceuticals Inc.</bold></ext-link> and <ext-link xlink:href="http://www.biocentury.com/companies/Isis_Pharmaceuticals_Inc?utm_source=1"><bold>Isis Pharmaceuticals Inc.</bold></ext-link></p>
		 
		 <p><ext-link xlink:href="http://www.biocentury.com/companies/miRagen_Therapeutics_Inc?utm_source=1"><bold>miRagen Therapeutics Inc.</bold></ext-link> has multiple miRNA-targeting compounds in preclinical development to treat cardiovascular indications.</p>
	</sec>
	 <sec>
		 <title>Licensing Status</title>
		 <p>Several patent applications filed covering diagnostic and therapeutic application of miRNAs in cardiovascular disease; available for licensing</p>
		 </sec>
	</body>
	<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Thum</surname><given-names>T.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2008</year>
            <month>11</month>
            <day>30</day>
            <elocation-id content-type="doi">10.1038/nature07511</elocation-id>
            <named-content content-type="contact">Stefan Engelhardt, University of W&#xFC;rzburg, W&#xFC;rzburg, Germany
<email>stefan.engelhardt@virchow.uni-wuerzburg.de</email></named-content>
        </element-citation></ref>
     </ref-list>
    </back>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="81" validatedBy="DTD" type="fatal-error" column="1">XML document structures must start and end within the same entity.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="Not XML"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="Not XML" mediaType="application/xml" postQueryString="false" accept="application/xml"><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request>abc</con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="1" validatedBy="DTD" type="fatal-error" column="1">Content is not allowed in prolog.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3b -Valid value -JM-journal-id"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3b -Valid value -JM-journal-id" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3b - Invalid value -JM-journal-id"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3b - Invalid value -JM-journal-id" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publishers">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="6" validatedBy="schematron" column="50" location="/article[1]/front[1]/journal-meta[1]/journal-id[1]" id="jmeta1">The "journal-id" element should have attribute: journal-id-type="publisher".</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3b - Blank value -JM-journal-id"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3b - Blank value -JM-journal-id" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="6" validatedBy="schematron" column="40" location="/article[1]/front[1]/journal-meta[1]/journal-id[1]" id="jmeta1">The "journal-id" element should have attribute: journal-id-type="publisher".</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3b - Element missing-JM-journal-id"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3b - Element missing-JM-journal-id" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="10" validatedBy="DTD" type="error" column="20">The content of element type "journal-meta" must match "(journal-id+,journal-title-group*,issn+,isbn*,publisher?,notes?)".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3a -Valid value -JM-journal-title"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3a -Valid value -JM-journal-title" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3a - InValid value -JM-journal-title"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3a - InValid value -JM-journal-title" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Dummy</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="7" validatedBy="schematron" column="30" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]" id="jmeta3a">Journal titles must be from the prescribed list of journal names. "Dummy" is not on this list - check spelling, spacing of words or use of the ampersand. Other rules are based on having a correct journal title and therefore will not be run. Please resubmit this file when the title has been corrected.</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta2 - Element missing - journal-title"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta2 - Element missing - journal-title" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
	]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="5" validatedBy="schematron" column="19" location="/article[1]/front[1]/journal-meta[1]" id="jmeta2a">Journal title is missing from the journal metadata section. Other rules are based on having a correct journal title and therefore will not be run. Please resubmit this file when the title has been added.</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3c -Valid value -JM-journal-title and Journal-id"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3c -Valid value -JM-journal-title and Journal-id" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="50ya"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scientificamerican</journal-id>
        <journal-title-group><journal-title>Scientific American</journal-title></journal-title-group>
        <issn pub-type="ppub">0036-8733</issn>
        <publisher><publisher-name>Scientific American, Inc.</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">50ya</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Scientific American, Inc.</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="95" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="106" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="115" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="117" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3c -InValid value -JM-journal-title and Journal-id"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3c -InValid value -JM-journal-title and Journal-id" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="adv"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scientificamericans</journal-id>
        <journal-title-group><journal-title>Scientific American</journal-title></journal-title-group>
        <issn pub-type="ppub">0036-8733</issn>
        <publisher><publisher-name>Scientific American, Inc.</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">adv</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Scientific American, Inc.</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="7" validatedBy="schematron" column="30" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]" id="jmeta3b">Journal id is incorrect. For Scientific American, it should be: scientificamerican. Other rules are based on having a correct journal id and therefore will not be run. Please resubmit this file when the journal id has been corrected.</message>
  <message line="95" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="106" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="115" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="117" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta4 -with Children for Journal-title"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta4 -with Children for Journal-title" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="antig"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scientificamerican</journal-id>
        <journal-title-group><journal-title>Scientific American</journal-title><journal-title>abc</journal-title>
        <abbrev-journal-title>abc</abbrev-journal-title>
<abbrev-journal-title>abc</abbrev-journal-title></journal-title-group>
        <issn pub-type="ppub">0036-8733</issn>
        <publisher><publisher-name>Scientific American, Inc.</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">antig</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Scientific American, Inc.</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="97" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="108" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="117" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="119" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="7" validatedBy="schematron" column="95" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]/journal-title[2]" id="jmeta4b">More than one journal title found. Only one journal title should be used.</message>
  <message line="9" validatedBy="schematron" column="23" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]/abbrev-journal-title[2]" id="jmeta4c">More than one abbreviated journal title found. Only one abbreviated journal title should be used.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta4 -with Children for Journal-title1"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta4 -with Children for Journal-title1" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="vr"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scientificamerican</journal-id>
        <journal-title-group><journal-title>Scientific American</journal-title></journal-title-group>
        <abbrev-journal-title>abc</abbrev-journal-title>
        <issn pub-type="ppub">0036-8733</issn>
        <publisher><publisher-name>Scientific American, Inc.</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">vr</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Scientific American, Inc.</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="11" validatedBy="DTD" type="error" column="20">The content of element type "journal-meta" must match "(journal-id+,journal-title-group*,issn+,isbn*,publisher?,notes?)".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta5b -issn valid value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta5b -issn valid value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="50ya"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scientificamerican</journal-id>
        <journal-title-group><journal-title>Scientific American</journal-title></journal-title-group>

        <issn pub-type="ppub">0036-8733</issn>
        <publisher><publisher-name>Scientific American, Inc.</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">50ya</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Scientific American, Inc.</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta5b -issn Invalid value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta5b -issn Invalid value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="50ya"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scientificamerican</journal-id>
        <journal-title-group><journal-title>Scientific American</journal-title></journal-title-group>
       <issn pub-type="ppub">0036-87345</issn>
        <publisher><publisher-name>Scientific American, Inc.</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">50ya</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Scientific American, Inc.</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>

]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="8" validatedBy="schematron" column="30" location="/article[1]/front[1]/journal-meta[1]/issn[1]" id="jmeta5b">Unexpected ISSN value for Scientific American (0036-87345)</message>
  <message line="95" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="106" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="115" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="117" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta9 -Publisher Name -Invalid"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta9 -Publisher Name -Invalid" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Groups</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="10" validatedBy="schematron" column="36" location="/article[1]/front[1]/journal-meta[1]/publisher[1]/publisher-name[1]" id="jmeta9">The publisher-name (Nature Publishing Groups) should match the copyright-holder (Nature Publishing Group).</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta6 -isbn -used"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta6 -isbn -used" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <isbn>abc</isbn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="97" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="108" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="117" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="119" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="10" validatedBy="schematron" column="15" location="/article[1]/front[1]/journal-meta[1]/isbn[1]" id="jmeta6">Do not use the ISBN element in journal metadata.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ameta1a -Valid XML"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ameta1a -Valid XML" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta3a -Blank value -JM-journal-title"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta3a -Blank value -JM-journal-title" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title></journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="7" validatedBy="schematron" column="30" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]" id="jmeta3a">Journal titles must be from the prescribed list of journal names. "" is not on this list - check spelling, spacing of words or use of the ampersand. Other rules are based on having a correct journal title and therefore will not be run. Please resubmit this file when the title has been corrected.</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ameta1b  Multiple Article Ctaegories"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ameta1b  Multiple Article Ctaegories" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="93" validatedBy="DTD" type="error" column="20">The content of element type "article-meta" must match "(article-id*,article-categories?,title-group,(contrib-group|aff)*,author-notes?,pub-date+,volume?,volume-id*,volume-series?,issue?,issue-id*,issue-title*,issue-sponsor*,issue-part?,isbn*,supplement?,((fpage,lpage?,page-range?)|elocation-id)?,(email|ext-link|uri|product|supplementary-material)*,history?,permissions?,self-uri*,related-article*,abstract*,trans-abstract*,kwd-group*,funding-group*,conference*,counts?,custom-meta-group?)".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ameta2a -Valid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ameta2a -Valid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="102" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="113" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="122" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="124" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ameta2a -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ameta2a -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
             <subj-group subj-group-type="categorys">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>

        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="20" validatedBy="schematron" column="29" location="/article[1]/front[1]/article-meta[1]/article-categories[1]" id="ameta2a">Article categories should contain a "subj-group" element with attribute "subj-group-type='category'". The value of the child "subject" element should be the same as the main article-type attribute: cstory.</message>
  <message line="103" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="114" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="123" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="125" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="arttitle1 -title-group -Valid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="arttitle1 -title-group -Valid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="102" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="113" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="122" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="124" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="arttitle1 -title-group -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="arttitle1 -title-group -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
 <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
       
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="36" validatedBy="DTD" type="error" column="23">The content of element type "title-group" must match "(article-title,subtitle*,trans-title-group*,alt-title*,fn-group?)".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate0c"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate0c" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="aop">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
       

        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="104" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="115" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="124" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="126" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate0a-pub-type=missing"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate0a-pub-type=missing" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date>
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
       
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="19" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate0a">"pub-date" element should have attribute "pub-type" declared. Allowed values are: issue-date, aop, collection, epub, epreprint and embargo. Please check with NPG Editorial Production.</message>
  <message line="103" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="114" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="123" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="125" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate1a"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate1a" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="aop">
            <day>12</day>
            <month>08</month>
            <year>20</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="34" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate1a">Invalid year value: 20. It should be a 4-digit number starting with 19 or 20.</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate1b"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate1b" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="aop">
            <day>12</day>
            <month>011</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="34" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate1b">Invalid month value: 011. It should be a 2-digit number between 01 and 12.</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate1c"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate1c" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="aop">
            <day>33</day>
            <month>02</month>
            <year>2007</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="34" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate1c">Invalid day value: 33. It should be a 2-digit number between 01 and 31.</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate2"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate2" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="aop">
            <day>29</day>
            <month>02</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="34" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate2">Invalid publication date - the day value (29) does not exist for the month (02) in the year (2010).</message>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate3"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate3" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="aop">
            <day>29</day>
            
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="96" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="107" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="116" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="118" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="39" validatedBy="schematron" column="34" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate3">Missing month in pub-date. Currently only contains year and day.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate4  -Valid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate4  -Valid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>3</volume>
        <issue>31</issue>
<history>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="109" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="120" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="129" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="131" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="artinfo1a -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="artinfo1a -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue></issue>
<fpage></fpage>
<lpage></lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="290"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="52" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/issue[1]" id="artinfo1a">Empty "issue" element should not be used - please delete.</message>
  <message line="53" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/fpage[1]" id="artinfo1a">Empty "fpage" element should not be used - please delete.</message>
  <message line="54" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/lpage[1]" id="artinfo1a">Empty "lpage" element should not be used - please delete.</message>
  <message line="118" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="129" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="138" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="artinfo2  -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="artinfo2  -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>abc</issue>
<fpage></fpage>
<lpage></lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="290"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="53" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/fpage[1]" id="artinfo1a">Empty "fpage" element should not be used - please delete.</message>
  <message line="54" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/lpage[1]" id="artinfo1a">Empty "lpage" element should not be used - please delete.</message>
  <message line="52" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/issue[1]" id="artinfo2">Invalid value for "issue" (abc) - this should only contain numerals.</message>
  <message line="118" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="129" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="138" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="artinfo3a  -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="artinfo3a  -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>abc</issue>
<fpage>12</fpage>



<history>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="290"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="52" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/issue[1]" id="artinfo2">Invalid value for "issue" (abc) - this should only contain numerals.</message>
  <message line="53" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/fpage[1]" id="artinfo3a">As "fpage" is used, we also expect "lpage" and "counts"/"page-count" elements to be used in article metadata.</message>
  <message line="118" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="129" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="138" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="artinfo4  -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="artinfo4  -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="290"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="97" validatedBy="schematron" column="26" location="/article[1]/front[1]/article-meta[1]/counts[1]/page-count[1]" id="artinfo4">Incorrect value given for "page-count" attribute "count" (290). Expected value is: 291.</message>
  <message line="118" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="129" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="138" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="histdate0b  -date-type=abc"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="histdate0b  -date-type=abc" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="abc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>


</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="58" validatedBy="schematron" column="23" location="/article[1]/front[1]/article-meta[1]/history[1]/date[1]" id="histdate0b">Unexpected value for "date-type" attribute on "date" element (abc). Allowed values are: created, received, rev-recd (revision received), accepted and misc. Please check with NPG Editorial Production.</message>
  <message line="120" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="131" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="142" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="histdate0b -InValid Value -1"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="histdate0b -InValid Value -1" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date ><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="58" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/history[1]/date[1]" id="histdate0a">"date" element should have attribute "date-type" declared. Allowed values are: created, received, rev-recd (revision received), accepted and misc. Please check with NPG Editorial Production.</message>
  <message line="118" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="129" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="138" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="histdate0c  -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="histdate0c  -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="119" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="139" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="141" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="59" validatedBy="schematron" column="24" location="/article[1]/front[1]/article-meta[1]/history[1]/date[2]" id="histdate0c">There should only be one instance of the "date" element with "date-type" attribute value of "misc". Please check with NPG Editorial Production.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="histdate1a1b1c  -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="histdate1a1b1c  -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>20081</year></date>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>33</day><month>13</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="58" validatedBy="schematron" column="24" location="/article[1]/front[1]/article-meta[1]/history[1]/date[1]" id="histdate1a">Invalid year value: 20081. It should be a 4-digit number starting with 19 or 20.</message>
  <message line="61" validatedBy="schematron" column="28" location="/article[1]/front[1]/article-meta[1]/history[1]/date[4]" id="histdate1b">Invalid month value: 13. It should be a 2-digit number between 01 and 12.</message>
  <message line="61" validatedBy="schematron" column="28" location="/article[1]/front[1]/article-meta[1]/history[1]/date[4]" id="histdate1c">Invalid day value: 33. It should be a 2-digit number between 01 and 31.</message>
  <message line="119" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="139" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="141" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="59" validatedBy="schematron" column="24" location="/article[1]/front[1]/article-meta[1]/history[1]/date[2]" id="histdate0c">There should only be one instance of the "date" element with "date-type" attribute value of "misc". Please check with NPG Editorial Production.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="histdate2 -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="histdate2 -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>20081</year></date>
<date date-type="misc"><month>09</month><year>2008</year></date>
<date date-type="received"><day>29</day><month>02</month><year>2009</year></date>
<date date-type="rev-recd"><day>33</day><month>13</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>12</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="58" validatedBy="schematron" column="24" location="/article[1]/front[1]/article-meta[1]/history[1]/date[1]" id="histdate1a">Invalid year value: 20081. It should be a 4-digit number starting with 19 or 20.</message>
  <message line="61" validatedBy="schematron" column="28" location="/article[1]/front[1]/article-meta[1]/history[1]/date[4]" id="histdate1b">Invalid month value: 13. It should be a 2-digit number between 01 and 12.</message>
  <message line="61" validatedBy="schematron" column="28" location="/article[1]/front[1]/article-meta[1]/history[1]/date[4]" id="histdate1c">Invalid day value: 33. It should be a 2-digit number between 01 and 31.</message>
  <message line="60" validatedBy="schematron" column="28" location="/article[1]/front[1]/article-meta[1]/history[1]/date[3]" id="histdate2">Invalid history date - the day value (29) does not exist for the month (02) in the year (2009).</message>
  <message line="119" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="139" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="141" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="59" validatedBy="schematron" column="24" location="/article[1]/front[1]/article-meta[1]/history[1]/date[2]" id="histdate0c">There should only be one instance of the "date" element with "date-type" attribute value of "misc". Please check with NPG Editorial Production.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="histdate3  and histdate1b -InValid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="histdate3  and histdate1b -InValid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>

<date date-type="received"><day>28</day><month>02</month><year>2009</year></date>
<date date-type="rev-recd"><day>31</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month></month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="62" validatedBy="schematron" column="28" location="/article[1]/front[1]/article-meta[1]/history[1]/date[4]" id="histdate1b">Invalid month value: . It should be a 2-digit number between 01 and 12.</message>
  <message line="119" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="139" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="141" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="copy1a - Invalid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="copy1a - Invalid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>

<date date-type="received"><day>28</day><month>02</month><year>2009</year></date>
<date date-type="rev-recd"><day>31</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>12</month><year>2009</year></date>
</history>
       
 

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="15" validatedBy="schematron" column="19" location="/article[1]/front[1]/article-meta[1]" id="copy1a">Article metadata should include a "permissions" element.</message>
  <message line="119" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="139" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="141" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="copy1b - Invalid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="copy1b - Invalid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>

<date date-type="received"><day>28</day><month>02</month><year>2009</year></date>
<date date-type="rev-recd"><day>31</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>12</month><year>2009</year></date>
</history>
       
 <permissions><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="65" validatedBy="schematron" column="15" location="/article[1]/front[1]/article-meta[1]/permissions[1]" id="copy1b">Permissions should include the copyright year.</message>
  <message line="119" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="139" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="141" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="copy1c and copy 2- Invalid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="copy1c and copy 2- Invalid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>

<date date-type="received"><day>28</day><month>02</month><year>2009</year></date>
<date date-type="rev-recd"><day>31</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>12</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>3099</copyright-year></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="65" validatedBy="schematron" column="15" location="/article[1]/front[1]/article-meta[1]/permissions[1]" id="copy1c">Permissions should include the copyright holder: Nature Publishing Group.</message>
  <message line="65" validatedBy="schematron" column="31" location="/article[1]/front[1]/article-meta[1]/permissions[1]/copyright-year[1]" id="copy2">Invalid year value for copyright: 3099. It should be a 4-digit number starting with 19 or 20.</message>
  <message line="119" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="130" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="139" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="141" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="copy3 - Invalid Value"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="copy3 - Invalid Value" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date date-type="misc"><month>09</month><year>2008</year></date>

<date date-type="received"><day>28</day><month>02</month><year>2009</year></date>
<date date-type="rev-recd"><day>31</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>12</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Groups</copyright-holder></permissions>


        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="65" validatedBy="schematron" column="70" location="/article[1]/front[1]/article-meta[1]/permissions[1]/copyright-holder[1]" id="copy3">The copyright-holder for Science-Business eXchange should be: Nature Publishing Group</message>
  <message line="120" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="131" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="142" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate0a-pub-type=abc"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate0a-pub-type=abc" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="abc">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
       
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="34" location="/article[1]/front[1]/article-meta[1]/pub-date[1]" id="pubdate0b">Unexpected value for "pub-type" attribute on "pub-date" element (abc). Allowed values are: issue-date, aop, collection, epub, epreprint and embargo. Please check with NPG Editorial Production.</message>
  <message line="103" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="114" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="123" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="125" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate0b-pub-type duplicated -DTD"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate0b-pub-type duplicated -DTD" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
<pub-date pub-type="aop" pub-type="aop" >
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
       
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="45" validatedBy="DTD" type="fatal-error" column="35">Attribute "pub-type" was already specified for element "pub-date".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="histdate0a and histdate0b-date type=Blank and date-type=Invalid"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="histdate0a and histdate0b-date type=Blank and date-type=Invalid" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="ppub">1945-3477</issn>
         <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>

    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1039/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.9401</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
       
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>

        <volume>12</volume>
<issue>12</issue>
<fpage>12</fpage>
<lpage>302</lpage>


<history>
<date ><month>09</month><year>2008</year></date>
<date date-type="abc"><day>12</day><month>11</month><year>2008</year></date>
<date date-type="rev-recd"><day>24</day><month>12</month><year>2008</year></date>
<date date-type="accepted"><day>17</day><month>02</month><year>2009</year></date>
</history>
       
 <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>

        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
<counts>
<page-count count="291"/>
</counts>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="58" validatedBy="schematron" column="8" location="/article[1]/front[1]/article-meta[1]/history[1]/date[1]" id="histdate0a">"date" element should have attribute "date-type" declared. Allowed values are: created, received, rev-recd (revision received), accepted and misc. Please check with NPG Editorial Production.</message>
  <message line="59" validatedBy="schematron" column="23" location="/article[1]/front[1]/article-meta[1]/history[1]/date[2]" id="histdate0b">Unexpected value for "date-type" attribute on "date" element (abc). Allowed values are: created, received, rev-recd (revision received), accepted and misc. Please check with NPG Editorial Production.</message>
  <message line="118" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="129" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="138" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="140" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="jmeta2b -  - journal-title - multiple"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="jmeta2b -  - journal-title - multiple" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory"  xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title>
<journal-title>abc</journal-title></journal-title-group>
 <issn pub-type="ppub">1945-3477</issn>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject content-type="article-type">cstory</subject>
            </subj-group>
            <subj-group subj-group-type="subjects">
            <subject content-type="subject">scibx-14</subject>
            </subj-group>
            <subj-group subj-group-type="indications">
                <subject>Tuberculosis (TB)</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title>New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <contrib-group>
            <contrib contrib-type="author">
                <name>
                <surname>Cain</surname>
                <given-names>Chris</given-names>
            </name>
                <role>Staff Writer</role>
            </contrib>
        </contrib-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <related-article related-article-type="see-also" xlink:href="scibx.2010.954" ext-link-type="article-id"/>
        <abstract abstract-type="editor">
            <p>Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR<sub>&#x3B3;</sub> agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds previously dismissed due to poor agonist activity but that now may offer therapeutic benefits with the potential for fewer side effects than marketed PPAR<sub>&#x3B3;</sub> agonists.</p>
        </abstract>
        <kwd-group>
            <kwd>peroxisome proliferation&#x2013;activated receptor-&#x3B3;</kwd>
				<kwd>PPARG</kwd>
				<kwd>PPAR<sub>&#x3B3;</sub></kwd>
				<kwd>insulin</kwd>
				<kwd>INT131</kwd>
				<kwd>Avandia rosiglitazone</kwd>
				<kwd>Actos pioglitazone</kwd>
				<kwd>thiazolidinedione</kwd>
				<kwd>TZD</kwd>
				<kwd>cyclin dependent kinase 5</kwd>
				<kwd>CDK<sup>5</sup></kwd>
				<kwd>adiponectin</kwd>
				<kwd>glucose</kwd>
				<kwd>MBX-102</kwd>
				<kwd>Balaglitazone</kwd>
				<kwd>DRF 2593</kwd>
				<kwd>Dana-Farber Cancer Institute</kwd>
				<kwd>GlaxoSmithKline plc</kwd>
				<kwd>Harvard Medical School</kwd>
				<kwd>InteKrin Therapeutics Inc.</kwd>
				<kwd>Metabolex Inc.</kwd>
				<kwd>Scripps Florida</kwd>
				<kwd>Takeda Pharmaceutical Co. Ltd.</kwd>
            <kwd>The University of Texas Southwestern Medical Center at Dallas</kwd>
        </kwd-group>
    </article-meta>
</front>
<body>
     <p>Researchers at the <ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link> and <ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link> have found an alternative mechanism by which peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists exert their antidiabetic effects.<xref ref-type="bibr" rid="b1"/> By blocking phosphorylation of the protein, these compounds actually may improve insulin sensitivity independent of receptor agonism.</p>
	 <p><xref ref-type="other" rid="illus1"/></p>
    <p>The findings offer a reason for drug companies to take a fresh look at antidiabetic compounds that may have been previously dismissed due to their reduced agonistic activity but now may be seen to offer therapeutic benefits with the potential for fewer side effects than marketed peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists.</p>
	 <p>Indeed, the alternative mechanism may explain how partial PPAR<sub>&#x3B3;</sub> agonists in clinical development, including <ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>'s INT131, can exhibit potent antidiabetic effects similar to those of full agonists such as <ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link>'s Avandia rosiglitazone and <ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link>'s Actos pioglitazone.</p>
	 <p>Avandia and Actos are marketed to treat type 2 diabetes and had combined worldwide sales of over $4.5 billion in 2009. However, patients taking these thiazolidinedione (TZD) drugs can experience side effects such as weight gain and edema. An FDA advisory panel recently split on whether Avandia should be taken off the market due to a potential increase in the risk of cardiovascular events.<xref ref-type="bibr" rid="b2"/></p>
	 <p>Patents on Actos and Avandia will begin to expire in 2011 and 2012, respectively, placing further commercial pressure on companies targeting PPAR<sub>&#x3B3;</sub>.</p>
	 <p>Now, a team led by Bruce Spiegelman, Korsmeyer professor of cell biology at <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> and Dana-Farber, and Patrick Griffin, professor and chair of molecular therapeutics and director of the Translational Research Institute at Scripps Florida, has shown that PPAR<sub>&#x3B3;</sub> is phosphorylated by the obesity-activated cyclin dependent kinase 5 (CDK<sup>5</sup>), which results in misregulation of a subset of genes that are important for insulin sensitivity (<italic>see</italic> <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref><bold>, &#x201C;A new way to target PPAR<sub>&#x3B3;</sub>&#x201D;</bold>).</p>
	 <p>The researchers then went on to show that some PPAR<sub>&#x3B3;</sub> agonists can block this CDK<sup>5</sup>-mediated phosphorylation (<italic>see</italic> <xref ref-type="fig" rid="t1"><bold>Table 1</bold></xref><bold>, &#x201C;Targeting PPAR<sub>&#x3B3;</sub>&#x201D;</bold>). Critically, the extent to which a compound agonizes PPAR<sub>&#x3B3;</sub> is not correlated with the extent to which it inhibits phosphorylation, suggesting that these compounds have two distinct and separable activities.</p>
    <p>The results were published in <bold><italic>Nature</italic></bold>.</p>
	 <p>&#x201C;It always seemed strange that so-called 'full' agonists such as TZDs and 'partial' agonists such as non-TZDs had similar antidiabetic function <italic>in vivo</italic>,&#x201D; said Spiegelman. &#x201C;It just didn't make sense. It now appears likely that a substantial portion of the therapeutic benefit of PPAR<sub>&#x3B3;</sub> ligands is through the inhibition of CDK<sup>5</sup>-mediated phosphorylation.&#x201D;</p>
	 <p>PPAR<sub>&#x3B3;</sub> agonism has classically been measured as a compound's ability to stimulate transcription of a PPAR<sub>&#x3B3;</sub>-responsive reporter gene in cell culture. A compound was dubbed a partial agonist if it stimulated less reporter activity than rosiglitazone, the standard benchmark.</p>
	 <p>&#x201C;For a number of years compounds have been identified that bound to PPAR<sub>&#x3B3;</sub>, had little or no transcriptional agonism in a traditional sense and yet had antidiabetic properties in animal models,&#x201D;<xref ref-type="bibr" rid="b3 b4 b5"/> noted Steven Kliewer, professor of molecular biology at <ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link> and a member of InteKrin's scientific advisory board. &#x201C;This paper presents a potential mechanism for understanding this, and it's a big advance.&#x201D;</p>
    <p>Spiegelman's team demonstrated the function of CDK<sup>5</sup>-mediated phosphorylation by transplanting fibroblasts subcutaneously into mice and allowing them to differentiate into adipocytes. Transplantation of adipocytes that expressed PPAR<sub>&#x3B3;</sub> lacking this phosphorylation site led to greater levels of adiponectin, a key hormone that maintains insulin sensitivity, whereas transplantation of adipocytes that expressed wild-type PPAR<sub>&#x3B3;</sub> did not (ref. <xref ref-type="bibr" rid="b7">7</xref>).</p>
	 <p>In contrast, mutation of this phosphorylation site had no effect on the level of PPAR<sub>&#x3B3;</sub> agonism in classical transcriptional reporter assays, whether in the presence or absence of rosiglitazone.</p>
	 <p>However the most striking result was shown in patients taking a TZD agonist, in this case Avandia, in which a decrease in PPAR<sub>&#x3B3;</sub> phosphorylation was significantly correlated with improvement in glucose infusion rate, a measure of insulin sensitivity (<italic>p</italic>=0.001).</p>
	 <p>&#x201C;This is the most exciting result,&#x201D; said Kliewer. &#x201C;It's a killer figure.&#x201D;</p>
	 <sec>
	 <title>Agonizing over mechanism</title>
	 <p>Spiegelman reached out to Griffin to gain structural insight into how chemically distinct PPAR<sub>&#x3B3;</sub>-agonizing compounds also prevent its phosphorylation. Although all these compounds were known to interact with a large ligand-binding pocket on PPAR<sub>&#x3B3;</sub>, Griffin's laboratory used hydrogen-deuterium exchange mass spectroscopy (HDX-MS) to show that they cause distinct conformational changes in the receptor that could influence subsequent phosphorylation.</p>
	 <p>&#x201C;We knew from our previous work that partial agonists altered the conformational dynamics of specific regions of PPAR<sub>&#x3B3;</sub> differently from full agonists,&#x201D; Griffin told <italic>SciBX</italic>. &#x201C;We hypothesized that they might affect coactivator recruitment by generating a new interaction surface or by altering post-translational modifications.<xref ref-type="bibr" rid="b6"/> Here we show that one way they may act is by stabilizing the phosphorylated region of the protein in a configuration that is less favorable to CDK<sup>5</sup>.&#x201D;</p>
	 <p>These details are important because they provide a mechanistic explanation for how non-TZDs still have potent antidiabetic effects even though they only partially agonize the PPAR<sub>&#x3B3;</sub> receptor. These types of compounds are often referred to as selective PPAR modulators (SPPARMs) and include <ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>'s MBX-102 and InteKrin's INT131.<disp-quote id="pq1"><p>&#x201C;This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p><address><institution>Metabolex Inc.</institution></address><attrib>David Karpf</attrib></disp-quote></p>
	 <p>&#x201C;PPAR<sub>&#x3B3;</sub> full agonists are associated with weight gain, fluid retention, edema, congestive heart failure and bone fracture,&#x201D; said Linda Higgins, president and CEO of InteKrin. &#x201C;SPPARMs such as INT131 have been characterized that achieve separation of side effects from antidiabetic activity. It is not known yet whether INT131 blocks this phosphorylation event, but the central thesis of this paper predicts that it would.&#x201D;</p>
	 <p>InteKrin has completed a Phase IIb trial of INT131 and plans to move forward with Phase III testing in type 2 diabetes, although it hasn't provided a timeline. INT131 is the SPPARM furthest along in development.</p>
	 <p>MBX-102 was shown by Spiegelman's group to inhibit phosphorylation of PPAR<sub>&#x3B3;</sub>. Although the compound made it to Phase II testing for type 2 diabetes, it is no longer in development for that indication.</p>
	 <p>&#x201C;We were one of the first companies to demonstrate the promise of selective modulation of PPAR<sub>&#x3B3;</sub>, by demonstrating glucose lowering without any weight gain or edema, even in diabetic patients also taking insulin,&#x201D; said Metabolex CMO David Karpf. &#x201C;The efficacy can be separated from classic PPAR<sub>&#x3B3;</sub> side effects. This paper is a game changer because it suggests agonizing the receptor may not be necessary at all.&#x201D;</p>
	 <p>Karpf did note that &#x201C;the glycemic efficacy of MBX-102 didn't reach the commercial threshold to enter into a Phase III trial for type 2 diabetes. However, MBX-102 is also an effective uricosuric agent, where its insulin-sensitizing effects may provide an additional benefit for treatment of gout.&#x201D;<xref ref-type="bibr" rid="b7"/></p>
	 <p>Metabolex is considering doing a Phase II trial in gout or partnering the compound.</p></sec>
	 <sec>
	 <title>PPARanoia</title>
	 <p>Although companies could re-examine compounds that bind PPAR<sub>&#x3B3;</sub> but were dismissed due to a lack of agonism in classical transcriptional reporter assays, the stigma attached to PPAR<sub>&#x3B3;</sub> as a therapeutic target still may dissuade further investigation.</p>
	 <p>&#x201C;Companies have run away from PPAR<sub>&#x3B3;</sub>, and it will be interesting to see if this reignites their interest,&#x201D; said Kliewer. &#x201C;I believe the stigma surrounding PPAR<sub>&#x3B3;</sub> is unwarranted; it is a validated target with a big market, and it is surprising that many companies have completely left it behind.&#x201D;</p>
	 <p>One problem, according to Kliewer, is that &#x201C;no one knows which PPAR<sub>&#x3B3;</sub> target genes cause the unwanted side effects. Until we know why patients taking Avandia have an increased rate of heart attack, companies will be reticent to target PPAR<sub>&#x3B3;</sub>.&#x201D;</p>
	 <p>At the same time, he noted, &#x201C;while <italic>in vivo</italic> data suggest that SPPARM compounds are safer, we really don't know why that is.&#x201D;</p>
	 <p>Spiegelman thinks companies are in a good position to take advantage of the findings. &#x201C;The cool thing is that they probably have freezers full of PPAR<sub>&#x3B3;</sub> agonist derivatives,&#x201D; he said. &#x201C;They should be able to reassess what they have already made rather quickly and dial this mechanism in while dialing agonism out.&#x201D;</p>
	 <p>Future studies from Spiegelman and Griffin will focus on separating the effects of agonism from the effects of inhibiting phosphorylation. The team is developing compounds that block only the CDK<sup>5</sup> phosphorylation site and do not agonize PPAR<sub>&#x3B3;</sub>. They also are developing mice with a mutation at the PPAR<sub>&#x3B3;</sub> phosphorylation site to address its <italic>in vivo</italic> function in metabolism.</p>
	 <p>Spiegelman said a patent application has been filed covering this work. It is available for licensing.</p></sec>
	 <sec>
	 <title>Companies and institutions mentioned</title>
	 <p><list id="l1">
	 <list-item><p><ext-link xlink:href="http://www.dana-farber.org/"><bold>Dana-Farber Cancer Institute</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK), London, U.K.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link>, Boston, Mass.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link>, Los Altos, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link>, Hayward, Calif.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.scripps.edu/florida/"><bold>Scripps Florida</bold></ext-link>, Jupiter, Fla.</p></list-item>
	 <list-item><p><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo:4502), Osaka, Japan</p></list-item>
<list-item><p><ext-link xlink:href="http://www.utsouthwestern.edu/"><bold>The University of Texas Southwestern Medical Center at Dallas</bold></ext-link>, Dallas, Texas</p></list-item></list></p></sec>
</body>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Choi</surname><given-names>J.H.</given-names></name>
            <etal/>
            <source>Nature</source>
            <year>2010</year>
            <month>07</month>
            <day>21</day>
            <elocation-id content-type="doi">10.1038/nature09291</elocation-id>
            <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email>bruce_spiegelman@dfci.harvard.edu</email></named-content>
        </element-citation></ref>
        <ref id="b2"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Usdin</surname><given-names>S.</given-names></name> <etal/> 
            <source>BioCentury</source><volume>18</volume><issue>32</issue><fpage>A6</fpage>
            <year>2010</year><month>07</month><day>19</day>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <ref id="b3"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Motani</surname><given-names>A.</given-names></name> <etal/> 
            <source>J. Mol. Biol.</source>
            <volume>386</volume><fpage>1301</fpage><lpage>1311</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b4"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Gregoire</surname><given-names>F.M.</given-names></name> <etal/> 
            <source>Mol. Endocrinol.</source>
            <volume>23</volume><fpage>975</fpage><lpage>988</lpage><year>2009</year>
        </element-citation></ref>
        <ref id="b5"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Acton</surname><given-names>J.J.</given-names><suffix>III</suffix></name> <etal/> 
            <source>Bioorg. Med. Chem. Lett.</source>
            <volume>15</volume><fpage>357</fpage><lpage>362</lpage><year>2005</year>
        </element-citation></ref>
        <ref id="b6"><element-citation xlink:role="original-article" publication-type="journal">
            <name><surname>Bruning</surname><given-names>J.B.</given-names></name> <etal/> 
            <source>Structure</source>
            <volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><year>2007</year>
        </element-citation></ref>
        <ref id="b7"><element-citation xlink:role="original-article" publication-type="book">
            <name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name>
            <person-group person-group-type="editor">
                <name><surname>Leitner</surname><given-names>T</given-names></name>
                <etal/>
            </person-group>
            <source>HIV Sequence Compendium 2005</source><fpage>33</fpage><lpage>40</lpage>
            <year>2005</year>
            <publisher-name>Los Alamos National Laboratory</publisher-name>
            <publisher-loc>Los Alamos, N.M.</publisher-loc>
            <elocation-id content-type="doi"></elocation-id>
        </element-citation></ref>
        <!-- <bib id="b7"><reftxt><refau><snm>Flanagan</snm>, <fnm>M.</fnm></refau> <jtl>BioCentury</jtl> <vid>18</vid>(<iid>32</iid>), <ppf>A12</ppf>; <cd day="19" month="07" year="2010">July 19, 2010</cd></reftxt></bib> -->
    </ref-list>
    </back>
    <floats-group>
    <fig id="f1" position="float">
        <caption>
            <title>A new way to target PPAR<sub>&#x3B3;</sub>.</title>
            <p><ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers suggest that compounds that block phosphorylation of peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) could provide a better way of treating obesity and type 2 diabetes than marketed thiazolidinediones (TZDs), which agonize the transcription factor, resulting in not only insulin sensitivity but also unwanted downstream effects.</p>
<p>In adipocytes of mice fed a high-fat diet, cyclin dependent kinase 5 (CDK<sup>5</sup>)-dependent phosphorylation (P) of PPAR<sub>&#x3B3;</sub> at serine 273 is increased, which decreases downstream expression of insulin-sensitizing genes [<bold>a</bold>]. By blocking CDK<sup>5</sup>-dependent phosphorylation, PPAR<sub>&#x3B3;</sub> is able to increase the expression of these genes [<bold>b</bold>].</p>
        </caption>
        <alternatives>
            <graphic content-type="figure" mimetype="image" mime-subtype="jpeg" xlink:href="scibx.2010.940-F1.jpg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-F1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint" />
        </alternatives>
    </fig>
    <graphic id="illus1" xlink:href="scibx.2010.940-I1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor" content-type="illustration"/>
    <table-wrap id="t1" orientation="portrait">
        <caption><title><bold>Targeting PPAR<sub>&#x3B3;</sub>.</bold> A study by <ext-link xlink:href="http://hms.harvard.edu/hms/home.asp"><bold>Harvard Medical School</bold></ext-link> researchers found that the peroxisome proliferation&#x2013;activated receptor-&#x3B3; (PPARG; PPAR<sub>&#x3B3;</sub>) agonists Avandia rosiglitazone and MBX-102 blocked cyclin dependent kinase 5 (CDK<sup>5</sup>) phosphorylation of PPAR<sub>&#x3B3;</sub>. Below are other compounds that agonize PPAR<sub>&#x3B3;</sub> on the market or in development that may also block CDK<sup>5</sup> phosphorylation. <italic>Source: BCIQ: BioCentury Online Intelligence</italic></title></caption>
            <oasis:table frame="topbot" colsep="0" rowsep="0">
                <oasis:tgroup cols="4" colsep="0" rowsep="0" align="center">
                <oasis:colspec colnum="1" colname="1" align="left" colwidth="1*"/>
                <oasis:colspec colnum="2" colname="2" align="left" colwidth="1*"/>
                <oasis:colspec colnum="3" colname="3" align="left" colwidth="1*"/>
                <oasis:colspec colnum="4" colname="4" align="left" colwidth="1*"/>
                <oasis:thead valign="top">
                    <oasis:row rowsep="1">
                        <oasis:entry>Company</oasis:entry>
                        <oasis:entry>Product</oasis:entry>
                        <oasis:entry>Compound class</oasis:entry>
                        <oasis:entry>Lead status</oasis:entry>
                    </oasis:row>
                </oasis:thead>
                <oasis:tbody valign="top">
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/GlaxoSmithKline_plc?utm_source=1"><bold>GlaxoSmithKline plc</bold></ext-link> (LSE:GSK; NYSE:GSK)</oasis:entry>
                        <oasis:entry>Avandia rosiglitazone</oasis:entry>
                        <oasis:entry>Thiazolidinedione (TZD)</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Takeda_Pharmaceutical_Co_Ltd?utm_source=1"><bold>Takeda Pharmaceutical Co. Ltd.</bold></ext-link> (Tokyo :4502)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Eli_Lilly_and_Co?utm_source=1"><bold>Eli Lilly and Co.</bold></ext-link> (NYSE:LLY)/<break/><ext-link xlink:href="http://www.biocentury.com/companies/Pfizer_Inc?utm_source=1"><bold>Pfizer Inc.</bold></ext-link> (NYSE:PFE)</oasis:entry>
                        <oasis:entry>Actos pioglitazone</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Marketed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Dr_Reddys_Laboratories_Ltd?utm_source=1"><bold>Dr. Reddy's Laboratories Ltd.</bold></ext-link> (NYSE:RDY)/<ext-link xlink:href="http://www.biocentury.com/companies/Nordic_Bioscience_Holding?utm_source=1"><bold>Nordic Bioscience Holding</bold></ext-link></oasis:entry>
                        <oasis:entry>Balaglitazone (DRF 2593)</oasis:entry>
                        <oasis:entry>TZD</oasis:entry>
                        <oasis:entry>Phase III</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/InteKrin_Therapeutics_Inc?utm_source=1"><bold>InteKrin Therapeutics Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>INT131</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Phase IIb completed</oasis:entry></oasis:row>
                    <oasis:row>
                        <oasis:entry><ext-link xlink:href="http://www.biocentury.com/companies/Metabolex_Inc?utm_source=1"><bold>Metabolex Inc.</bold></ext-link></oasis:entry>
                        <oasis:entry>MBX-102</oasis:entry>
                        <oasis:entry>Non-TZD</oasis:entry>
                        <oasis:entry>Not applicable<xref ref-type="fn" rid="t1-fn1"><sup>A</sup></xref></oasis:entry>
                    </oasis:row>                    
                </oasis:tbody></oasis:tgroup>
        </oasis:table>
        <alternatives>
            <graphic xlink:href="scibx.2010.940-T1.jpg" mimetype="image" mime-subtype="jpeg" position="anchor"/>
            <media content-type="powerpoint-slide" xlink:href="scibx.2010.940-T1.ppt" mimetype="application/vnd.ms-powerpoint" mime-subtype="ppt" />
        </alternatives>
        <table-wrap-foot>
            <fn id="t1-fn1"><p><sup>A</sup>No longer in development for diabetes.</p></fn>
        </table-wrap-foot>
    </table-wrap>
    
</floats-group>
</article>
	]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//reports[1]</path><content><![CDATA[<reports status="FAILURE">
  <report>
    <message line="97" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
    <message line="108" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[2]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
    <message line="117" validatedBy="schematron" column="8" location="/article[1]/body[1]/sec[3]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
    <message line="119" validatedBy="schematron" column="20" location="/article[1]/body[1]/sec[3]/p[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
    <message line="8" validatedBy="schematron" column="16" location="/article[1]/front[1]/journal-meta[1]/journal-title-group[1]/journal-title[2]" id="jmeta4b">More than one journal title found. Only one journal title should be used.</message>
  </report>
</reports>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="pubdate1d  - pub-date/season"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="pubdate1d  - pub-date/season" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="le" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nnano</journal-id>
            <journal-title-group>
                <journal-title>Nature Nanotechnology</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">1748-3387</issn>
            <issn pub-type="epub">1748-3395</issn>
            <publisher>
                <publisher-name>Nature Publishing Group</publisher-name>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.1038/nnano.2009.48</article-id>
            <article-id pub-id-type="publisher-id">nnano.2009.48</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>le</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Tunnelling readout of hydrogen-bonding-based recognition</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>01</day>
                <month>05</month>
                <year>2009</year>
            </pub-date>
            <pub-date pub-type="aop">
                             
<season>Autumn</season>
                <year>2009</year>
            </pub-date>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>297</fpage>
            <lpage>301</lpage>
            <history>
                <date date-type="created">
                    <month>09</month>
                    <year>2008</year>
                </date>
                <date date-type="received">
                    <day>12</day>
                    <month>11</month>
                    <year>2008</year>
                </date>
                <date date-type="rev-recd">
                    <day>24</day>
                    <month>12</month>
                    <year>2008</year>
                </date>
                <date date-type="accepted">
                    <season>Jan-Mar</season>
                    <year>2009</year>
                </date>
           </history>
            <permissions>
                <copyright-statement>Copyright &#x00A9; 2009, Rights Managed by Nature Publishing Group</copyright-statement>
                <copyright-year>2009</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
            <counts>
                <page-count count="5"/>
            </counts>
         </article-meta>
    </front>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="34" validatedBy="schematron" column="9" location="/article[1]/front[1]/article-meta[1]/pub-date[2]/season[1]" id="pubdate1d">Do not use "season" (Autumn). "Day" and "month" are the only other elements which should be used.</message>
  <message line="57" validatedBy="schematron" column="29" location="/article[1]/front[1]/article-meta[1]/history[1]/date[4]/season[1]" id="histdate1d">Do not use "season" (Jan-Mar). "Day" and "month" are the only other elements which should be used.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="Blank file"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="Blank file" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request/><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="-1" validatedBy="DTD" type="fatal-error" column="-1">Premature end of file.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="NON UTF-8"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="NON UTF-8" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">scientificamerican</journal-id>
            <journal-title-group>
                <journal-title>Scientific American</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0036-8733</issn>
            <publisher>
                <publisher-name>Scientific American, Inc.</publisher-name>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">scientificamerican0910-84</article-id>
            <article-id pub-id-type="doi">10.1038/scientificamerican0910-84</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
           </article-categories>
            <title-group>
                <article-title>Could Time End?</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <month>09</month>
                <year>2010</year>
            </pub-date>
            <volume>303</volume>
            <issue>3</issue>
            <fpage>84</fpage>
            <lpage>91</lpage>
            <permissions>
                <copyright-year>2010</copyright-year>
                <copyright-holder>Scientific American, Inc.</copyright-holder>
            </permissions>
            <abstract abstract-type="editor" specific-use="issue">
                <title>Relativity</title>
                <p>Einstein's general theory of relativity predicts that time ends at moments called singularities, such as when matter reaches the center of a black hole or the universe collapses in a Ԣig crunch.ԠYet the theory also predicts that singularities are physically impossible.</p>
                <p>-The Editors</p>
            </abstract>
            <abstract abstract-type="synopsis">
                <p>A way to resolve this paradox is to consider time's death as gradual rather than abrupt. Time might lose its many attributes one by one: its directionality, its notion of duration and its role in ordering events causally. Finally, time might give way to deeper, timeless physics.</p>
            </abstract>
            <abstract abstract-type="key-points">
                <p>Relativity. Einstein. Etc</p>
            </abstract>
            <counts>
                <page-count count="8"/>
            </counts>
        </article-meta>
    </front>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ack 2 - title"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ack 2 - title" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <ack>
     <title>References</title>
<p>This work is supported by <bold>National Basic Research Program</bold><xref ref-type="fn" rid="fn2"><sup>&#x2020;</sup></xref> of Chinese Ministry of Science and Technology to L.Z. (2006CB504200) and by the Tenth Five-year Key Technologies R&amp;D Programme of China:2004BA719A14-1, 2004BA719A14-2. We also thank Mark Goldin for helpful suggestions.</p>

    


</ack>
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>
        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="39" validatedBy="schematron" column="13" location="/article[1]/back[1]/ack[1]/title[1]" id="ack2">Acknowledgements should only contain paragraphs - do not use "title".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="app"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="app" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="re" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">bdj</journal-id>
            <journal-title-group>
                <journal-title>British Dental Journal</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0007-0610</issn>
            <issn pub-type="epub">1476-5373</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">4812905</article-id>
            <article-id pub-id-type="doi">10.1038/sj.bdj.4812905</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>re</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Measuring access to health services: General Dental Services in Scotland</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>12</day>
                <month>11</month>
                <year>2005</year>
            </pub-date>
            <volume>199</volume>
            <issue>9</issue>
            <permissions>
                <copyright-statement>&#x00A9; British Dental Journal 2005</copyright-statement>
                <copyright-year>2005</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <app-group>
            <app>
                <title>Appendix 1</title>
                <p>We assume that there are <italic>I</italic> + 1 groups of individuals within the population. We use <italic>i</italic> = 0, 1, 2, .., <italic>I</italic> to indicate a specific group and assume that group <italic>i</italic> has <italic>n</italic><sub>i</sub> constituent members. For groups <italic>i</italic> &gt; 0 we assume that each of these individuals accesses the services of a GDP every <italic>i</italic> years while for group <italic>i</italic> = 0, we assume that the individuals never visit a dentist. To account for population dynamics, we augment the framework to allow for a fixed proportion <italic>&#x3B4;</italic> of the population to exit (death and out-migration) each year, offset by fixed proportion <italic>&#x3C1;</italic> entrants (births and in-migrants). We are interested in knowing how important each of these groups is as a percentage of the population and in order to obtain a closed-form solution for the population groups <italic>n</italic><sub>i</sub> we assume that <italic>&#x3B4;</italic> = <italic>&#x3C1;</italic>, which is approximately true for the Scottish population. Hence the number of distinct patients observed in year 1 is: deleted illustration</p>
                <p>while in the following year the new patients will be comprised of: deleted illustration</p>
                <p>In subsequent years, account must be taken of both the survival of the births from previous years appearing for the first time (in proportion to their treatment group) to be treated and the exit of those as yet untreated members of infrequent treatment groups.</p>
                <p>The resulting equations can be summarised as: deleted illustration</p>
                <p>or in matrix notation:</p>
                <p>N = Mn.</p>
                <p>The solution of these equations can then be obtained from:</p>
                <p>n = M<sup>&#x2212;1</sup>N.</p>
                <p>We apply this method to data on N derived from our sample and the results, which express the importance of the different groups of participants as a percentage of the total population, are reported in Table 4.</p></app>
            <app>
                <title>Appendix 2</title>
                <p>Some more stuff</p>
            </app>
        </app-group>
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p><bold>Refereed paper</bold></p></fn>
        </fn-group>
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back -1"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back -1" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="er" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">ncpuro</journal-id>
        <journal-title-group><journal-title>Nature Clinical Practice Urology</journal-title></journal-title-group>
        <issn pub-type="ppub">1743-4270</issn>
        <issn pub-type="epub">1743-4289</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="publisher-id">ncpuro0992</article-id>
        <article-id pub-id-type="doi">10.1038/ncpuro0992</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject>er</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Modern management of pheochromocytoma</article-title>
        </title-group>
        <pub-date pub-type="issue-date">
            <month>12</month>
            <year>2007</year>
        </pub-date>
        <volume>4</volume>
        <issue>12</issue>
        <permissions><copyright-year>2007</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
    </article-meta>
</front>
<back>
    <ref-list>
        <title>Further Reading</title>
        <ref id="b1"><mixed-citation publication-type="journal"><string-name><prefix>Prof.</prefix> <surname>Zarnegar</surname>, <given-names>R</given-names></string-name> <etal/>. (<year>2006</year>) <article-title>Malignant pheochromocytoma</article-title>. <source>Surg Oncol Clin N Am</source> <volume>15</volume>: <fpage>555</fpage>&#x2013;<lpage>571</lpage></mixed-citation></ref>
        <ref id="b2"><mixed-citation publication-type="journal"><string-name><surname>Pritchard</surname>, <given-names>H. D.</given-names></string-name> <etal/>. <article-title>Corrected ICESat altimetry data, surface mass balance, and firn elevation change on Antarctic ice shelves</article-title>. <uri xlink:href="http://dx.doi.org/10.1594/PANGAEA.775984">http://dx.doi.org/10.1594/PANGAEA.775984</uri> (PANGAEA Data Publisher for Earth &amp; Environmental Science, <year>2012</year>)</mixed-citation></ref>
    </ref-list>
    </back>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back -2"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back -2" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="af" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">ng</journal-id>
            <journal-title-group>
                <journal-title>Nature Genetics</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">1061-4036</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">ng0399_271</article-id>
            <article-id pub-id-type="doi">10.1038/6784</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>af</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Mutations in <italic>ATP2A2</italic>, encoding a Ca<sup>2+</sup> pump, cause Darier disease</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <month>03</month>
                <year>1999</year>
            </pub-date>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <lpage>277</lpage>
            <permissions>
                <copyright-statement>&#x00A9; 1999 Nature America Inc.</copyright-statement>
                <copyright-year>1999</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
            <counts>
                <page-count count="7"/>
            </counts>
        </article-meta>
    </front>
    <back>
        <ack><p>We thank the clinicians and the families who participated; R. Cox and E. Levy for their contribution in the physical mapping and cytogenetic parts of the project; R. Gibbs for the freely available sequence from the NIH-funded Human Genome Sequencing effort at the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC); and J. Bell for support and encouragement. A.S. has a fellowship from the Royal Thai Government and the faculty of Medicine, Ramathibodi Hospital, Mahidol University; S.M. had a Wellcome Trust prize studentship; A.P.M. is a Wellcome Principal Research Fellow; A.H. held a Wellcome Trust and an EC research fellowship. S.C. was supported by a Wellcome Trust Project Grant awarded to T.S., C.S.M. and J.R.; V.R.-P. holds an EC fellowship. The work in Cardiff was supported by grants from the Wellcome Trust. N.C. is a Wellcome Senior Research Fellow.</p></ack>
        <notes notes-type="database-links">
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A1"><italic>ATP2A1</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="U96781">U96781</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="P11719">P11719</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A2a"><italic>ATP2A2a</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="M23115">M23115</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="1JTG">1JTG</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="AF482946"><italic>AF482946</italic></ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="NP_035333">NP_035333</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link></p>
        </notes>
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back -3"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back -3" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="rhighlts" dtd-version="3.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">nrc</journal-id>
        <journal-title-group><journal-title>Nature Reviews Cancer</journal-title></journal-title-group>
        <issn pub-type="ppub">1474-175X</issn>
        <issn pub-type="epub">1474-1768</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="publisher-id">nrc3250</article-id>
        <article-id pub-id-type="doi">10.1038/nrc3250</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject>rhighlts</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Combinations that work</article-title>
        </title-group>
        <pub-date pub-type="issue-date">
            <month>04</month>
            <year>2012</year>
        </pub-date>
        <volume>12</volume>
        <issue>4</issue>
        <fpage>231</fpage>
        <lpage>231</lpage>
        <permissions><copyright-year>2012</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
        <counts>
            <page-count count="1"/>
        </counts>
    </article-meta>
</front>
<back>
    <ref-list content-type="link-group">
        <title>DATABASES</title>
        <ref-list>
            <title>OMIM</title>
            <ref><element-citation><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=104300">Alzheimer</ext-link></element-citation></ref>
            <ref><element-citation><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=143100">Huntington</ext-link></element-citation></ref></ref-list>
    </ref-list>
    <ref-list content-type="link-group">
        <title>linkout</title>
        <ref><element-citation><ext-link ext-link-type="uri" xlink:href="http://www.ibecbarcelona.eu/">IBEC (Institute for Bioengineering of Catalonia)</ext-link></element-citation></ref>
        <ref><element-citation><ext-link ext-link-type="uri" xlink:href="http://www.upf.edu/en/">Pompeu Fabra University</ext-link></element-citation></ref>
    </ref-list>
    <ref-list>
        <title>ORIGINAL RESEARCH PAPERS</title>
        <ref id="b1">
            <mixed-citation publication-type="journal"><string-name><surname>Kohrt</surname>, <given-names>H. E.</given-names></string-name> <etal/>. <article-title>Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer</article-title>. <source>J. Clin. Invest.</source> <year>2012</year> <month>02</month> <day>13</day> (doi: <elocation-id content-type="doi">10.1172/JCI61226</elocation-id>)</mixed-citation>
        </ref>
    </ref-list>
    <ref-list>
        <title>FURTHER READING</title>
        <ref id="b2">
            <mixed-citation publication-type="journal"><string-name><surname>Vanneman</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Dranoff</surname>, <given-names>G.</given-names></string-name> <article-title>Combining immunotherapy and targeted therapies in cancer treatment</article-title>. <source>Nature Rev. Cancer</source> <volume>12</volume>, <fpage>237</fpage>-<lpage>251</lpage> <elocation-id content-type="doi">10.1038/nrc3237</elocation-id> (<year>2011</year>)</mixed-citation></ref>
        <ref id="b3">
            <mixed-citation publication-type="book">&#x201C;<source>Sources of Nitrogen Compounds in the United States</source>.&#x201D; By <string-name><prefix>Dr.</prefix> <given-names>C. G.</given-names> <surname>Gilbert</surname></string-name>. (Smithsonian Institution, Washington, <year>1916</year>.)</mixed-citation>
        </ref>
    </ref-list>
  </back>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back -4"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back -4" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="cstory" dtd-version="3.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
<front>
    <journal-meta>
        <journal-id journal-id-type="publisher">scibx</journal-id>
        <journal-title-group><journal-title>Science-Business eXchange</journal-title></journal-title-group>
        <issn pub-type="epub">1945-3477</issn>
        <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="publisher-id">scibx.2010.940</article-id>
        <article-id pub-id-type="doi">10.1038/scibx.2010.940</article-id>
        <article-categories>
            <subj-group subj-group-type="category">
                <subject>cstory</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Resolving the PPAR<sub>&#x3B3;</sub> paradox</article-title>
            <alt-title alt-title-type="alt-title">New antidiabetic mechanism of PPAR<sub>&#x3B3;</sub> agonists</alt-title>
        </title-group>
        <pub-date pub-type="issue-date">
            <day>12</day>
            <month>08</month>
            <year>2010</year>
        </pub-date>
        <volume>3</volume>
        <issue>31</issue>
        <permissions><copyright-year>2010</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions>
    </article-meta>
</front>
<back>
    <ref-list>
        <title>References</title>
        <ref id="b1">
            <mixed-citation publication-type="journal"><string-name><surname>Choi</surname>, <given-names>J.H.</given-names></string-name> <etal/>. <source>Nature</source>; published online  <year>2010</year> <month>07</month> <day>21</day>; <elocation-id content-type="doi">10.1038/nature09291</elocation-id> <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email xlink:href="bruce_spiegelman@dfci.harvard.edu">bruce_spiegelman@dfci.harvard.edu</email></named-content></mixed-citation>
        </ref>
        <ref id="b2">
            <mixed-citation publication-type="journal"><string-name><surname>Usdin</surname>, <given-names>S.</given-names></string-name> <source>BioCentury</source> <volume>18</volume>(<issue>32</issue>), <fpage>A6</fpage>; <year>2010</year><month>07</month><day>09</day></mixed-citation>
        </ref>
        <ref id="b3">
            <mixed-citation publication-type="journal"><string-name><surname>Motani</surname>, <given-names>A.</given-names></string-name> <etal/>. <source>J. Mol. Biol.</source> <volume>386</volume>, <fpage>1301</fpage>&#x2013;<lpage>1311</lpage> (<year>2009</year>)</mixed-citation>
        </ref>
        <ref id="b4">
            <mixed-citation publication-type="journal"><string-name><surname>Gregoire</surname>, <given-names>F.M.</given-names></string-name> <etal/>. <source>Mol. Endocrinol.</source> <volume>23</volume>, <fpage>975</fpage>&#x2013;<lpage>988</lpage> (<year>2009</year>)</mixed-citation>
        </ref>
        <ref id="b5">
            <mixed-citation publication-type="journal"><string-name><surname>Acton</surname>, <given-names>J.J.</given-names> <suffix>III</suffix></string-name> <etal/>. <source>Bioorg. Med. Chem. Lett.</source> <volume>15</volume>, <fpage>357</fpage>&#x2013;<lpage>362</lpage> (<year>2005</year>)</mixed-citation>
        </ref>
        <ref id="b6">
            <mixed-citation publication-type="journal"><string-name><surname>Bruning</surname>, <given-names>J.B.</given-names></string-name> <etal/>. <source>Structure</source> <volume>15</volume>, <fpage>1258</fpage>&#x2013;<lpage>1271</lpage> (<year>2007</year>)
        </mixed-citation></ref>
    </ref-list>
    </back>
</article>
]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ack 2 - ref list"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ack 2 - ref list" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <ack>
<p>This work is supported by <bold>National Basic Research Program</bold><xref ref-type="fn" rid="fn2"><sup>&#x2020;</sup></xref> of Chinese Ministry of Science and Technology to L.Z. (2006CB504200) and by the Tenth Five-year Key Technologies R&amp;D Programme of China:2004BA719A14-1, 2004BA719A14-2. We also thank Mark Goldin for helpful suggestions.</p>
     <ref-list>
        <title>References</title>
        <ref id="b1">
            <mixed-citation publication-type="journal"><string-name><surname>Choi</surname>, <given-names>J.H.</given-names></string-name> <etal/>. <source>Nature</source>; published online  <year>2010</year> <month>07</month> <day>21</day>; <elocation-id content-type="doi">10.1038/nature09291</elocation-id> <named-content content-type="contact">Bruce Spiegelman, Harvard Medical School, Boston, Mass. <email xlink:href="bruce_spiegelman@dfci.harvard.edu">bruce_spiegelman@dfci.harvard.edu</email></named-content></mixed-citation>
        </ref>
        <ref id="b2">
            <mixed-citation publication-type="journal"><string-name><surname>Usdin</surname>, <given-names>S.</given-names></string-name> <source>BioCentury</source> <volume>18</volume>(<issue>32</issue>), <fpage>A6</fpage>; <year>2010</year><month>07</month><day>09</day></mixed-citation>
        </ref>
        <ref id="b3">
            <mixed-citation publication-type="journal"><string-name><surname>Motani</surname>, <given-names>A.</given-names></string-name> <etal/>. <source>J. Mol. Biol.</source> <volume>386</volume>, <fpage>1301</fpage>&#x2013;<lpage>1311</lpage> (<year>2009</year>)</mixed-citation>
        </ref>
        <ref id="b4">
            <mixed-citation publication-type="journal"><string-name><surname>Gregoire</surname>, <given-names>F.M.</given-names></string-name> <etal/>. <source>Mol. Endocrinol.</source> <volume>23</volume>, <fpage>975</fpage>&#x2013;<lpage>988</lpage> (<year>2009</year>)</mixed-citation>
        </ref>
        <ref id="b5">
            <mixed-citation publication-type="journal"><string-name><surname>Acton</surname>, <given-names>J.J.</given-names> <suffix>III</suffix></string-name> <etal/>. <source>Bioorg. Med. Chem. Lett.</source> <volume>15</volume>, <fpage>357</fpage>&#x2013;<lpage>362</lpage> (<year>2005</year>)</mixed-citation>
        </ref>
        <ref id="b6">
            <mixed-citation publication-type="journal"><string-name><surname>Bruning</surname>, <given-names>J.B.</given-names></string-name> <etal/>. <source>Structure</source> <volume>15</volume>, <fpage>1258</fpage>&#x2013;<lpage>1271</lpage> (<year>2007</year>)
        </mixed-citation></ref>
    </ref-list>


    


</ack>
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>
        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="40" validatedBy="schematron" column="16" location="/article[1]/back[1]/ack[1]/ref-list[1]" id="ack2">Acknowledgements should only contain paragraphs - do not use "ref-list".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ack 2 - label"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ack 2 - label" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <ack>
   <label>abckkkkk</label>
<p>This work is supported by <bold>National Basic Research Program</bold><xref ref-type="fn" rid="fn2"><sup>&#x2020;</sup></xref> of Chinese Ministry of Science and Technology to L.Z. (2006CB504200) and by the Tenth Five-year Key Technologies R&amp;D Programme of China:2004BA719A14-1, 2004BA719A14-2. We also thank Mark Goldin for helpful suggestions.</p>



    


</ack>
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>
        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="39" validatedBy="schematron" column="11" location="/article[1]/back[1]/ack[1]/label[1]" id="ack2">Acknowledgements should only contain paragraphs - do not use "label".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="ack 2 - missing"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="ack 2 - missing" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
      
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>
        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="app=missing"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="app=missing" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="re" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">bdj</journal-id>
            <journal-title-group>
                <journal-title>British Dental Journal</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0007-0610</issn>
            <issn pub-type="epub">1476-5373</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">4812905</article-id>
            <article-id pub-id-type="doi">10.1038/sj.bdj.4812905</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>re</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Measuring access to health services: General Dental Services in Scotland</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>12</day>
                <month>11</month>
                <year>2005</year>
            </pub-date>
            <volume>199</volume>
            <issue>9</issue>
            <permissions>
                <copyright-statement>&#x00A9; British Dental Journal 2005</copyright-statement>
                <copyright-year>2005</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
     
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p><bold>Refereed paper</bold></p></fn>
        </fn-group>
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="app1- group =2"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="app1- group =2" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="re" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">bdj</journal-id>
            <journal-title-group>
                <journal-title>British Dental Journal</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0007-0610</issn>
            <issn pub-type="epub">1476-5373</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">4812905</article-id>
            <article-id pub-id-type="doi">10.1038/sj.bdj.4812905</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>re</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Measuring access to health services: General Dental Services in Scotland</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>12</day>
                <month>11</month>
                <year>2005</year>
            </pub-date>
            <volume>199</volume>
            <issue>9</issue>
            <permissions>
                <copyright-statement>&#x00A9; British Dental Journal 2005</copyright-statement>
                <copyright-year>2005</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <app-group>
            <app>
                <title>Appendix 1</title>
                <p>We assume that there are <italic>I</italic> + 1 groups of individuals within the population. We use <italic>i</italic> = 0, 1, 2, .., <italic>I</italic> to indicate a specific group and assume that group <italic>i</italic> has <italic>n</italic><sub>i</sub> constituent members. For groups <italic>i</italic> &gt; 0 we assume that each of these individuals accesses the services of a GDP every <italic>i</italic> years while for group <italic>i</italic> = 0, we assume that the individuals never visit a dentist. To account for population dynamics, we augment the framework to allow for a fixed proportion <italic>&#x3B4;</italic> of the population to exit (death and out-migration) each year, offset by fixed proportion <italic>&#x3C1;</italic> entrants (births and in-migrants). We are interested in knowing how important each of these groups is as a percentage of the population and in order to obtain a closed-form solution for the population groups <italic>n</italic><sub>i</sub> we assume that <italic>&#x3B4;</italic> = <italic>&#x3C1;</italic>, which is approximately true for the Scottish population. Hence the number of distinct patients observed in year 1 is: deleted illustration</p>
                <p>while in the following year the new patients will be comprised of: deleted illustration</p>
                <p>In subsequent years, account must be taken of both the survival of the births from previous years appearing for the first time (in proportion to their treatment group) to be treated and the exit of those as yet untreated members of infrequent treatment groups.</p>
                <p>The resulting equations can be summarised as: deleted illustration</p>
                <p>or in matrix notation:</p>
                <p>N = Mn.</p>
                <p>The solution of these equations can then be obtained from:</p>
                <p>n = M<sup>&#x2212;1</sup>N.</p>
                <p>We apply this method to data on N derived from our sample and the results, which express the importance of the different groups of participants as a percentage of the total population, are reported in Table 4.</p></app>
            <app>
                <title>Appendix 2</title>
                <p>Some more stuff</p>
            </app>
        </app-group>
 <app-group>
            <app>
                <title>Appendix 1</title>
                <p>We assume that there are <italic>I</italic> + 1 groups of individuals within the population. We use <italic>i</italic> = 0, 1, 2, .., <italic>I</italic> to indicate a specific group and assume that group <italic>i</italic> has <italic>n</italic><sub>i</sub> constituent members. For groups <italic>i</italic> &gt; 0 we assume that each of these individuals accesses the services of a GDP every <italic>i</italic> years while for group <italic>i</italic> = 0, we assume that the individuals never visit a dentist. To account for population dynamics, we augment the framework to allow for a fixed proportion <italic>&#x3B4;</italic> of the population to exit (death and out-migration) each year, offset by fixed proportion <italic>&#x3C1;</italic> entrants (births and in-migrants). We are interested in knowing how important each of these groups is as a percentage of the population and in order to obtain a closed-form solution for the population groups <italic>n</italic><sub>i</sub> we assume that <italic>&#x3B4;</italic> = <italic>&#x3C1;</italic>, which is approximately true for the Scottish population. Hence the number of distinct patients observed in year 1 is: deleted illustration</p>
                <p>while in the following year the new patients will be comprised of: deleted illustration</p>
                <p>In subsequent years, account must be taken of both the survival of the births from previous years appearing for the first time (in proportion to their treatment group) to be treated and the exit of those as yet untreated members of infrequent treatment groups.</p>
                <p>The resulting equations can be summarised as: deleted illustration</p>
                <p>or in matrix notation:</p>
                <p>N = Mn.</p>
                <p>The solution of these equations can then be obtained from:</p>
                <p>n = M<sup>&#x2212;1</sup>N.</p>
                <p>We apply this method to data on N derived from our sample and the results, which express the importance of the different groups of participants as a percentage of the total population, are reported in Table 4.</p></app>
            <app>
                <title>Appendix 2</title>
                <p>Some more stuff</p>
            </app>
        </app-group>
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p><bold>Refereed paper</bold></p></fn>
        </fn-group>
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="57" validatedBy="schematron" column="13" location="/article[1]/back[1]/app-group[2]" id="app1">There should only be one appendix grouping.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="app2a - other elements"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="app2a - other elements" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="re" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">bdj</journal-id>
            <journal-title-group>
                <journal-title>British Dental Journal</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0007-0610</issn>
            <issn pub-type="epub">1476-5373</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">4812905</article-id>
            <article-id pub-id-type="doi">10.1038/sj.bdj.4812905</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>re</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Measuring access to health services: General Dental Services in Scotland</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>12</day>
                <month>11</month>
                <year>2005</year>
            </pub-date>
            <volume>199</volume>
            <issue>9</issue>
            <permissions>
                <copyright-statement>&#x00A9; British Dental Journal 2005</copyright-statement>
                <copyright-year>2005</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>

        <app-group>
<label>ghdagha</label>
   <p>or in matrix notation:</p>

    
            <app>
                <title>Appendix 1</title>
                <p>We assume that there are <italic>I</italic> + 1 groups of individuals within the population. We use <italic>i</italic> = 0, 1, 2, .., <italic>I</italic> to indicate a specific group and assume that group <italic>i</italic> has <italic>n</italic><sub>i</sub> constituent members. For groups <italic>i</italic> &gt; 0 we assume that each of these individuals accesses the services of a GDP every <italic>i</italic> years while for group <italic>i</italic> = 0, we assume that the individuals never visit a dentist. To account for population dynamics, we augment the framework to allow for a fixed proportion <italic>&#x3B4;</italic> of the population to exit (death and out-migration) each year, offset by fixed proportion <italic>&#x3C1;</italic> entrants (births and in-migrants). We are interested in knowing how important each of these groups is as a percentage of the population and in order to obtain a closed-form solution for the population groups <italic>n</italic><sub>i</sub> we assume that <italic>&#x3B4;</italic> = <italic>&#x3C1;</italic>, which is approximately true for the Scottish population. Hence the number of distinct patients observed in year 1 is: deleted illustration</p>
                <p>while in the following year the new patients will be comprised of: deleted illustration</p>
                <p>In subsequent years, account must be taken of both the survival of the births from previous years appearing for the first time (in proportion to their treatment group) to be treated and the exit of those as yet untreated members of infrequent treatment groups.</p>
                <p>The resulting equations can be summarised as: deleted illustration</p>
                <p>or in matrix notation:</p>
                <p>N = Mn.</p>
                <p>The solution of these equations can then be obtained from:</p>
                <p>n = M<sup>&#x2212;1</sup>N.</p>
                <p>We apply this method to data on N derived from our sample and the results, which express the importance of the different groups of participants as a percentage of the total population, are reported in Table 4.</p></app>
            <app>
                <title>Appendix 2</title>
                <p>Some more stuff</p>
            </app>
   <app>
                <title>Appendix 1</title>
                <p>We assume that there are <italic>I</italic> + 1 groups of individuals within the population. We use <italic>i</italic> = 0, 1, 2, .., <italic>I</italic> to indicate a specific group and assume that group <italic>i</italic> has <italic>n</italic><sub>i</sub> constituent members. For groups <italic>i</italic> &gt; 0 we assume that each of these individuals accesses the services of a GDP every <italic>i</italic> years while for group <italic>i</italic> = 0, we assume that the individuals never visit a dentist. To account for population dynamics, we augment the framework to allow for a fixed proportion <italic>&#x3B4;</italic> of the population to exit (death and out-migration) each year, offset by fixed proportion <italic>&#x3C1;</italic> entrants (births and in-migrants). We are interested in knowing how important each of these groups is as a percentage of the population and in order to obtain a closed-form solution for the population groups <italic>n</italic><sub>i</sub> we assume that <italic>&#x3B4;</italic> = <italic>&#x3C1;</italic>, which is approximately true for the Scottish population. Hence the number of distinct patients observed in year 1 is: deleted illustration</p>
                <p>while in the following year the new patients will be comprised of: deleted illustration</p>
                <p>In subsequent years, account must be taken of both the survival of the births from previous years appearing for the first time (in proportion to their treatment group) to be treated and the exit of those as yet untreated members of infrequent treatment groups.</p>
                <p>The resulting equations can be summarised as: deleted illustration</p>
                <p>or in matrix notation:</p>
                <p>N = Mn.</p>
                <p>The solution of these equations can then be obtained from:</p>
                <p>n = M<sup>&#x2212;1</sup>N.</p>
                <p>We apply this method to data on N derived from our sample and the results, which express the importance of the different groups of participants as a percentage of the total population, are reported in Table 4.</p></app>
            <app>
                <title>Appendix 2</title>
                <p>Some more stuff</p>
            </app>
        </app-group>

        <fn-group content-type="endnotes">
            <fn fn-type="other"><p><bold>Refereed paper</bold></p></fn>
        </fn-group>
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="42" validatedBy="schematron" column="8" location="/article[1]/back[1]/app-group[1]/label[1]" id="app2">Only "p" and "app" should be used in "app-group". Do not use "label".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="bio 1- 1 bio"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="bio 1- 1 bio" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
      
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
  <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
        <fn-group content-type="endnotes">
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>
        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="40" validatedBy="schematron" column="8" location="/article[1]/back[1]/bio[2]" id="bio1">There should only be one "bio" (author information section) in "back".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="bio2- Others"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="bio2- Others" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
      
          <bio>
<label>absghsgh</label>
<p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p>
</bio>

        <fn-group content-type="endnotes">
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>
        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="40" validatedBy="schematron" column="8" location="/article[1]/back[1]/bio[1]/label[1]" id="bio2">"bio" (author information section) in "back" should only contain paragraphs - do not use "label".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back-fn1 - no label or title in fn-group"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back-fn1 - no label or title in fn-group" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <ack>
     <title>References</title>
<p>This work is supported by <bold>National Basic Research Program</bold><xref ref-type="fn" rid="fn2"><sup>&#x2020;</sup></xref> of Chinese Ministry of Science and Technology to L.Z. (2006CB504200) and by the Tenth Five-year Key Technologies R&amp;D Programme of China:2004BA719A14-1, 2004BA719A14-2. We also thank Mark Goldin for helpful suggestions.</p>

    


</ack>
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
        <fn-group content-type="endnotes">
<label>hsdsdj</label>
<title>hghasd</title>
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>

        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="13" location="/article[1]/back[1]/ack[1]/title[1]" id="ack2">Acknowledgements should only contain paragraphs - do not use "title".</message>
  <message line="48" validatedBy="schematron" column="8" location="/article[1]/back[1]/fn-group[1]/label[1]" id="back-fn1">Do not use "label" at start of footnote group in "back" matter.</message>
  <message line="49" validatedBy="schematron" column="8" location="/article[1]/back[1]/fn-group[1]/title[1]" id="back-fn1">Do not use "title" at start of footnote group in "back" matter.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back-fn2a - content-type declared on fn-group"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back-fn2a - content-type declared on fn-group" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <ack>
     <title>References</title>
<p>This work is supported by <bold>National Basic Research Program</bold><xref ref-type="fn" rid="fn2"><sup>&#x2020;</sup></xref> of Chinese Ministry of Science and Technology to L.Z. (2006CB504200) and by the Tenth Five-year Key Technologies R&amp;D Programme of China:2004BA719A14-1, 2004BA719A14-2. We also thank Mark Goldin for helpful suggestions.</p>

    


</ack>
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
        <fn-group content-type="endnotes">
<label>hsdsdj</label>
<title>hghasd</title>
            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>

        </fn-group>
        <fn-group>
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="54" validatedBy="schematron" column="19" location="/article[1]/back[1]/fn-group[2]" id="back-fn2a">Footnote groups in back matter should have 'content-type' attribute stated. Allowed values are "endnotes" or "footnotes".</message>
  <message line="39" validatedBy="schematron" column="13" location="/article[1]/back[1]/ack[1]/title[1]" id="ack2">Acknowledgements should only contain paragraphs - do not use "title".</message>
  <message line="48" validatedBy="schematron" column="8" location="/article[1]/back[1]/fn-group[1]/label[1]" id="back-fn1">Do not use "label" at start of footnote group in "back" matter.</message>
  <message line="49" validatedBy="schematron" column="8" location="/article[1]/back[1]/fn-group[1]/title[1]" id="back-fn1">Do not use "title" at start of footnote group in "back" matter.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back2b - fn group content type=en or fn"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back2b - fn group content type=en or fn" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <ack>
 
<p>This work is supported by <bold>National Basic Research Program</bold><xref ref-type="fn" rid="fn2"><sup>&#x2020;</sup></xref> of Chinese Ministry of Science and Technology to L.Z. (2006CB504200) and by the Tenth Five-year Key Technologies R&amp;D Programme of China:2004BA719A14-1, 2004BA719A14-2. We also thank Mark Goldin for helpful suggestions.</p>

    


</ack>
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
  
        <fn-group content-type="abc">

            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>

        </fn-group>
        <fn-group content-type="ram">
            <fn id="fn1"><p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="48" validatedBy="schematron" column="38" location="/article[1]/back[1]/fn-group[1]" id="back-fn2b">Allowed values for 'content-type' attribute on "fn-group" are "endnotes" or "footnotes".</message>
  <message line="54" validatedBy="schematron" column="38" location="/article[1]/back[1]/fn-group[2]" id="back-fn2b">Allowed values for 'content-type' attribute on "fn-group" are "endnotes" or "footnotes".</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="back3"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="back3" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="fe" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">nature</journal-id>
            <journal-title-group>
                <journal-title>Nature</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0028-0836</issn>
            <issn pub-type="epub">1476-4687</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">455609a</article-id>
            <article-id pub-id-type="doi">10.1038/455609a</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>fe</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The changing face of HIV<xref ref-type="fn" rid="fn1"/> in China</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <day>02</day>
                <month>10</month>
                <year>2008</year>
            </pub-date>
            <permissions>
                <copyright-statement>&#x00A9; 2008 Macmillan Publishers Limited. All rights reserved.</copyright-statement>
                <copyright-year>2008</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
        </article-meta>
    </front>
    <back>
        <ack>
 
<p>This work is supported by <bold>National Basic Research Program</bold><xref ref-type="fn" rid="fn2"><sup>&#x2020;</sup></xref> of Chinese Ministry of Science and Technology to L.Z. (2006CB504200) and by the Tenth Five-year Key Technologies R&amp;D Programme of China:2004BA719A14-1, 2004BA719A14-2. We also thank Mark Goldin for helpful suggestions.</p>

    


</ack>
          <bio><p>Correspondence should be addressed to L.Z. (<email xlink:href="lzhang07@hotmail.com">lzhang07@hotmail.com</email> or <email xlink:href="jiangyan03@263.net">jiangyan03@263.net</email>) or <email xlink:href="randy_hornmeister@scientist.com">Dr Randy Hornmeister</email>. L.L. and M.J. contributed equally to this work.</p></bio>
  
        <fn-group content-type="endnotes">

            <fn fn-type="other"><p>See Editorial, <related-article related-article-type="see-also" ext-link-type="article-id" xlink:role="xnav" xlink:href="455566b"><italic>page</italic> 566</related-article>.</p></fn>
            <fn fn-type="other"><p><bold>Author Contributions</bold> E.E.E., D.A.N., D.A., A.F., J.R.L. and S.T.S. wrote the manuscript. A.M.B, L.D.B., N.P.C., D.M.C., M.G., C.L., J.C.M., J.K.P., J.S., D.S., D.V. and R.H.W. contributed to the plan design and provided comments and suggestions during preparation of the manuscript.</p></fn>

        </fn-group>
        <fn-group content-type="footnotes">
            <fn id="fn1">
<label>gjsjs</label>

<p>HIV = Human Immunodeficiency Virus</p></fn>
            <fn id="fn2"><p><sup>&#x2020;</sup> also called 973 Program</p></fn>
        </fn-group>
  

    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="56" validatedBy="schematron" column="8" location="/article[1]/back[1]/fn-group[2]/fn[1]/label[1]" id="back-fn3">Do not use "label" in footnotes in back matter - any symbols should be included at the start of the footnote text.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="notes1"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="notes1" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="af" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">ng</journal-id>
            <journal-title-group>
                <journal-title>Nature Genetics</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">1061-4036</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">ng0399_271</article-id>
            <article-id pub-id-type="doi">10.1038/6784</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>af</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Mutations in <italic>ATP2A2</italic>, encoding a Ca<sup>2+</sup> pump, cause Darier disease</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <month>03</month>
                <year>1999</year>
            </pub-date>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <lpage>277</lpage>
            <permissions>
                <copyright-statement>&#x00A9; 1999 Nature America Inc.</copyright-statement>
                <copyright-year>1999</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
            <counts>
                <page-count count="7"/>
            </counts>
        </article-meta>
    </front>
    <back>
        <ack><p>We thank the clinicians and the families who participated; R. Cox and E. Levy for their contribution in the physical mapping and cytogenetic parts of the project; R. Gibbs for the freely available sequence from the NIH-funded Human Genome Sequencing effort at the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC); and J. Bell for support and encouragement. A.S. has a fellowship from the Royal Thai Government and the faculty of Medicine, Ramathibodi Hospital, Mahidol University; S.M. had a Wellcome Trust prize studentship; A.P.M. is a Wellcome Principal Research Fellow; A.H. held a Wellcome Trust and an EC research fellowship. S.C. was supported by a Wellcome Trust Project Grant awarded to T.S., C.S.M. and J.R.; V.R.-P. holds an EC fellowship. The work in Cardiff was supported by grants from the Wellcome Trust. N.C. is a Wellcome Senior Research Fellow.</p></ack>
        <notes notes-type="database-links">
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A1"><italic>ATP2A1</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="U96781">U96781</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="P11719">P11719</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A2a"><italic>ATP2A2a</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="M23115">M23115</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="1JTG">1JTG</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="AF482946"><italic>AF482946</italic></ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="NP_035333">NP_035333</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link></p>
        </notes>
        <notes notes-type="database-links">
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A1"><italic>ATP2A1</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="U96781">U96781</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="P11719">P11719</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A2a"><italic>ATP2A2a</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="M23115">M23115</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="1JTG">1JTG</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="AF482946"><italic>AF482946</italic></ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="NP_035333">NP_035333</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link></p>
        </notes>
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="55" validatedBy="schematron" column="44" location="/article[1]/back[1]/notes[2]" id="notes1">There should only be one "notes" (accession group) in "back".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="notes2a"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="notes2a" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="af" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">ng</journal-id>
            <journal-title-group>
                <journal-title>Nature Genetics</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">1061-4036</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">ng0399_271</article-id>
            <article-id pub-id-type="doi">10.1038/6784</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>af</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Mutations in <italic>ATP2A2</italic>, encoding a Ca<sup>2+</sup> pump, cause Darier disease</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <month>03</month>
                <year>1999</year>
            </pub-date>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <lpage>277</lpage>
            <permissions>
                <copyright-statement>&#x00A9; 1999 Nature America Inc.</copyright-statement>
                <copyright-year>1999</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
            <counts>
                <page-count count="7"/>
            </counts>
        </article-meta>
    </front>
    <back>
        <ack><p>We thank the clinicians and the families who participated; R. Cox and E. Levy for their contribution in the physical mapping and cytogenetic parts of the project; R. Gibbs for the freely available sequence from the NIH-funded Human Genome Sequencing effort at the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC); and J. Bell for support and encouragement. A.S. has a fellowship from the Royal Thai Government and the faculty of Medicine, Ramathibodi Hospital, Mahidol University; S.M. had a Wellcome Trust prize studentship; A.P.M. is a Wellcome Principal Research Fellow; A.H. held a Wellcome Trust and an EC research fellowship. S.C. was supported by a Wellcome Trust Project Grant awarded to T.S., C.S.M. and J.R.; V.R.-P. holds an EC fellowship. The work in Cardiff was supported by grants from the Wellcome Trust. N.C. is a Wellcome Senior Research Fellow.</p></ack>
        <notes notes-type="abc">
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A1"><italic>ATP2A1</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="U96781">U96781</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="P11719">P11719</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A2a"><italic>ATP2A2a</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="M23115">M23115</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="1JTG">1JTG</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="AF482946"><italic>AF482946</italic></ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="NP_035333">NP_035333</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link></p>
        </notes>
       
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="44" validatedBy="schematron" column="33" location="/article[1]/back[1]/notes[1]" id="notes2a">Notes should have attribute @notes-type="database-links".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="notes3a"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="notes3a" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="af" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">ng</journal-id>
            <journal-title-group>
                <journal-title>Nature Genetics</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">1061-4036</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">ng0399_271</article-id>
            <article-id pub-id-type="doi">10.1038/6784</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>af</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Mutations in <italic>ATP2A2</italic>, encoding a Ca<sup>2+</sup> pump, cause Darier disease</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <month>03</month>
                <year>1999</year>
            </pub-date>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <lpage>277</lpage>
            <permissions>
                <copyright-statement>&#x00A9; 1999 Nature America Inc.</copyright-statement>
                <copyright-year>1999</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
            <counts>
                <page-count count="7"/>
            </counts>
        </article-meta>
    </front>
    <back>
        <ack><p>We thank the clinicians and the families who participated; R. Cox and E. Levy for their contribution in the physical mapping and cytogenetic parts of the project; R. Gibbs for the freely available sequence from the NIH-funded Human Genome Sequencing effort at the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC); and J. Bell for support and encouragement. A.S. has a fellowship from the Royal Thai Government and the faculty of Medicine, Ramathibodi Hospital, Mahidol University; S.M. had a Wellcome Trust prize studentship; A.P.M. is a Wellcome Principal Research Fellow; A.H. held a Wellcome Trust and an EC research fellowship. S.C. was supported by a Wellcome Trust Project Grant awarded to T.S., C.S.M. and J.R.; V.R.-P. holds an EC fellowship. The work in Cardiff was supported by grants from the Wellcome Trust. N.C. is a Wellcome Senior Research Fellow.</p></ack>
        <notes notes-type="database-links">
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A1"><italic>ATP2A1</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="U96781">U96781</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="P11719">P11719</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A2a"><italic>ATP2A2a</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="M23115">M23115</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="1JTG">1JTG</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="AF482946"><italic>AF482946</italic></ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="NP_035333">NP_035333</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link></p>
        </notes>
    
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="53" validatedBy="schematron" column="16" location="/article[1]/back[1]/notes[1]/p[9]" id="notes3a">Take a new paragraph for each "ext-link" in the database link (notes) section.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="notes4a 4b 4c 4d"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="notes4a 4b 4c 4d" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="af" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">ng</journal-id>
            <journal-title-group>
                <journal-title>Nature Genetics</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">1061-4036</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">ng0399_271</article-id>
            <article-id pub-id-type="doi">10.1038/6784</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>af</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Mutations in <italic>ATP2A2</italic>, encoding a Ca<sup>2+</sup> pump, cause Darier disease</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <month>03</month>
                <year>1999</year>
            </pub-date>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <lpage>277</lpage>
            <permissions>
                <copyright-statement>&#x00A9; 1999 Nature America Inc.</copyright-statement>
                <copyright-year>1999</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
            <counts>
                <page-count count="7"/>
            </counts>
        </article-meta>
    </front>
    <back>
        <ack><p>We thank the clinicians and the families who participated; R. Cox and E. Levy for their contribution in the physical mapping and cytogenetic parts of the project; R. Gibbs for the freely available sequence from the NIH-funded Human Genome Sequencing effort at the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC); and J. Bell for support and encouragement. A.S. has a fellowship from the Royal Thai Government and the faculty of Medicine, Ramathibodi Hospital, Mahidol University; S.M. had a Wellcome Trust prize studentship; A.P.M. is a Wellcome Principal Research Fellow; A.H. held a Wellcome Trust and an EC research fellowship. S.C. was supported by a Wellcome Trust Project Grant awarded to T.S., C.S.M. and J.R.; V.R.-P. holds an EC fellowship. The work in Cardiff was supported by grants from the Wellcome Trust. N.C. is a Wellcome Senior Research Fellow.</p></ack>
        <notes notes-type="database-links">
            <p><ext-link  xlink:href="ATP2A1"><italic>ATP2A1</italic></ext-link></p>
            <p><ext-link ext-link-type="abc" xlink:href="U96781">U96781</ext-link></p>
            <p><ext-link ext-link-type="genbank">P11719</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A2b"><italic>ATP2A2a</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="M23115">M23117</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="1JTG">1JTG</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="AF482946"><italic>AF482946</italic></ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="NP_035333">NP_035333</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link></p>
        </notes>
    
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="47" location="/article[1]/back[1]/notes[1]/p[1]/ext-link[1]" id="notes4a">External links to databases should have 'ext-link-type' attribute stated. Allowed values are "genbank" or "pdb".</message>
  <message line="46" validatedBy="schematron" column="66" location="/article[1]/back[1]/notes[1]/p[2]/ext-link[1]" id="notes4b">Allowed values for 'ext-link-type' attribute on "ext-link" in notes section are "genbank" or "pdb".</message>
  <message line="47" validatedBy="schematron" column="50" location="/article[1]/back[1]/notes[1]/p[3]/ext-link[1]" id="notes4c">External database links should have attribute 'xlink:href' declared.</message>
  <message line="48" validatedBy="schematron" column="71" location="/article[1]/back[1]/notes[1]/p[4]/ext-link[1]" id="notes4d">'xlink:href' should be equal to the link text (ATP2A2a).</message>
  <message line="49" validatedBy="schematron" column="70" location="/article[1]/back[1]/notes[1]/p[5]/ext-link[1]" id="notes4d">'xlink:href' should be equal to the link text (M23117).</message>
  <message line="53" validatedBy="schematron" column="16" location="/article[1]/back[1]/notes[1]/p[9]" id="notes3a">Take a new paragraph for each "ext-link" in the database link (notes) section.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="notes2b"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="notes2b" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:encoding>UTF-8</con:encoding><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article article-type="af" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">ng</journal-id>
            <journal-title-group>
                <journal-title>Nature Genetics</journal-title>
            </journal-title-group>
            <issn pub-type="ppub">1061-4036</issn>
            <publisher><publisher-name>Nature Publishing Group</publisher-name></publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">ng0399_271</article-id>
            <article-id pub-id-type="doi">10.1038/6784</article-id>
            <article-categories>
                <subj-group subj-group-type="category">
                    <subject>af</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Mutations in <italic>ATP2A2</italic>, encoding a Ca<sup>2+</sup> pump, cause Darier disease</article-title>
            </title-group>
            <pub-date pub-type="issue-date">
                <month>03</month>
                <year>1999</year>
            </pub-date>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <lpage>277</lpage>
            <permissions>
                <copyright-statement>&#x00A9; 1999 Nature America Inc.</copyright-statement>
                <copyright-year>1999</copyright-year>
                <copyright-holder>Nature Publishing Group</copyright-holder>
            </permissions>
            <counts>
                <page-count count="7"/>
            </counts>
        </article-meta>
    </front>
    <back>
        <ack><p>We thank the clinicians and the families who participated; R. Cox and E. Levy for their contribution in the physical mapping and cytogenetic parts of the project; R. Gibbs for the freely available sequence from the NIH-funded Human Genome Sequencing effort at the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC); and J. Bell for support and encouragement. A.S. has a fellowship from the Royal Thai Government and the faculty of Medicine, Ramathibodi Hospital, Mahidol University; S.M. had a Wellcome Trust prize studentship; A.P.M. is a Wellcome Principal Research Fellow; A.H. held a Wellcome Trust and an EC research fellowship. S.C. was supported by a Wellcome Trust Project Grant awarded to T.S., C.S.M. and J.R.; V.R.-P. holds an EC fellowship. The work in Cardiff was supported by grants from the Wellcome Trust. N.C. is a Wellcome Senior Research Fellow.</p></ack>
        <notes notes-type="database-links" id="abc">
            <p><ext-link  xlink:href="ATP2A1"><italic>ATP2A1</italic></ext-link></p>
            <p><ext-link ext-link-type="abc" xlink:href="U96781">U96781</ext-link></p>
            <p><ext-link ext-link-type="genbank">P11719</ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="ATP2A2b"><italic>ATP2A2a</italic></ext-link></p>
            <p><ext-link ext-link-type="genbank" xlink:href="M23115">M23117</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="1JTG">1JTG</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="AF482946"><italic>AF482946</italic></ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="NP_035333">NP_035333</ext-link></p>
            <p><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link><ext-link ext-link-type="pdb" xlink:href="P29352">P29352</ext-link></p>
        </notes>
    
    </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="47" location="/article[1]/back[1]/notes[1]/p[1]/ext-link[1]" id="notes4a">External links to databases should have 'ext-link-type' attribute stated. Allowed values are "genbank" or "pdb".</message>
  <message line="46" validatedBy="schematron" column="66" location="/article[1]/back[1]/notes[1]/p[2]/ext-link[1]" id="notes4b">Allowed values for 'ext-link-type' attribute on "ext-link" in notes section are "genbank" or "pdb".</message>
  <message line="47" validatedBy="schematron" column="50" location="/article[1]/back[1]/notes[1]/p[3]/ext-link[1]" id="notes4c">External database links should have attribute 'xlink:href' declared.</message>
  <message line="48" validatedBy="schematron" column="71" location="/article[1]/back[1]/notes[1]/p[4]/ext-link[1]" id="notes4d">'xlink:href' should be equal to the link text (ATP2A2a).</message>
  <message line="49" validatedBy="schematron" column="70" location="/article[1]/back[1]/notes[1]/p[5]/ext-link[1]" id="notes4d">'xlink:href' should be equal to the link text (M23117).</message>
  <message line="44" validatedBy="schematron" column="53" location="/article[1]/back[1]/notes[1]" id="notes2b">Do not use "id" attribute on "notes" in back matter.</message>
  <message line="53" validatedBy="schematron" column="16" location="/article[1]/back[1]/notes[1]/p[9]" id="notes3a">Take a new paragraph for each "ext-link" in the database link (notes) section.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec1a"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec1a" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
      <sec >
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
      <sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="71" validatedBy="schematron" column="13" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec1b"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec1b" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
      <sec sec-type="procedure" >
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
      <sec specific-use="heading-level-1" sec-type="heading-level-12">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p>
  <sec  sec-type="materials">
         <title>Objectives</title>
         <p><list id="l11" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>

</sec>
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="74" validatedBy="schematron" column="71" location="/article[1]/body[1]/sec[2]" id="sec2a">Unexpected value for "sec-type" attribute (heading-level-12). Allowed values are: materials, procedures.</message>
  <message line="74" validatedBy="schematron" column="71" location="/article[1]/body[1]/sec[2]" id="sec1b">"sec" should only use one "sec-type" or "specific-use" attribute, not both.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec1c"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec1c" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
      <sec sec-type="materials" xml:lang="eng">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
      <sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="71" validatedBy="schematron" column="48" location="/article[1]/body[1]/sec[1]" id="sec1d">Do not use "xml:lang" attribute on "sec".&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec2a"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec2a" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
      <sec sec-type="procedures">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
      <sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="71" validatedBy="schematron" column="34" location="/article[1]/body[1]/sec[1]" id="sec2a">Unexpected value for "sec-type" attribute (procedures). Allowed values are: materials, procedures.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec2b"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec2b" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
      <sec sec-type="procedures">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
      <sec specific-use="heading-level-a1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="71" validatedBy="schematron" column="34" location="/article[1]/body[1]/sec[1]" id="sec2a">Unexpected value for "sec-type" attribute (procedures). Allowed values are: materials, procedures.</message>
  <message line="74" validatedBy="schematron" column="44" location="/article[1]/body[1]/sec[2]" id="sec2b">The "specific-use" attribute on "sec" (heading-level-a1) should be used to show the section heading level. It should be "heading-level-" followed by a number.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec3a b"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec3a b" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>

      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
<sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
<sec specific-use="heading-level-2">
         <title>Objectives</title>
         <p><list id="l9" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>

      <sec sec-type="materials">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
   
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="80" validatedBy="schematron" column="37" location="/article[1]/body[1]/sec[2]" id="sec3b">Section heading level 2 should be a child of section heading level 1 - check nesting and "specific-use" attribute values.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec3c"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec3c" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>

      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
<sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
<sec specific-use="heading-level-3">
         <title>Objectives</title>
         <p><list id="l9" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>

      <sec sec-type="materials">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
   
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="80" validatedBy="schematron" column="37" location="/article[1]/body[1]/sec[2]" id="sec3c">Section heading level 3 should be a child of section heading level 2 - check nesting and "specific-use" attribute values.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec3d"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec3d" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>

      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
<sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
<sec specific-use="heading-level-4">
         <title>Objectives</title>
         <p><list id="l9" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>

      <sec sec-type="materials">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
   
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="80" validatedBy="schematron" column="37" location="/article[1]/body[1]/sec[2]" id="sec3d">Section heading level 4 should be a child of section heading level 3 - check nesting and "specific-use" attribute values.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="sec3e"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="sec3e" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>

      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
<sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
<sec specific-use="heading-level-5">
         <title>Objectives</title>
         <p><list id="l9" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>

      <sec sec-type="materials">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
   
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="80" validatedBy="schematron" column="37" location="/article[1]/body[1]/sec[2]" id="sec3e">Section heading level 5 should be a child of section heading level 4 - check nesting and "specific-use" attribute values.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="title1a b  list2d"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="title1a b  list2d" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>

      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
<sec specific-use="heading-level-1">

         <title>Objectives</title>
        
         <p><list id="l1" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p>

<sec specific-use="heading-level-2">
         <title id="fn12">Objectives</title>
         <p><list id="l9" list-type="lcroman">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p>
<sec specific-use="heading-level-3">
         <title id="fn13" content-type="topic"> Objectives</title>
         <p><list id="abcdef" list-type="lcroman"    specific-use="heading-level-12">
            <list-item><p>To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p>


</sec>

</sec>

</sec>


      <sec sec-type="materials">
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
   
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="84" validatedBy="schematron" column="27" location="/article[1]/body[1]/sec[1]/sec[1]/title[1]" id="title1a">Unnecessary use of "id" attribute on "title" element.</message>
  <message line="92" validatedBy="schematron" column="48" location="/article[1]/body[1]/sec[1]/sec[1]/sec[1]/title[1]" id="title1a">Unnecessary use of "id" attribute on "title" element.</message>
  <message line="92" validatedBy="schematron" column="48" location="/article[1]/body[1]/sec[1]/sec[1]/sec[1]/title[1]" id="title1b">Unnecessary use of "content-type" attribute on "title" element.</message>
  <message line="93" validatedBy="schematron" column="86" location="/article[1]/body[1]/sec[1]/sec[1]/sec[1]/p[1]/list[1]" id="list2d">Do not use "specific-use" attribute on "list" element.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="para1b"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="para1b" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
      <sec>
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
      <sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p id="abcd">To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p>Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="71" validatedBy="schematron" column="12" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="77" validatedBy="schematron" column="37" location="/article[1]/body[1]/sec[2]/p[1]/list[1]/list-item[1]/p[1]" id="para1b">Do not use "id" attribute on "p" element.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="int1a"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="int1a" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="qa">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">stemcells</journal-id>
         <journal-title-group>
            <journal-title>Nature Reports Stem Cells</journal-title>
         </journal-title-group>
         <issn pub-type="epub">1754-8705</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">stemcells.2009.75</article-id>
         <article-id pub-id-type="doi">10.1038/stemcells.2009.75</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>qa</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Elaine Fuchs: more secrets of skin renewal</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>14</day>
            <month>05</month>
            <year>2009</year>
         </pub-date>
         <permissions>
            <copyright-year>2009</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p><ext-link ext-link-type="uri" xlink:href="http://www.rockefeller.edu/research/abstract.php?id=42">Elaine Fuchs</ext-link> of Rockefeller University in New York City studies how stem cells in the skin maintain their orderly but complicated cycle of skin renewal, how they adjust so effectively to heal wounds and what goes wrong in disease.</p>
      <p><list list-content="interview">
         <list-item>
            <list list-content="question"><list-item>
                  <p>Possible to have two paras in question - so adding this in for illustration purposes.</p>
                  <p>If you could list only five markers or transcription factors that people who study skin stem cells really need to know, what would they be?</p>
            </list-item></list>
            <list list-content="answer">
               <list-item><p>Key factors for the hair follicle stem cells are Sox9, Tcf3, K15, CD34 and Lgr5. Key markers that encompass epidermal and hair follicle stem cells are p63, K14 and K5, but these proteins are expressed by all keratinocytes with proliferative capacity, irrespective of whether they are stem cells or transit amplifying cells.</p></list-item>
            </list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>One thing you've done a lot of is marking and following cells. How do you decide what labels to use?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>There is no crystal ball as to how to accomplish this, as you always run the risk of altering the biology of the protein. You just have to do the controls to test for preservation of protein function. Let me offer a few examples:</p>
               <p>If we just want to look at Sox9 expression, but only in cells that express Sox9, then we would engineer the Sox9 locus to express GFP [green fluorescent protein] under the control of the Sox9 promoter, so that GFP expression will be exclusive to the cells that express endogenous Sox9. Here it would be important to use a short-lived GFP, such that the minute the cell switches off endogenous Sox9 expression, you'll lose GFP protein.</p>
               <p>If you want to follow what happens to progeny of Sox9-expressing cells, then you want to first engineer a gene encoding Cre-lox recombinase driven by a Sox9 promoter. Then, mate this mouse to another mouse harbouring a gene containing a constitutively active promoter followed by a stop codon that's flanked by lox recombinant sites and then [a] GFP coding sequence. In that way, whenever the cells express Sox9 they activate the recombinase, the recombinase removes the stop codon and those cells start expressing GFP. Then all the progeny will always be marked by GFP, because from this point onward, GFP expression is regulated by a constitutively active promoter.</p>
               <p>And then if you control the timing of when cells express the Cre (using [a] progesterone or tamoxifen inducible system), you can choose when to start marking and following the GFP-expressing progeny that came from cells that express Sox9.</p>
            </list-item></list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>I wanted to talk to you about the orientation of skin cell division. It seems like in the embryo, skin cells are dividing out to cover the embryo, whereas in the adult skin, cells are dividing up to be shed from the surface. What are the big questions in understanding this transition?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>One surprising finding for us really built off an observation made many years back when I was still at the University of Chicago. We noticed that the plane of the spindle orientation undergoes a quite dramatic change during embryonic development, where it goes from being parallel to the basement membrane to [being] perpendicular. We now have some insights on the molecular features that enable the epithelium to undergo these changes in the division plane.</p>
               <p>A simple epithelium doesn't have to think about this &#x2014; it's always dividing parallel to the basement layer. But if you're going to have a stratified epithelium, organized in layers, there has to be some mechanism that allows this stratification. When embryonic epidermal cells divide asymmetrically relative to the basement membrane, they do so by sensing polarity cues. Genetics has told us that flies use a set of evolutionarily conserved proteins to polarize divisions in the neuroblasts and produce divisions that yield one undifferentiated daughter and one daughter committed to make a neuron. We've found that this group of proteins is there at the right place in time to play a similar role in orienting divisions in the skin epithelium, perhaps to generate one proliferative daughter and one daughter committed to stratify and terminally differentiate. What's interesting about the skin is that the epidermis doesn't restrict divisions to be exclusively symmetric or asymmetric. It does <italic>both</italic>. When and how the skin controls these division choices will be interesting to decipher in the future.</p>
            </list-item></list>
         </list-item>
      </list>
</p>
      <p>Editor's note: These are some more specialized questions than the ones discussed in a broader interview.</p>
   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="39" validatedBy="schematron" column="41" location="/article[1]/body[1]/p[2]/list[1]" id="int1a">Interviews should be modelled as block-level lists and should not be enclosed in paragraphs or other lists.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="para1c"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="para1c" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table"
         dtd-version="3.0"
         xml:lang="en"
         article-type="re">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">bdj</journal-id>
         <journal-title-group>
            <journal-title>British Dental Journal</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0007-0610</issn>
         <issn pub-type="epub">1476-5373</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">4801175</article-id>
         <article-id pub-id-type="doi">10.1038/sj.bdj.4801175</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>re</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The relationship between Index of Complexity, Outcome and Need, and patients' perceptions of malocclusion: a study in general dental practice</article-title>
            <subtitle content-type="topic">General Practice</subtitle>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <pub-date pub-type="collection">
            <day>22</day>
            <month>09</month>
            <year>2001</year>
         </pub-date>
         <volume>191</volume>
         <issue>6</issue>
         <fpage>325</fpage>
         <lpage>329</lpage>
         <history>
            <date date-type="received">
               <day>06</day>
               <month>11</month>
               <year>2000</year>
            </date>
            <date date-type="accepted">
               <day>07</day>
               <month>06</month>
               <year>2001</year>
            </date>
         </history>
         <permissions>
            <copyright-year>2001</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="5"/>
         </counts>
      </article-meta>
   </front>
   <body>
      <p>With the ever-increasing importance of clinical effectiveness and audit, the only way of ensuring the proper undertaking of evidence-based research on a large scale is to standardize methods of measurement. Indices have been used for a long time to standardize methods of measurement, thus facilitating comparisons when conducting epidemiological surveys in populations. Furthermore, they have been used to objectively assess the need for treatment to maximize benefit from limited resources.</p>
      <sec>
         <title>Aim</title>
         <p>To examine the relationship between ICON and the subjective opinions of patients attending for routine dental care.</p></sec>
      <sec specific-use="heading-level-1">
         <title>Objectives</title>
         <p><list id="l1" list-type="lcroman">
            <list-item><p id="abcd">To calibrate examiners to an acceptable level of reliability.</p></list-item>
            <list-item><p>To determine the subjective opinions of 11&#x2013;14 and 30&#x2013;40 year olds with respect to aesthetics, function, speech and treatment need.</p></list-item>
            <list-item><p>To highlight the differences in ICON scores between the two age groups, and the two genders.</p></list-item>
            <list-item><p>To determine the strength of association between the ICON and patients' subjective opinions.</p></list-item>
            <list-item><p>To determine the sensitivity and specificity of the ICON with respect to treatment need.</p></list-item></list></p></sec>
   </body>
   <back>
      <app-group>
         <app>
            <title>Appendix 1 ICON &#x2013; Index of Complexity, Outcome and Need</title>
            <p><list id="l2" list-type="bullet">
               <list-item><p>Based on expert opinion of 97 practising specialist orthodontists from Germany, Greece, Hungary, Italy, Netherlands, Norway, Spain, United Kingdom and the USA</p></list-item>
               <list-item><p>For use on patients or dental casts</p></list-item>
               <list-item><p>A single assessment method to record complexity, outcome and need</p></list-item>
               <list-item><p>For use in clinical governance, audit, research and decision making</p></list-item>
               <list-item><p>Five components, taking about 1 minute to measure</p></list-item></list></p>
            <p>The aesthetic component was first published as a scan. Evans R, Shaw W C. A Preliminary evaluation of an illustrated scale for rating dental attractiveness <italic>Eur J Orthod</italic>, 1987; <bold>9</bold>:314-318.</p>
            <p><bold>Component I Aesthetic assessment</bold></p>
            <p>Ten pictures ranking dental attractiveness</p>
            <p><bold>Component 2 Upper arch crowding/spacing</bold></p>
            <p><list id="l3" list-type="number">
               <list-item><p>The difference between the sum of the mesio-distal tooth diameters and the available arch circumference in the upper arch reduced to a 5-point score</p></list-item>
               <list-item><p>Impacted teeth in either arch immediately score 5. Impacted teeth must be unerupted and either:
                  <list id="l4" list-type="lcletter"><list-item><p>Ectopic or impacted against an adjacent tooth (excluding third molars but including supernumerary teeth)</p></list-item>
                     <list-item><p>Possess less than or equal to 4 mm of space between the adjacent permanent teeth. Use average canine and premolar widths to estimate the potential crowding in the mixed dentition, namely, 7 mm for pre-molars, lower canine, and 8 mm for upper canine</p></list-item></list></p></list-item>
               <list-item><p>Spacing in one part of the arch will cancel out crowding elsewhere</p></list-item>
               <list-item><p>Retained deciduous teeth (without permanent successor) and erupted supernumerary teeth score as space (unless they are to be retained to obviate the need for prosthesis)</p></list-item>
               <list-item><p>Lost teeth caused by trauma or extraction should be counted as space (unless space is maintained for a prosthetic replacement).</p></list-item></list></p>
            <p><bold>Component 3 Crossbite</bold></p>
            <p><list id="l5" list-type="ucroman">
               <list-item><p>Anterior and posterior transverse discrepancies of cusp to cusp or greater m intercuspal position</p></list-item></list></p>
            <p><bold>Component 4 Incisor open bite/overbite</bold></p>
            <p><list id="l6" list-type="ucletter">
               <list-item><p xml:lang="en" specific-use="heading-level-14">Open bite (except developmental conditions) is measured to the mid-incisal edges</p></list-item>
               <list-item><p>Deep bite is measured to deepest part of overbite</p></list-item>
               <list-item><p>If both traits are present only the highest score is counted</p></list-item></list></p>
            <p><bold>Component 5 Buccal segment antero-posterior</bold></p>
            <p><list id="l7" list-type="bullet">
               <list-item><p>Quality of buccal segment interdigitation is measured (not Angle's classification)</p></list-item>
               <list-item><p>Both sides are scored then added together</p></list-item></list></p>
         </app>
      </app-group>
   </back>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="71" validatedBy="schematron" column="12" location="/article[1]/body[1]/sec[1]" id="sec1a">"sec" should have "sec-type" or "specific-use" attribute.</message>
  <message line="77" validatedBy="schematron" column="37" location="/article[1]/body[1]/sec[2]/p[1]/list[1]/list-item[1]/p[1]" id="para1b">Do not use "id" attribute on "p" element.</message>
  <message line="110" validatedBy="schematron" column="76" location="/article[1]/back[1]/app-group[1]/app[1]/p[10]/list[1]/list-item[1]/p[1]" id="para1c">Do not use "specific-use" attribute on "p" element.</message>
  <message line="110" validatedBy="schematron" column="76" location="/article[1]/back[1]/app-group[1]/app[1]/p[10]/list[1]/list-item[1]/p[1]" id="para1d">Do not use "xml:lang" attribute on "p" element.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="int1b"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="int1b" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="qa">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">stemcells</journal-id>
         <journal-title-group>
            <journal-title>Nature Reports Stem Cells</journal-title>
         </journal-title-group>
         <issn pub-type="epub">1754-8705</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">stemcells.2009.75</article-id>
         <article-id pub-id-type="doi">10.1038/stemcells.2009.75</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>qa</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Elaine Fuchs: more secrets of skin renewal</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>14</day>
            <month>05</month>
            <year>2009</year>
         </pub-date>
         <permissions>
            <copyright-year>2009</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p><ext-link ext-link-type="uri" xlink:href="http://www.rockefeller.edu/research/abstract.php?id=42">Elaine Fuchs</ext-link> of Rockefeller University in New York City studies how stem cells in the skin maintain their orderly but complicated cycle of skin renewal, how they adjust so effectively to heal wounds and what goes wrong in disease.</p>
      <p><list list-content="interview" id="abc">
         <list-item>
            <list list-content="question"><list-item>
                  <p>Possible to have two paras in question - so adding this in for illustration purposes.</p>
                  <p>If you could list only five markers or transcription factors that people who study skin stem cells really need to know, what would they be?</p>
            </list-item></list>
            <list list-content="answer">
               <list-item><p>Key factors for the hair follicle stem cells are Sox9, Tcf3, K15, CD34 and Lgr5. Key markers that encompass epidermal and hair follicle stem cells are p63, K14 and K5, but these proteins are expressed by all keratinocytes with proliferative capacity, irrespective of whether they are stem cells or transit amplifying cells.</p></list-item>
            </list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>One thing you've done a lot of is marking and following cells. How do you decide what labels to use?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>There is no crystal ball as to how to accomplish this, as you always run the risk of altering the biology of the protein. You just have to do the controls to test for preservation of protein function. Let me offer a few examples:</p>
               <p>If we just want to look at Sox9 expression, but only in cells that express Sox9, then we would engineer the Sox9 locus to express GFP [green fluorescent protein] under the control of the Sox9 promoter, so that GFP expression will be exclusive to the cells that express endogenous Sox9. Here it would be important to use a short-lived GFP, such that the minute the cell switches off endogenous Sox9 expression, you'll lose GFP protein.</p>
               <p>If you want to follow what happens to progeny of Sox9-expressing cells, then you want to first engineer a gene encoding Cre-lox recombinase driven by a Sox9 promoter. Then, mate this mouse to another mouse harbouring a gene containing a constitutively active promoter followed by a stop codon that's flanked by lox recombinant sites and then [a] GFP coding sequence. In that way, whenever the cells express Sox9 they activate the recombinase, the recombinase removes the stop codon and those cells start expressing GFP. Then all the progeny will always be marked by GFP, because from this point onward, GFP expression is regulated by a constitutively active promoter.</p>
               <p>And then if you control the timing of when cells express the Cre (using [a] progesterone or tamoxifen inducible system), you can choose when to start marking and following the GFP-expressing progeny that came from cells that express Sox9.</p>
            </list-item></list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>I wanted to talk to you about the orientation of skin cell division. It seems like in the embryo, skin cells are dividing out to cover the embryo, whereas in the adult skin, cells are dividing up to be shed from the surface. What are the big questions in understanding this transition?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>One surprising finding for us really built off an observation made many years back when I was still at the University of Chicago. We noticed that the plane of the spindle orientation undergoes a quite dramatic change during embryonic development, where it goes from being parallel to the basement membrane to [being] perpendicular. We now have some insights on the molecular features that enable the epithelium to undergo these changes in the division plane.</p>
               <p>A simple epithelium doesn't have to think about this &#x2014; it's always dividing parallel to the basement layer. But if you're going to have a stratified epithelium, organized in layers, there has to be some mechanism that allows this stratification. When embryonic epidermal cells divide asymmetrically relative to the basement membrane, they do so by sensing polarity cues. Genetics has told us that flies use a set of evolutionarily conserved proteins to polarize divisions in the neuroblasts and produce divisions that yield one undifferentiated daughter and one daughter committed to make a neuron. We've found that this group of proteins is there at the right place in time to play a similar role in orienting divisions in the skin epithelium, perhaps to generate one proliferative daughter and one daughter committed to stratify and terminally differentiate. What's interesting about the skin is that the epidermis doesn't restrict divisions to be exclusively symmetric or asymmetric. It does <italic>both</italic>. When and how the skin controls these division choices will be interesting to decipher in the future.</p>
            </list-item></list>
         </list-item>
      </list>
</p>
      <p>Editor's note: These are some more specialized questions than the ones discussed in a broader interview.</p>
   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="50" location="/article[1]/body[1]/p[2]/list[1]" id="int1a">Interviews should be modelled as block-level lists and should not be enclosed in paragraphs or other lists.</message>
  <message line="39" validatedBy="schematron" column="50" location="/article[1]/body[1]/p[2]/list[1]" id="int1b">The "id" attribute is not necessary on interviews.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="int1c"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="int1c" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="qa">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">stemcells</journal-id>
         <journal-title-group>
            <journal-title>Nature Reports Stem Cells</journal-title>
         </journal-title-group>
         <issn pub-type="epub">1754-8705</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">stemcells.2009.75</article-id>
         <article-id pub-id-type="doi">10.1038/stemcells.2009.75</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>qa</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Elaine Fuchs: more secrets of skin renewal</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>14</day>
            <month>05</month>
            <year>2009</year>
         </pub-date>
         <permissions>
            <copyright-year>2009</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p><ext-link ext-link-type="uri" xlink:href="http://www.rockefeller.edu/research/abstract.php?id=42">Elaine Fuchs</ext-link> of Rockefeller University in New York City studies how stem cells in the skin maintain their orderly but complicated cycle of skin renewal, how they adjust so effectively to heal wounds and what goes wrong in disease.</p>
      <p><list list-content="interview" list-type="avava">
         <list-item>
            <list list-content="question"><list-item>
                  <p>Possible to have two paras in question - so adding this in for illustration purposes.</p>
                  <p>If you could list only five markers or transcription factors that people who study skin stem cells really need to know, what would they be?</p>
            </list-item></list>
            <list list-content="answer">
               <list-item><p>Key factors for the hair follicle stem cells are Sox9, Tcf3, K15, CD34 and Lgr5. Key markers that encompass epidermal and hair follicle stem cells are p63, K14 and K5, but these proteins are expressed by all keratinocytes with proliferative capacity, irrespective of whether they are stem cells or transit amplifying cells.</p></list-item>
            </list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>One thing you've done a lot of is marking and following cells. How do you decide what labels to use?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>There is no crystal ball as to how to accomplish this, as you always run the risk of altering the biology of the protein. You just have to do the controls to test for preservation of protein function. Let me offer a few examples:</p>
               <p>If we just want to look at Sox9 expression, but only in cells that express Sox9, then we would engineer the Sox9 locus to express GFP [green fluorescent protein] under the control of the Sox9 promoter, so that GFP expression will be exclusive to the cells that express endogenous Sox9. Here it would be important to use a short-lived GFP, such that the minute the cell switches off endogenous Sox9 expression, you'll lose GFP protein.</p>
               <p>If you want to follow what happens to progeny of Sox9-expressing cells, then you want to first engineer a gene encoding Cre-lox recombinase driven by a Sox9 promoter. Then, mate this mouse to another mouse harbouring a gene containing a constitutively active promoter followed by a stop codon that's flanked by lox recombinant sites and then [a] GFP coding sequence. In that way, whenever the cells express Sox9 they activate the recombinase, the recombinase removes the stop codon and those cells start expressing GFP. Then all the progeny will always be marked by GFP, because from this point onward, GFP expression is regulated by a constitutively active promoter.</p>
               <p>And then if you control the timing of when cells express the Cre (using [a] progesterone or tamoxifen inducible system), you can choose when to start marking and following the GFP-expressing progeny that came from cells that express Sox9.</p>
            </list-item></list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>I wanted to talk to you about the orientation of skin cell division. It seems like in the embryo, skin cells are dividing out to cover the embryo, whereas in the adult skin, cells are dividing up to be shed from the surface. What are the big questions in understanding this transition?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>One surprising finding for us really built off an observation made many years back when I was still at the University of Chicago. We noticed that the plane of the spindle orientation undergoes a quite dramatic change during embryonic development, where it goes from being parallel to the basement membrane to [being] perpendicular. We now have some insights on the molecular features that enable the epithelium to undergo these changes in the division plane.</p>
               <p>A simple epithelium doesn't have to think about this &#x2014; it's always dividing parallel to the basement layer. But if you're going to have a stratified epithelium, organized in layers, there has to be some mechanism that allows this stratification. When embryonic epidermal cells divide asymmetrically relative to the basement membrane, they do so by sensing polarity cues. Genetics has told us that flies use a set of evolutionarily conserved proteins to polarize divisions in the neuroblasts and produce divisions that yield one undifferentiated daughter and one daughter committed to make a neuron. We've found that this group of proteins is there at the right place in time to play a similar role in orienting divisions in the skin epithelium, perhaps to generate one proliferative daughter and one daughter committed to stratify and terminally differentiate. What's interesting about the skin is that the epidermis doesn't restrict divisions to be exclusively symmetric or asymmetric. It does <italic>both</italic>. When and how the skin controls these division choices will be interesting to decipher in the future.</p>
            </list-item></list>
         </list-item>
      </list>
</p>
      <p>Editor's note: These are some more specialized questions than the ones discussed in a broader interview.</p>
   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="59" location="/article[1]/body[1]/p[2]/list[1]" id="int1a">Interviews should be modelled as block-level lists and should not be enclosed in paragraphs or other lists.</message>
  <message line="39" validatedBy="schematron" column="59" location="/article[1]/body[1]/p[2]/list[1]" id="int1c">The "list-type" attribute is not necessary on interviews.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="Int2"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="Int2" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="qa">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">stemcells</journal-id>
         <journal-title-group>
            <journal-title>Nature Reports Stem Cells</journal-title>
         </journal-title-group>
         <issn pub-type="epub">1754-8705</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">stemcells.2009.75</article-id>
         <article-id pub-id-type="doi">10.1038/stemcells.2009.75</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>qa</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Elaine Fuchs: more secrets of skin renewal</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>14</day>
            <month>05</month>
            <year>2009</year>
         </pub-date>
         <permissions>
            <copyright-year>2009</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p><ext-link ext-link-type="uri" xlink:href="http://www.rockefeller.edu/research/abstract.php?id=42">Elaine Fuchs</ext-link> of Rockefeller University in New York City studies how stem cells in the skin maintain their orderly but complicated cycle of skin renewal, how they adjust so effectively to heal wounds and what goes wrong in disease.</p>
      <p><list list-content="interview">
         <list-item>
            <list list-content="question"><list-item>
                  <p>Possible to have two paras in question - so adding this in for illustration purposes.</p>
                  <p>If you could list only five markers or transcription factors that people who study skin stem cells really need to know, what would they be?</p>
            </list-item></list>
        
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>One thing you've done a lot of is marking and following cells. How do you decide what labels to use?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>There is no crystal ball as to how to accomplish this, as you always run the risk of altering the biology of the protein. You just have to do the controls to test for preservation of protein function. Let me offer a few examples:</p>
               <p>If we just want to look at Sox9 expression, but only in cells that express Sox9, then we would engineer the Sox9 locus to express GFP [green fluorescent protein] under the control of the Sox9 promoter, so that GFP expression will be exclusive to the cells that express endogenous Sox9. Here it would be important to use a short-lived GFP, such that the minute the cell switches off endogenous Sox9 expression, you'll lose GFP protein.</p>
               <p>If you want to follow what happens to progeny of Sox9-expressing cells, then you want to first engineer a gene encoding Cre-lox recombinase driven by a Sox9 promoter. Then, mate this mouse to another mouse harbouring a gene containing a constitutively active promoter followed by a stop codon that's flanked by lox recombinant sites and then [a] GFP coding sequence. In that way, whenever the cells express Sox9 they activate the recombinase, the recombinase removes the stop codon and those cells start expressing GFP. Then all the progeny will always be marked by GFP, because from this point onward, GFP expression is regulated by a constitutively active promoter.</p>
               <p>And then if you control the timing of when cells express the Cre (using [a] progesterone or tamoxifen inducible system), you can choose when to start marking and following the GFP-expressing progeny that came from cells that express Sox9.</p>
            </list-item></list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>I wanted to talk to you about the orientation of skin cell division. It seems like in the embryo, skin cells are dividing out to cover the embryo, whereas in the adult skin, cells are dividing up to be shed from the surface. What are the big questions in understanding this transition?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>One surprising finding for us really built off an observation made many years back when I was still at the University of Chicago. We noticed that the plane of the spindle orientation undergoes a quite dramatic change during embryonic development, where it goes from being parallel to the basement membrane to [being] perpendicular. We now have some insights on the molecular features that enable the epithelium to undergo these changes in the division plane.</p>
               <p>A simple epithelium doesn't have to think about this &#x2014; it's always dividing parallel to the basement layer. But if you're going to have a stratified epithelium, organized in layers, there has to be some mechanism that allows this stratification. When embryonic epidermal cells divide asymmetrically relative to the basement membrane, they do so by sensing polarity cues. Genetics has told us that flies use a set of evolutionarily conserved proteins to polarize divisions in the neuroblasts and produce divisions that yield one undifferentiated daughter and one daughter committed to make a neuron. We've found that this group of proteins is there at the right place in time to play a similar role in orienting divisions in the skin epithelium, perhaps to generate one proliferative daughter and one daughter committed to stratify and terminally differentiate. What's interesting about the skin is that the epidermis doesn't restrict divisions to be exclusively symmetric or asymmetric. It does <italic>both</italic>. When and how the skin controls these division choices will be interesting to decipher in the future.</p>
            </list-item></list>
         </list-item>
      </list>
</p>
      <p>Editor's note: These are some more specialized questions than the ones discussed in a broader interview.</p>
   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="39" validatedBy="schematron" column="41" location="/article[1]/body[1]/p[2]/list[1]" id="int1a">Interviews should be modelled as block-level lists and should not be enclosed in paragraphs or other lists.</message>
  <message line="40" validatedBy="schematron" column="21" location="/article[1]/body[1]/p[2]/list[1]/list-item[1]" id="int2">Interview list-items should contain one question and one answer.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="quiz1a"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="quiz1a" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="egame">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">nphys</journal-id>
         <journal-title-group>
            <journal-title>Nature Physics</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">1745-2473</issn>
         <issn pub-type="epub">1745-2481</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">nphys439</article-id>
         <article-id pub-id-type="doi">10.1038/nphys439</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>egame</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>New wave</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <month>11</month>
            <year>2006</year>
         </pub-date>
         <volume>2</volume>
         <issue>11</issue>
         <fpage>788</fpage>
         <lpage>788</lpage>
         <permissions>
            <copyright-year>2006</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="1"/>
         </counts>
      </article-meta>
   </front>
   <body>
  <p>   <list list-content="quiz">
         <list-item>
            <list list-content="question"><list-item><p>This apparatus, held in London's Science Museum, has some significant purpose &#x2014; or curiosity value &#x2014; in the history of physics. Can you guess what it is?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p content-type="cross-head">Last month: Caroline Herschel's telescope</p>
               <p>This reflecting telescope was built in about 1795 by Sir William Herschel, who gave it to his sister Caroline. A dedicated assistant to her brother, Caroline was a celebrated astronomer in her own right, discovering eight comets and three nebulae. She described vividly the experience of astronomical observing on "star-lit nights on a grass-plot covered with dew or hoar frost, without a human being near enough to be within call".</p>
               <p>The Herschels left their native city of Hanover, Germany, for Bath in England, where William made his living as a musician. However his passion was astronomy and in 1773, dissatisfied with the quality of equipment available, he began making his own telescopes. He perfected the art of mirror polishing and his superior instruments enabled him to make detailed surveys of the night sky. In 1781, he observed a fuzzy object, which he at first assumed might be a comet. Further observation revealed it to be a planet &#x2014; the first new one to be spotted since prehistoric times. Herschel named it Georgium sidus (the Georgian star) after King George III, but this name proved unpopular with astronomers and we know it today as Uranus.</p>
               <p>Caroline Herschel described the telescope pictured here as looking exactly like the one used by her brother in the discovery of Uranus. It has a 7-foot octagonal wooden tube and is operated using pulley ropes and gears. The 6-1/8-inch mirror is made of speculum metal, an alloy of copper and tin.</p>
               <p>In 1782, William Herschel was awarded a pension in recognition of his achievements, enabling him to give up work as a musician and, at 42, become the world's first professional astronomer. His son John continued the family tradition, charting the Southern skies from Cape Town, South Africa. The Herschel name still features prominently in astronomy today: in 2007, the European Space Agency will launch the Herschel Space Observatory, to study the skies at far-infrared and sub-millimetre wavelengths. It will have the largest mirror ever deployed in space &#x2014; a fitting tribute to William and Caroline.</p></list-item></list>
         </list-item>
      </list>
</p>
   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message line="45" validatedBy="schematron" column="35" location="/article[1]/body[1]/p[1]/list[1]" id="quiz1a">Quizzes should be modelled as block-level lists and should not be enclosed in paragraphs or other lists.&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="quiz1b c"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="quiz1b c" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="egame">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">nphys</journal-id>
         <journal-title-group>
            <journal-title>Nature Physics</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">1745-2473</issn>
         <issn pub-type="epub">1745-2481</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">nphys439</article-id>
         <article-id pub-id-type="doi">10.1038/nphys439</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>egame</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>New wave</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <month>11</month>
            <year>2006</year>
         </pub-date>
         <volume>2</volume>
         <issue>11</issue>
         <fpage>788</fpage>
         <lpage>788</lpage>
         <permissions>
            <copyright-year>2006</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="1"/>
         </counts>
      </article-meta>
   </front>
   <body>
  <list list-content="quiz" id="ajaah" list-type="ahjaghahg">
         <list-item>
            <list list-content="question"><list-item><p>This apparatus, held in London's Science Museum, has some significant purpose &#x2014; or curiosity value &#x2014; in the history of physics. Can you guess what it is?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p content-type="cross-head">Last month: Caroline Herschel's telescope</p>
               <p>This reflecting telescope was built in about 1795 by Sir William Herschel, who gave it to his sister Caroline. A dedicated assistant to her brother, Caroline was a celebrated astronomer in her own right, discovering eight comets and three nebulae. She described vividly the experience of astronomical observing on "star-lit nights on a grass-plot covered with dew or hoar frost, without a human being near enough to be within call".</p>
               <p>The Herschels left their native city of Hanover, Germany, for Bath in England, where William made his living as a musician. However his passion was astronomy and in 1773, dissatisfied with the quality of equipment available, he began making his own telescopes. He perfected the art of mirror polishing and his superior instruments enabled him to make detailed surveys of the night sky. In 1781, he observed a fuzzy object, which he at first assumed might be a comet. Further observation revealed it to be a planet &#x2014; the first new one to be spotted since prehistoric times. Herschel named it Georgium sidus (the Georgian star) after King George III, but this name proved unpopular with astronomers and we know it today as Uranus.</p>
               <p>Caroline Herschel described the telescope pictured here as looking exactly like the one used by her brother in the discovery of Uranus. It has a 7-foot octagonal wooden tube and is operated using pulley ropes and gears. The 6-1/8-inch mirror is made of speculum metal, an alloy of copper and tin.</p>
               <p>In 1782, William Herschel was awarded a pension in recognition of his achievements, enabling him to give up work as a musician and, at 42, become the world's first professional astronomer. His son John continued the family tradition, charting the Southern skies from Cape Town, South Africa. The Herschel name still features prominently in astronomy today: in 2007, the European Space Agency will launch the Herschel Space Observatory, to study the skies at far-infrared and sub-millimetre wavelengths. It will have the largest mirror ever deployed in space &#x2014; a fitting tribute to William and Caroline.</p></list-item></list>
         </list-item>
      </list>

   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="62" location="/article[1]/body[1]/list[1]" id="quiz1b">The "id" attribute is not necessary on quizzes.</message>
  <message line="45" validatedBy="schematron" column="62" location="/article[1]/body[1]/list[1]" id="quiz1c">The "list-type" attribute is not necessary on quizzes.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="quiz2"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="quiz2" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="egame">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">nphys</journal-id>
         <journal-title-group>
            <journal-title>Nature Physics</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">1745-2473</issn>
         <issn pub-type="epub">1745-2481</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">nphys439</article-id>
         <article-id pub-id-type="doi">10.1038/nphys439</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>egame</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>New wave</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <month>11</month>
            <year>2006</year>
         </pub-date>
         <volume>2</volume>
         <issue>11</issue>
         <fpage>788</fpage>
         <lpage>788</lpage>
         <permissions>
            <copyright-year>2006</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="1"/>
         </counts>
      </article-meta>
   </front>
   <body>
  <list list-content="quiz" id="ajaah" list-type="ahjaghahg">
         <list-item>
            <list list-content="question"><list-item><p>This apparatus, held in London's Science Museum, has some significant purpose &#x2014; or curiosity value &#x2014; in the history of physics. Can you guess what it is?</p></list-item></list>
          </list-item>

      </list>

   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="62" location="/article[1]/body[1]/list[1]" id="quiz1b">The "id" attribute is not necessary on quizzes.</message>
  <message line="45" validatedBy="schematron" column="62" location="/article[1]/body[1]/list[1]" id="quiz1c">The "list-type" attribute is not necessary on quizzes.</message>
  <message line="46" validatedBy="schematron" column="21" location="/article[1]/body[1]/list[1]/list-item[1]" id="quiz2">Quiz list-items should contain one question and one answer.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="intquiz1 list3a list2a list2e"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="intquiz1 list3a list2a list2e" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="egame">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">nphys</journal-id>
         <journal-title-group>
            <journal-title>Nature Physics</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">1745-2473</issn>
         <issn pub-type="epub">1745-2481</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">nphys439</article-id>
         <article-id pub-id-type="doi">10.1038/nphys439</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>egame</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>New wave</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <month>11</month>
            <year>2006</year>
         </pub-date>
         <volume>2</volume>
         <issue>11</issue>
         <fpage>788</fpage>
         <lpage>788</lpage>
         <permissions>
            <copyright-year>2006</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="1"/>
         </counts>
      </article-meta>
   </front>
   <body>
  <list id="ajaah" >
         <list-item id="ahhahaha">
            <list list-content="question"><list-item id="ajajajjajaj"><p>This apparatus, held in London's Science Museum, has some significant purpose &#x2014; or curiosity value &#x2014; in the history of physics. Can you guess what it is?</p></list-item></list>
          </list-item>

      </list>


   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="21" location="/article[1]/body[1]/list[1]" id="list2a">Regular lists should be enclosed in paragraphs or other lists.</message>
  <message line="45" validatedBy="schematron" column="21" location="/article[1]/body[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="47" validatedBy="schematron" column="43" location="/article[1]/body[1]/list[1]/list-item[1]/list[1]" id="intquiz1">Question lists (list-content="question") should only be used in interviews or quizzes.</message>
  <message line="46" validatedBy="schematron" column="35" location="/article[1]/body[1]/list[1]/list-item[1]" id="list2e">Do not use "id" attribute on "list-item" element.</message>
  <message line="47" validatedBy="schematron" column="71" location="/article[1]/body[1]/list[1]/list-item[1]/list[1]/list-item[1]" id="list2e">Do not use "id" attribute on "list-item" element.</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="list4"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="list4" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="egame">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">nphys</journal-id>
         <journal-title-group>
            <journal-title>Nature Physics</journal-title>
         </journal-title-group>
         <issn pub-type="ppub">1745-2473</issn>
         <issn pub-type="epub">1745-2481</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">nphys439</article-id>
         <article-id pub-id-type="doi">10.1038/nphys439</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>egame</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>New wave</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <month>11</month>
            <year>2006</year>
         </pub-date>
         <volume>2</volume>
         <issue>11</issue>
         <fpage>788</fpage>
         <lpage>788</lpage>
         <permissions>
            <copyright-year>2006</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
         <counts>
            <page-count count="1"/>
         </counts>
      </article-meta>
   </front>
   <body>
  <list id="ajaah" >
         <list-item id="ahhahaha">
<label>kakakak</label>
            <list list-content="question"><list-item id="ajajajjajaj"><p>This apparatus, held in London's Science Museum, has some significant purpose &#x2014; or curiosity value &#x2014; in the history of physics. Can you guess what it is?</p></list-item></list>
          </list-item>

      </list>


   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content><![CDATA[<report>
  <message line="45" validatedBy="schematron" column="21" location="/article[1]/body[1]/list[1]" id="list2a">Regular lists should be enclosed in paragraphs or other lists.</message>
  <message line="45" validatedBy="schematron" column="21" location="/article[1]/body[1]/list[1]" id="list3a">Use "list-type" attribute to show type of list used. Allowed values are: bullet, number, lcletter, ucletter, lcroman and ucroman.</message>
  <message line="48" validatedBy="schematron" column="43" location="/article[1]/body[1]/list[1]/list-item[1]/list[1]" id="intquiz1">Question lists (list-content="question") should only be used in interviews or quizzes.</message>
  <message line="46" validatedBy="schematron" column="35" location="/article[1]/body[1]/list[1]/list-item[1]" id="list2e">Do not use "id" attribute on "list-item" element.</message>
  <message line="48" validatedBy="schematron" column="71" location="/article[1]/body[1]/list[1]/list-item[1]/list[1]/list-item[1]" id="list2e">Do not use "id" attribute on "list-item" element.</message>
  <message line="46" validatedBy="schematron" column="35" location="/article[1]/body[1]/list[1]/list-item[1]" id="list4">Do not use "label" element in "list-item".</message>
</report>]]></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:testStep type="restrequest" name="intm"><con:settings/><con:config service="NLM Transform - Java Service" resourcePath="/${#Project#Basepath}/${#Project#path}" methodName="POST" xsi:type="con:RestRequestStep" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><con:restRequest name="intm" mediaType="application/xml" postQueryString="false" accept=""><con:settings><con:setting id="com.eviware.soapui.impl.wsdl.WsdlRequest@request-headers">&lt;xml-fragment/></con:setting></con:settings><con:endpoint>${#Project#ServiceEndpoint}${#Project#Basepath}${#Project#path}</con:endpoint><con:request><![CDATA[<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" dtd-version="3.0" xml:lang="en" article-type="qa">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher">stemcells</journal-id>
         <journal-title-group>
            <journal-title>Nature Reports Stem Cells</journal-title>
         </journal-title-group>
         <issn pub-type="epub">1754-8705</issn>
         <publisher>
            <publisher-name>Nature Publishing Group</publisher-name>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="publisher-id">stemcells.2009.75</article-id>
         <article-id pub-id-type="doi">10.1038/stemcells.2009.75</article-id>
         <article-categories>
            <subj-group subj-group-type="category">
               <subject>qa</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Elaine Fuchs: more secrets of skin renewal</article-title>
         </title-group>
         <pub-date pub-type="issue-date">
            <day>14</day>
            <month>05</month>
            <year>2009</year>
         </pub-date>
         <permissions>
            <copyright-year>2009</copyright-year>
            <copyright-holder>Nature Publishing Group</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p><ext-link ext-link-type="uri" xlink:href="http://www.rockefeller.edu/research/abstract.php?id=42">Elaine Fuchs</ext-link> of Rockefeller University in New York City studies how stem cells in the skin maintain their orderly but complicated cycle of skin renewal, how they adjust so effectively to heal wounds and what goes wrong in disease.</p>
      <list list-content="interview">
         <list-item>
            <list list-content="question"><list-item>
                  <p>Possible to have two paras in question - so adding this in for illustration purposes.</p>
                  <p>If you could list only five markers or transcription factors that people who study skin stem cells really need to know, what would they be?</p>
            </list-item></list>
            <list list-content="answer">
               <list-item><p>Key factors for the hair follicle stem cells are Sox9, Tcf3, K15, CD34 and Lgr5. Key markers that encompass epidermal and hair follicle stem cells are p63, K14 and K5, but these proteins are expressed by all keratinocytes with proliferative capacity, irrespective of whether they are stem cells or transit amplifying cells.</p></list-item>
            </list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>One thing you've done a lot of is marking and following cells. How do you decide what labels to use?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>There is no crystal ball as to how to accomplish this, as you always run the risk of altering the biology of the protein. You just have to do the controls to test for preservation of protein function. Let me offer a few examples:</p>
               <p>If we just want to look at Sox9 expression, but only in cells that express Sox9, then we would engineer the Sox9 locus to express GFP [green fluorescent protein] under the control of the Sox9 promoter, so that GFP expression will be exclusive to the cells that express endogenous Sox9. Here it would be important to use a short-lived GFP, such that the minute the cell switches off endogenous Sox9 expression, you'll lose GFP protein.</p>
               <p>If you want to follow what happens to progeny of Sox9-expressing cells, then you want to first engineer a gene encoding Cre-lox recombinase driven by a Sox9 promoter. Then, mate this mouse to another mouse harbouring a gene containing a constitutively active promoter followed by a stop codon that's flanked by lox recombinant sites and then [a] GFP coding sequence. In that way, whenever the cells express Sox9 they activate the recombinase, the recombinase removes the stop codon and those cells start expressing GFP. Then all the progeny will always be marked by GFP, because from this point onward, GFP expression is regulated by a constitutively active promoter.</p>
               <p>And then if you control the timing of when cells express the Cre (using [a] progesterone or tamoxifen inducible system), you can choose when to start marking and following the GFP-expressing progeny that came from cells that express Sox9.</p>
            </list-item></list>
         </list-item>
         <list-item>
            <list list-content="question"><list-item><p>I wanted to talk to you about the orientation of skin cell division. It seems like in the embryo, skin cells are dividing out to cover the embryo, whereas in the adult skin, cells are dividing up to be shed from the surface. What are the big questions in understanding this transition?</p></list-item></list>
            <list list-content="answer"><list-item>
               <p>One surprising finding for us really built off an observation made many years back when I was still at the University of Chicago. We noticed that the plane of the spindle orientation undergoes a quite dramatic change during embryonic development, where it goes from being parallel to the basement membrane to [being] perpendicular. We now have some insights on the molecular features that enable the epithelium to undergo these changes in the division plane.</p>
               <p>A simple epithelium doesn't have to think about this &#x2014; it's always dividing parallel to the basement layer. But if you're going to have a stratified epithelium, organized in layers, there has to be some mechanism that allows this stratification. When embryonic epidermal cells divide asymmetrically relative to the basement membrane, they do so by sensing polarity cues. Genetics has told us that flies use a set of evolutionarily conserved proteins to polarize divisions in the neuroblasts and produce divisions that yield one undifferentiated daughter and one daughter committed to make a neuron. We've found that this group of proteins is there at the right place in time to play a similar role in orienting divisions in the skin epithelium, perhaps to generate one proliferative daughter and one daughter committed to stratify and terminally differentiate. What's interesting about the skin is that the epidermis doesn't restrict divisions to be exclusively symmetric or asymmetric. It does <italic>both</italic>. When and how the skin controls these division choices will be interesting to decipher in the future.</p>
            </list-item></list>
         </list-item>
      </list>
      <p>Editor's note: These are some more specialized questions than the ones discussed in a broader interview.</p>
   </body>
</article>]]></con:request><con:assertion type="XPath Match" name="Match content of [report]"><con:configuration><path>//report[1]</path><content>&lt;report>
  &lt;message>VALIDATION SUCCESSFUL&lt;/message>
&lt;/report></content><allowWildcards>false</allowWildcards><ignoreNamspaceDifferences>false</ignoreNamspaceDifferences><ignoreComments>false</ignoreComments></con:configuration></con:assertion><con:jmsConfig JMSDeliveryMode="PERSISTENT"/><con:jmsPropertyConfig/><con:parameters/></con:restRequest></con:config></con:testStep><con:properties/><con:reportParameters/></con:testCase><con:properties/><con:reportParameters/></con:testSuite><con:requirements/><con:properties><con:property><con:name>ServiceEndpoint</con:name><con:value>http://test-integral.nature.com</con:value></con:property><con:property><con:name>Basepath</con:name><con:value>/nlm</con:value></con:property><con:property><con:name>path</con:name><con:value>/nlm-consumer</con:value></con:property></con:properties><con:wssContainer/><con:databaseConnectionContainer/><con:reporting><con:reportTemplates/><con:xmlTemplates/><con:parameters/></con:reporting><con:sensitiveInformation/></con:soapui-project>